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ApoB Apolipoprotein B





CTL Cytotoxic T lymphocyte
dsRNA double-stranded RNA
DGAT2 Diglyceride acyltransferase 2
F.IX Factor IX
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HBsAg Hepatitis B surface antigen
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LNA Locked nucleic acid
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mRNA messenger RNA
miRNA micro RNA
MTP Microsomal triglyceride transfer protein
NHP Non-human primate
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nt nucleotide
ORF Open reading frame
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pA polyadenylation signal
PAMP Pathogen-associated molecular pattern
PKR Protein kinase R
PCSK9 Proprotein convertase subtilisin/kexin type 9
p.i. post injection
pre-miRNA precursor micro RNA
pri-miRNA primary micro RNA




siRNA small interfering RNA
SNALP Stable nucleic acid lipid particle
ssRNA single-stranded RNA
ss-siRNA single-stranded siRNA




TSS Transcription start site
TTS Transcription termination signal








Since its discovery RNA interference (RNAi) mechanism has become a valuable research 
tool for functional analysis of gene expression and a promising approach for treatment 
of many disorders including viral infections, hereditary disorders, and cancer. By 
introducing molecules that constitute substrates for the endogenous RNAi pathway, 
disease-related messenger RNA (mRNA) and thus production of related proteins can be 
inhibited. Liver plays a major role in the metabolism and has a number of functions in 
the body, including glycogen storage, decomposition of red blood cells, plasma protein 
synthesis, hormone production, and detoxification. Many liver diseases that currently 
cannot be adequately treated are good candidates for RNAi gene therapy. RNAi-based 
strategies have recently been explored for treating hepatocellular carcinoma (HCC), 
hepatitis B (HBV) and hepatitis C (HCV) virus, infections and genetic disorders such as 
familial hypercholesterolemia (FH) or alpha-1-antitrypsin deficiency (A1AD). The RNAi 
machinery can directly inhibit RNA, which plays important role in the etiology of these 
diseases i.e. target transcripts encoding for multidrug resistance proteins in HCC, viral 
genome of HBV, replication intermediates of HBV, HCV or mutated mRNAs which lead 
to production of amended proteins in FH and A1AD. Additionally, the RNAi machinery, 
in particular endogenous miRNAs can be exploited to regulate transgene expression. 
This approach was successfully applied to reduce immune response to Factor IX (F.IX) 
used for treatment of Hemophilia B by inhibiting F.IX expression in antigen presenting 
cells (APC) using hematopoietic cell-specific miRNA binding sites in 3’ untranslated 
region (3’UTR) of the transgene.
However, serious concerns have been raised about safety of the RNAi-based 
therapeutic approach when toxicity was described in rodents and non-human primates 
(NHP). This thesis addresses important questions about the long-term efficacy and 
safety of RNAi for treatment of liver diseases, which also involves aspects of processing 
of RNAi molecules in vivo, transcriptome analysis and liver functioning after injection 
with adeno-associated viruses (AAV) encoding RNAi-inducing molecules.
The natural RNAi pathway
RNAi is an evolutionary conserved mechanism for regulating gene expression. It 
plays an important role in defense against viruses but also in development and in 
normal functioning of the cell [1-3]. RNAi was initially discovered in plants where 
delivering DNA encoding the rate limiting enzyme in anthocyanin biosynthesis in 
order to generate petunias (Petunia hybryda) with darker color, unexpectedly induced 
the opposite effect of less pigmented or white flowers [4,5]. This “co-suppression” 
of endogenous gene phenomenon was suggested to function via hybridization 




destruction or led to translational repression. The same mechanism was later found 
to be conserved in other species i.e. fungi Neurospora Crassa [6] and Caenorhabditis 
elgans worm [7]. In 1998 a breakthrough discovery was made by A. Fire and C. Mello 
which provided the explanation for these previously described phenomenons [8]. 
They identified molecules which were responsible for inducing target degradation 
of mRNA and showed that a double-stranded RNA (dsRNA) contamination in 
mRNA preparations rather than single stranded RNA was inhibiting a gene with 
complementary sequences [8]. Their discovery was a milestone which was just 
beginning of identification of novel mechanism of gene regulation. In 2006, A. Fire 
and C. Mello were awarded the Noble prize for their discovery of RNA interference-
gene silencing by double-stranded RNA.
The RNAi mechanism is initiated by dsRNA molecules (Fig. 1). The natural RNAi 
mechanism in mammalian cells functions by endogenous miRNA molecules, which 
are synthesized in cells as longer primary RNA transcripts (pri-miRNAs). Most miRNA 
are usually transcribed by RNA polymerase II; however RNA polymerase III (Pol III) 
transcribes some miRNAs, especially those with upstream Alu sequences and transfer 
RNAs (tRNAs) [9]. Pri-miRNAs are cleaved by the nuclear Microprocessor complex 
(Drosha-DGCR8 complex) to produce miRNA precursors (pre-miRNAs) of 70 nucleotides 
(nt) [10], which are then transported by Exportin 5 to the cytoplasm and processed by 
the RNAse III endonuclease family enzyme Dicer to produce a mature miRNA duplex 
of ~21-25 basepairs (bp) [11]. The guide strand of the miRNA enters a multiprotein 
RNA-induced silencing complex (RISC) enabling it to bind to the 3′ untranslated region 
(3’UTR) of its target mRNA. Although either strand of the duplex may potentially act 
as a functional miRNA, one strand called “guide strand” or “antisense strand” is 
preferentially incorporated into the RISC complex. The selection of guide strand is 
highly influenced by the thermodynamic stability of 5’ and 3’ ends of Dicer products 
[12]. Generally, the strand with the lower 5’ stability will be preferentially loaded 
into RISC, while the other strand is degraded. The active components of the RISC 
complex are endonucleases called Argonaute proteins (Ago) and in human cells the 
Ago family consists of four Argonaute proteins (Ago1-4) [13]. It is known that only 
RISC association with Ago2 has the capability to cleave target mRNA, whereas Ago1 
association can mediate translational repression [12]. The process of loading Dicer 
substrates on different mammalian Agos in vivo is not well established and it is known 
that miRNA are not loaded into specific RISC-Ago complexes but can interact with 
any of them [12]. The RISC-Ago complex recognizes mRNA with the complementary 
target sequence and consequently induces cleavage or translational repression [14].  
The specificity of miRNA target recognition is primarily determined by the 
sequence from 2 to 8 nt from the 5′ end of the miRNA guide strand which is called the 




Figure 1. Endogenous RNAi pathway. (A) RNA Pol II or III transcribe the primary transcript of miRNA 
(pri-miRNA) (B) Microprocessor complex (Drosha-DGCR8) cleaves the single-stranded sequences 
flanking of pri-miRNA to produce pre-miRNA (C) pre-miRNA is exported with Exportin-5 from the 
nucleus to the cytoplasm (D) Dicer cleavage produces mature miRNA complex of ~21 bp. Dicer 
also processes exogenous dsRNA (E) miRNA guide strand (red) is incorporated into RISC, while the 
passenger strand (black) is degraded (F) Active RISC recognize target mRNA which in consequence 




therefore single miRNA is capable of regulating multiple cellular targets. Conversely, 
each gene can be controlled by several miRNAs [15].
RNA entering RNAi pathway can also originate from an exogenous source, for 
example during a viral infection [17,18], which -when processed- can also generate 
mature miRNA. By targeting viral mRNA this can inhibit the expression of crucial viral 
proteins and prevent the spread of the infections. In fact, RNAi does work effectively 
as an antiviral agent in plants and mammalian cells [19-21].  
RNAi therapeutics
Identification of the RNAi pathway structural components and intermediates initiated 
studies on the application of RNAi as therapeutics. The general idea is that by 
introduction of molecules that constitute substrates for the endogenous pathway, 
specific inhibition of disease-related mRNA can be induced and as a consequence 
reduction of disease-related proteins can be achieved. Therapeutic RNAi can be 
induced in different ways (Fig. 2). 
Therapeutic RNAi is generally induced by delivery of 20-25 nt-long small interfering 
RNAs (siRNAs) [22] which serve as substrates for the RISC complex (Fig. 2a). siRNA are 
chemically synthesized and can be delivered directly or by using chemical carriers: 
cationic lipids, cationic polymers or peptides to facilitate their penetration [23]. However 
siRNAs are rapidly cleared from the body and have to be re-administered weekly or bi-
monthly in order to induce long-term efficacy [24]. Poor uptake of exogenous nucleic 
acids by cells represents the major barrier to the development of siRNA-based drugs. 
To enhance intracellular uptake of nucleic acids for systemic administration, siRNA can 
be encapsulated within liposomes termed stable nucleic acid lipid particles (SNALP). 
Alternatively, siRNAs can be generated by embedding in a stem loop structure of 
short hairpin RNA (shRNA, Fig. 2b) [25], long hairpin RNA (lhRNA, Fig. 2c) [26-28] 
or artificial microRNA (miRNA, Fig. 2d) [29] and expressing from viral [30] or plasmid 
[31] vector for sustained gene silencing. After transcription all these have certain 
specific RNA structures: a central stem of variable length, a terminal loop region, and 
a single stranded RNA (ssRNA) region, being the characteristic features of endogenous 
substrates of RNAi machinery. These structures are recognized by Drosha and Dicer 
and serve as reference points for endonuclease digestions and processing into 
mature siRNA/miRNA. The guide strand of siRNA/miRNA that is embedded into RISC 
determines target recognition. Similar to endogenous miRNAs, siRNA, and shRNAs 
are not sorted into Ago-specific RISCs [12] yet, in contrast to cellular miRNA, siRNA 
and shRNA induce target mRNA cleavage rather than translational repression. The 
crucial difference between shRNAs, lhRNAs, and artificial miRNAs is in their tertiary 
structure, which determines the entry point, processing and finally functioning in the 




Table 1. Comparison of different approaches for inducing RNAi in cells
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bulge structure in their stem that at least partially can explain differences in their 
functioning. siRNA, shRNA and lhRNA are perfectly complementary to their targets, 
which induce degradation rather than translational repression.
Another important difference is the mechanism of transcription. shRNAs are generally 
expressed from constitutive polymerase III (pol III) promoters and directly generate a 
mature stem-loop product, which is exported and processed by Dicer [32]. Although 
shRNA can be expressed from pol II promoters [12,34-35], this has not been very 
successful due to inefficient processing of the hairpins by the RNAi machinery and the 
lack of detailed knowledge of the transcription start site (TSS), transcription termination 
signal (TTS), and hairpin location. Alternatively, siRNA can be expressed as a long hairpin 
RNA (lhRNA) in which the stem can be extended up to 300 bp and can incorporate 
multiple ~21 bp siRNA sequences. lhRNAs can be expressed with pol III or pol II promoters 
and undergo processing by Dicer [26,28,36]. In contrast to shRNA, miRNAs transcripts 
are generally expressed from pol II promoters that allow for the use of tissue-specific 
or regulated expression systems. They have additional flanking sequences adjacent to 
hairpin structure therefore miRNA processing requires an additional step of excision from 
the longer pre-miRNA sequence by the Drosha-DGCR8 complex [10,37]. miRNA can be 
expressed in clusters allowing expression of different siRNA, which can be used for viral 
infections or cancer, where multiple sequences have to be targeted [38].
There are advantages and disadvantages inherent to the various ways of inducing 
RNAi in cells and the choice greatly depends of the desired effect. Characteristic 
features of different RNAi systems are summarized in Table 1.
In addition to gene silencing, the intracellular RNAi machinery and miRNA expression 
profile can be used in other, more refined, therapeutic approaches. The genetic regulation 
by miRNA is important in the fundamental processes of cell growth and differentiation. 
Emerging studies showed evidence of quantitative and mutational changes in miRNA 
expression and their target binding sites, which promote the development and 




Figure 2. Induction of RNAi therapeutics in cells. RNAi induction in cells include resembles 
endogenous pathway. (A) RNA Pol II or III transcribe the primary transcript of shRNA, lhRNA and 
pri-miRNA siRNA can be delivered exogenously without transcription in nucleus (B) Microprocessor 
complex cleaves ssRNA flanking sequences of pri-miRNA to produce pre-miRNA (C) pre-miRNA, 
shRNA and lhRNA are exported via Exportin-5 from the nucleus to the cytoplasm (D) Dicer cleavage 
produce mature siRNA/miRNA complex of ~21 bp (E) siRNA/miRNA guide strand (red) is incorporated 
into RISC, while the passenger strand (black) is degraded.  (F) Active RISC recognizes target mRNA 





can restore normal functioning of cells [41,42]. This approach is intensively investigated 
to prevent or treat metastasis of cancer cells. Inhibition of particular miRNA’s resulting 
in inhibition of its target mRNA is a promising treatment for viral infections [40]. 
Additionally by incorporation in the 3′ UTR region of transgenes, an intracellular RNAi 
mechanism can be employed to regulate their expression in different cells [43,44]. In 
particular this approach is interesting for inhibition of transgene expression in non-
target cells because cells which are not expressing the particular miRNA will not inhibit 
expression. Hence, genetic regulation by endogenous miRNA is a promising strategy 
of avoiding immune responses to transgene (i.e. F.IX for hemophilia B) that are seen as 
“foreign” by the immune system of the patient lacking F.IX expression [45].
RNAi therapeutics in the liver
Despite the progress in understanding causes of many diseases, current therapies 
involving pharmacological and biological drugs only alleviate disease symptoms. 
Figure 3. Structure of (A) siRNA, (B) shRNA, (C) lhRNA and (D) miRNA targeting ApoB. 
Sequence and predicted structure for siApoB, shApoB, lhApoB and miApoB with the guide strand 




Inappropriate gene activity is being linked to a number of liver diseases and because 
RNAi controls gene expression at the level of RNA, a unique opportunity is being 
offered to stop the actual cause of diseases. Therefore, gene silencing in cells creates 
an entirely new horizon in the therapy of liver diseases allowing new treatment 
strategies to be developed.  Proof of concept for the therapeutic efficacy of RNAi 
has already been convincingly demonstrated in a number of preclinical models of FH, 
hepatitis, cancer and others. The key of RNAi approach success is mainly dependent 
on careful target selection, the RNA inducer used and a convenient delivery system. In 
this paragraph, a short description of disease etiology, conventional treatments and 
possible RNAi targets is given.
Familial hypercholesterolemia (FH)
FH is a genetic disorder characterized by high cholesterol levels in the blood, specifically 
very high levels of low density lipoprotein cholesterol (LDL-C) and early onset of 
cardiovascular disease [46]. The most common genetic defects in FH are mutations in 
genes that regulate for cholesterol homeostasis such as the LDL-C receptor (LDL-R) 
[47] and apolipoprotein B (ApoB), which is the part of LDL-C that binds with the 
receptor. Mutations in other genes including Proprotein convertase subtilisin/kexin 
type 9 (Pcsk9) or low density lipoprotein receptor adaptor protein 1 (Ldlrap1) in FH 
patients are rare [49-50], however they are also used as therapeutic targets in FH. 
Patients who have one abnormal copy of the mutated gene (heterozygous FH) have 
increased risk of cardiovascular disease, which can develop at age 30-40 [50]. Having 
two abnormal copies may cause severe cardiovascular disease onset early in the 
childhood [51]. Heterozygous FH is a common genetic disorder, occurring in 1:500 
people in most countries; homozygous FH is much rarer, occurring in 1 in a million 
births [52]. LDL-C normally circulates in the body for 2.5 days and subsequently 
binds to the LDL-R on the liver cells, undergoes endocytosis and is digested. As a 
consequence LDL-C is removed and de novo synthesis of cholesterol by the liver is 
suppressed in the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA) pathway 
[53]. When LDL-R function is reduced or absent, LDL-C circulates for an average 
duration of 4.5 days, resulting in significantly increased level of LDL-C in the blood 
with normal levels of other lipoproteins. The same effect is caused by mutations in the 
ApoB protein, where reduced binding of LDL-C particles to the receptor causes the 
increased level of LDL-C in plasma. Increased LDL-C circulation in blood increases the 
probability that it will be taken up by endothelial cells of vascular walls and through 
modifications such as oxidation will induce damage. This initiates immune system 
activation and a inflammatory cascade of events leading to arteriosclerosis plaque 
formation. Generally the type of FH determines the treatment that can be applied to 
a patient. Whereas the heterozygous form can be successfully treated with statins, 




treatment often fails to reduce LDL-C levels. Therefore homozygous FH was among 
the first monogenic diseases targets for treatments with RNAi and conventional gene 
substitution therapies. Recently, a single intravenous injection of an AAV8 vector 
containing the mouse LDL-R gene to a humanized mouse model of FH, the LDL-R-/- 
APOBEC-/- mouse, was found to significantly reduce plasma cholesterol levels in 
chow-fed animals [54]. In addition to the LDL-R gene augmentation approach, the 
successful use of the VLDL-R for the complementation of mutated LDL-R function in 
homozygote FH has also been shown [55]. As alternative strategy, inhibition of Pcsk9 
with siRNA has been shown to increase LDL-R levels in liver and in consequence 
reduce LDL-C levels [56]. However conventional gene therapy (resulting in LDL-R 
expression) and Pcsk9 inhibition is not suitable for FH patients that have ApoB 
mutations. In those cases RNAi can be used to target ApoB. In 2004, Soutschek et al. 
[57] showed silencing of ApoB in mice with systemically delivered modified siRNA, 
which was associated with reduction in plasma cholesterol.  Later, Zimmermann et al. 
showed siRNA mediated ApoB silencing in human primates [58], however the effect 
was stable only for up to 11 days. Albeit ApoB reduction by siRNAs was successful in 
lowering LDL-C levels in plasma, the effect was transient and treatment caused liver 
steatosis [57,58]. In order to achieve stable reduction of ApoB and in consequence 
LDL-C without the need to re-administration, siRNA has to be embedded in shRNA 
or miRNA scaffolds, expressed from a pol II or pol III promoters and delivered to the 
target cells by using an appropriate vector system. 
Alpha-1-antitrypsin deficiency (A1AD)
A1AD is a genetic disorder caused by defective production and secretion of alpha-1- 
antitrypsin (A1AT) from liver cells [59]. One of the A1AT functions is to protect the 
lungs from neutrophils’ elastase and consequently patients suffering from the disease 
develop emphysema. Because A1AT is not secreted properly from the liver, patients 
often also develop liver cirrhosis [60]. Circulating A1AT levels depend on the genotype 
and the most severe disease phenotype characterizes patients with PiZ mutation where 
only 10-15% of normal A1AT levels are present in blood [60,61]. Current treatment 
alleviates symptoms by infusions of isolated or recombinant A1AT protein; however 
some patients can be treated by simultaneous liver and lung transplantation. Since 
A1AD not only affects lung where levels are insufficient but also liver where mutated 
AAT accumulation leads to liver cirrhosis [62,63], gene therapy approaches should 
aim to both decrease levels of mutant A1AT and increase wild-type A1AT levels by 
expressing the correct version of the gene. Such an approach was implemented by 
Li et al., by delivering rAAV simultaneously expressing an shRNA, targeting mutated 
A1AT and an optimized A1AT cassette in mice expressing the human PiZ allele [64]. 
This resulted in inhibition of mutated A1AT and correction of wild type A1AT levels 




mice treated with rAAV vectors simultaneously expressing artificial miRNA targeting 
PiZ and codon optimized A1AT gene showed that serum PiZ level was stably reduced 
by an average of 80% [65]. In addition, decreased globular accumulation of misfolded 
Z-A1AT in hepatocytes and a reduction in inflammatory infiltrates in the liver were 
observed. Finally endogenous miRNAs were minimally affected by this treatment 
suggesting that miRNA mediated knockdown did not saturate the miRNA pathway.
Hepatocellular carcinoma (HCC)
HCC is the most common type of liver cancer. Most cases of HCC are secondary to 
viral infections or cirrhosis [66]. Prognosis and treatment depends on the stage of the 
disease, however ~70% of patients are diagnosed at intermediate and late stages when 
no curative treatment is available. These patients often develop multidrug resistance 
to chemotherapeutics due to overexpression of ABC family transporter proteins. 
Among them ABBC1 and ABBC2 are characterized for the liver and their implication in 
chemotherapy resistance is suggested [67]. Borel et al. showed successful inhibition of 
ABCC2 transporter in vivo by AAV delivered shRNA and artificial miRNA [68]. Despite 
effectiveness mice exhibited serious side effects due to oversaturation of endogenous 
RNAi machinery. Additionally, Borel et al. investigated panel of endogenous miRNA 
whose expression pattern change in hepatocellular cancerogenesis [69]. These miRNAs 
not only can be used as marker for disease’s prognosis but also by overexpression of 
miRNA which are downregulated, normal functioning of the cell may be restored i.e. 
restoration of mir-122 expression in liver cancer correlates with suppression of both the 
malignant phenotype and metastatic properties [70]. Restoring endogenous miRNA 
pathway can also improve response to chemotherapy as many of MDR transporter 
transcripts have been identified as miRNA targets [69,71,72].
Hepatitis B virus (HBV) infections
HBV infection is still a major health problem. Even though effective vaccines have 
been available for the last 20 years, worldwide, over 350 million people are infected 
with this virus [73]. Chronic HBV infections may have serious consequences, including 
liver cirrhosis and HCC; prevention of this infection is a key to then prevent the HCC 
[74]. HBV, which belongs to Hepadnaviruses, have small genome of 3,2 kb - partially 
double-stranded, partially single stranded circular DNA [75]. It contains four open 
reading frames (ORFs) that encode structural proteins of core, polymerase, surface 
and viral X protein. The core gene encodes the viral capsid protein, known as hepatitis 
B virus core antigen (HBsAg). Upon infection viral DNA is transported to the nucleus 
where is made completely double stranded and circular and serves as a template 
for transcription of four viral mRNAs. HBV is an excellent candidate for therapeutic 
RNAi, as its compact and overlapping transcripts can be simultaneously targeted with 




mutations. McCaffrey et al. showed 85% reduction in secreted HBsAg in mice plasma 
when HBV genome plasmid was delivered with a plasmid encoding shRNA targeting 
the HBV sAg [76]. Importantly, viral inhibition occurred in absence of active viral 
replication suggesting that this strategy is independent from viral replication thus can 
be used for treatment of chronic HBV infections. An alternative to anti-HBV shRNA 
cassettes involves utilization of pri-miRNA scaffold sequences [77]. This is an appealing 
strategy as multiple miRNA can be expressed from single transcripts and this approach 
has been already validated in vivo [78].  Another approach was used by Weinberg et 
al., who assessed the efficacy of lhRNAs targeting the conserved hepatitis B protein X 
(HBx) open reading frame of HBV [28]. After hydrodynamic injection in mice one of the 
lhRNA vectors decreased viral replication by 70–90% with no evidence of induction of 
an interferon response induction. RNAi therapy has a major disadvantage, being the 
inability to completely eliminate DNA genome, but it can complement conventional 
anti-HBV therapies by affecting multiple steps in the viral life cycle.
Hepatitis C  virus (HCV) infections
Like HBV, HCV is one of the major causes of liver morbidity and also a leading 
cause of liver transplantation, with around 170 million people infected [79]. HCV 
is small, enveloped member of family Flavividae [80]. Its genome consists of about 
9,6kb single stranded positive sense RNA, which is translated into large multiprotein 
complex and translationaly processed into the structural components of the virus. 
HCV is particularly attractive target for RNAi, which in theory can target not only 
the replicative forms but also genomic RNA templates and eventually lead to viral 
clearance. However due to the high mutation rate only highly conserved regions of 
the virus can be targeted to prevent escaping from RNAi activity [81]. As with HBV, 
HCV has been the target of both synthetic and expressed activators of the RNAi 
pathway and effective inhibition of markers of virus replication has been described in 
several studies. Yokota et al. used both synthetic siRNA and expressed shRNA effectors 
against the 5′-NTR (5’ Non translated region) and approximately 80% suppression 
was observed in a replicon model of the HCV [82]. Other studies also show that 
targeting HCV with RNAi can be promising strategy [83,84] and reviewed in [85]; 
however a major concern was raised about the ability of the virus to accumulate 
evading nucleotide sequence mutations [85]. A recent report showed emergence of 
resistant HCV RNAs after several treatments of replicon-expressing cultured cells with 
siRNA targeted against the NS5B coding region [86]. Resistant replicons remained 
sensitive to a siRNA that targets another part of the genome, suggesting that use 
of siRNA combinations limits evolution of escape. Recent studies also showed that 
modified lhRNAs comprising 50–100 bp were capable of silencing hepatitis C virus 
targets in cell culture [87-88]. Recently, an alternative strategy for inhibition of HCV 




mir-122 expression, which regulates HCV by binding directly to two adjacent sites 
close to the 5’ end of HCV RNA [89], Although the precise mechanism of regulation 
is not yet clear, inhibition of endogenous mir-122 function is a promising therapeutic 
approach. This can be accomplished by delivering single-stranded, modified RNA 
oligonucleotides complementary to miRNA guide strand, resulting in tight binding 
and efficient inhibition [90,91]. Santaris Pharma have developed drug- Miravirsen, 
which is a locked nucleic acid-based (LNA) antisense oligonucleotide to mir-122 
that is delivered to the liver with intravenous injection. This molecule reduced HCV 
replication in a small-scale trial in chimpanzees without inducing liver toxicity [90]. 
Hemophilia B
Hemophilia is caused by hereditary genetic disorders that impair the body’s ability to 
establish blood coagulation. The defect in blood clotting in hemophilia B is caused 
by the lack of functional clotting Factor IX (F.IX) as a result of mutations in the gene 
encoding this protein. As an X-linked recessive chromosomal disorder, almost all 
people living with haemophilia are male, while females are generally asymptomatic 
carriers of the mutated allele [92]. It occurs in around 1 in about 30,000 male births. 
F.IX deficiency leads to an increased risk for bleeding in response to mild trauma 
or even spontaneously, such as in joints (haemarthrosis) or muscles. Patients are 
grouped according to circulating levels of F.IX, which correlate closely with clinical 
severity. Plasma concentrations of F.IX of 5–25%, 1–5%, and <1% of normal levels 
refer to mild, moderate and severe hemophilia respectively. Protein replacement is 
the current standard of care. Frequent intravenous administrations (two to three 
times a week) of recombinant F.IX are required to stop or prevent bleeding. A goal 
for the treatment of hemophilia B is the development of a gene transfer strategy 
that can maintain sustained production of clotting F.IX in the liver, where it is 
normally produced. At present, gene transfer mediated by viral vectors delivering 
F.IX expressing cassette shows the greatest promise for long-term correction of 
hemophilia B in the preclinical setting [93-96]. Improvement of levels to above 1% 
is sufficient to prevent most spontaneous and nearly all life-threatening bleeding 
episodes [95]. Unfortunately, initial evaluation of viral vectors expressing F.IX  failed 
to achieve sustained F.IX expression in hemophilia B mice due to the recognition of 
F.IX as foreign antigen which resulted in anti-F.IX cellular immune response [97,98]. 
Further analysis suggested that this may be a result of off-target transgene expression 
in hematopoietic-lineage cells of the spleen which resulted in antigen presenting cells 
(APCs) maturation and activation of cytotoxic T lymphocytes (CTLs) [99,100]. As a 
consequence transduced hepatocytes were eliminated and expression diminished. 
To overcome this problem, a novel strategy that exploits endogenous miRNA 
activity to prevent vector expression in non-target cells has been developed [43,44]. 




specific microRNA, mir-142-3p in its 3’ UTR [45,101]. This allows expression in 
hepatocytes, while preventing F.IX production in hematopoietic cells- including 
APCs. By restricting transgene expression exclusively to the liver, while preventing 
F.IX production in hematopoietic cells including APCs, immunologic tolerance was 
induced. Importantly, analysis of miRNA revealed that the mir-142-3p–regulated 
vector did not affect the natural levels of expression of mir-142-3p or other miRNAs 
in either the liver or spleen. However these results are in opposite to F.IX gene 
transfer mediated by AAV vectors, which showed expression of clotting factor 
without inducing cellular response to transgene [96].  Interestingly expression 
of F.IX was limited by presence of anti-AAV immune response which probably 
eliminates transduced hepatocytes [102] while no anti-F.IX immune response was 
detected. Still this possibility has to be considered especially when strategies to 
overcome existing immune response to AAV will be applied (immune response to 
AAV is discussed in details in paragraph 7). Incorporation of mir-142-3p sites for 
transgenes expressed with AAV can be used as additional safety measure to prevent 
immune reaction and allowing long-term expression of transgenes.
RNAi toxicity
RNAi can interfere with normal functioning of cells and therefore safety is an important 
aspect of the implementation of RNAi based therapies. Non-specific effects resulting 
from the RNAi induction appear to have three separate mechanisms: innate immune 
response, off-target effects and oversaturation of the RNAi pathway. In addition, 
immune response to the delivery method can negatively contribute to the efficacy and 
safety of RNAi therapeutics. These side effects are often associated with severe toxicity 
that in some cases can be even fatal. In this chapter only RNAi toxicity and strategies 
to avoid them will be considered. Several toxicity issues involving response to the 
transgene or the RNAi inducer and the delivery vector will be described in paragraph 7. 
The first source of RNAi toxicity is related to activation of innate immune 
responses. It is now well established that RNAi therapeutics, in particular siRNAs 
can be potent inducers of interferon (IFN) and inflammatory cytokines both in vivo 
and in vitro [103]. Most often, the IFN response is caused by the activation of the 
dsRNA-dependent protein kinase R (PKR) leading to a global inhibition of protein 
synthesis [104]. However siRNAs with stem shorter than 30 bp were shown to evade 
PKR activation [105]. Another mechanism which leads to activation of inflammatory 
cytokines goes via Toll-like receptor (TLR) activation [106,107]. TLRs are activated by 
molecules referred to as pathogen-associated molecular patterns (PAMPs). PAMPs are 
normally not present in cells but commonly shared by pathogens. TLR3 recognizes 
dsRNA and poly I:C [108], whereas TLR7 and 8 can recognize small ssRNA [109,110]. 




activate early response genes and genes encoding cytokines [107]. TLR activation by 
RNAi therapeutics leads in consequence to activation of immune response. Activation 
of the immune system by siRNAs is sequence-dependent as U and GU rich regions 
seem to be preferentially recognized by TLR [110]. Therefore, chemical modification 
of siRNA can prevent the recognition by the immune system [111]. It has been shown 
that modification of 2’ ribose with 2’-O-methyl, 2’fluoro-, 2’deoxy- or locked nucleic 
acid can reduce immune stimulation [110]. Although immunostimulatory side effects 
must be taken in account when inducing RNAi, for certain applications i.e. cancer or 
viral infections, activation of the immune system can be beneficial.
A second source of RNAi toxicity is off-targeting, when non-targeted transcripts 
are down-regulated based on sequence complementarity to sh/miRNA seed sequences 
[112]. Because of the complexity of sh/miRNA processing and RISC loading these 
unanticipated interactions are difficult to evaluate. However off-targeting can be 
minimized by adopting a stringent design filter both for sense and antisense strands 
of the RNAi efector molecules. Most off-target effects appear to be due to miRNA-
like targeting, which is not detected by BLAST and therefore algorithms with high 
sensitivity such as Smith-Waterman should be included in this design [113,114]. 
This includes computing the distribution of unique shRNAs/miRNA targets in the 
transcriptome to avoid three or fewer matches with other than target genes. Seed 
sequence complementary to other genes should also be avoided and, as mentioned 
before, the selection criteria should include both sense and antisense strands. This 
is particularly important when miRNA are used because sense and antisense strands 
are not always identical and may contain bulges and G:U wobbles (Fig. 2 and 3). 
Hence, consequence off-targets for both stands can be different. The use of siRNA 
from hairpin constructs (shRNA, lhRNA, miRNA) provides additional complexity and 
imposes additional risk factors as the cleavage sites of sense and antisense strands 
slightly differ, resulting in production of a family of siRNAs with different 5’ and 3’ 
ends. Another serious consideration during sh/miRNA design is strand selection which 
should lead to preferential loading of the guide strand into the RISC. Although both 
strands of the siRNA can be incorporated into RISC, strand selection seems to follow 
the thermodynamic asymmetry rule in which the strand with the less stable 5’ end 
is incorporated into RISC [115,116]. The unwanted passenger strand functionality 
can be decreased by introduction mismatches at certain positions of the passenger 
strand [117]. There are other approaches to minimize off-targeting for example by 
reducing the concentration of the RNAi inducing agent. This strategy originated from 
observations that off-target effects are concentration dependent [118]. Dose reduction 
may cause a loss of RNAi efficacy and this can be solved by using siRNA pool against 
different sequences of the same target [111]. Chemical modification of nucleotides of 




off target effects [115,116]. Modifications should include both strands of the siRNA: 
sense being loaded into RISC and antisense binding to off-targets. Similarly for 
shRNA and miRNA passenger strand’s interaction with endogenous transcripts can be 
minimized by expressing the so called “sponge” transcript containing complementary 
binding sites for the passenger strand. When the passenger strand is loaded into RISC, 
the complex will bind to sponge transcript instead of endogenous target [119].
A third toxicity aspect is oversaturation of the natural RNAi pathway. Introducing 
RNAi agents which make use the endogenous RNAi pathway and substitute intermediate 
products can create competition with the endogenous miRNA processing [68,120,121]. 
High expression levels of therapeutic shRNA or artificial miRNA can saturate the 
endogenous RNAi machinery and in consequence lead to deregulation of the complex 
miRNA network. As referred in paragraph 3, shRNAs are generally expressed from pol 
III promoters, which provide constitutive high expression levels necessary for potent 
knockdown of target mRNA. Although these features are valuable for research purposes, 
they can be disadvantages for therapeutic applications. It has been reported that pol 
III-expressed shRNA can lead to severe toxicity when high doses are used [68,121,122]. 
Grimm et al. observed liver failure and mortality in mice injected with different AAV-
expressed shRNAs irrespective of hairpin length, sequence and target [121]. Toxic side 
effects were associated with saturation of the cellular RNAi machinery and changes 
in endogenous miRNA expression. Using lower doses of vectors encoding shRNA may 
circumvent toxicity but this may result in loss of RNAi silencing and therapeutic efficacy 
[123]. Alternatively, toxicity resulting from shRNA overexpression can be resolved by 
embedding the siRNA sequence into an artificial miRNA scaffold and expressing it from 
weaker pol II promoters [124,125]. Incorporation of a siRNA sequence in an artificial 
miRNA scaffold has been shown to abolish shRNA-induced neuronal cell death and to 
avoid disruption of the endogenous RNAi pathway [29,123]. However, in some cases 
miRNA were found to be less potent compared to shRNA [126]. Another disadvantage 
of pol III-expressed shRNAs is their constitutive expression in all cell types and organs. 
In order to limit their expression to target organs, the use of tissue-specific promoters 
has been applied for shRNA [34,35]. Unfortunately, this has been achieved with limited 
success as the rules for efficient transcription of shRNA from poll II promoters are 
poorly understood and these constructs show only mild knockdown efficacy. Others 
have used inducible systems regulated by tetracycline or by ecdysone for expression 
of shRNA or artificial miRNA, which allows time- and dose-dependent expression 
when the inducer is administered and no expression in its absence [127-130]. Proof 
of concept has been established in transgenic mice enabling inducible and reversible 
suppression of gene expression by a tetracycline-regulated shRNA which also resulted 
in phenotypic changes [128]. The applicability of such systems in preclinical and clinical 




regulatory proteins that are potentially immunogenic and inducer molecules that need 
to be safe for long-term applications.
Adeno-associated virus (AAV) delivery
Among the different options of vehicles for delivery of genetic material to living 
organisms, viruses seem to be a vector of choice because of their natural ability to 
infect cells. The majority of vectors used in clinical trials are engineered human or 
animal viruses including adenoviruses, AAV, herpes simplex virus, lentiviruses and 
retroviruses [131]. Adeno-associated viruses with their unique properties have been 
shown to be a very promising gene-therapy vector for many genetic diseases [132].
AAV is member of the Parvoviridae family with a small single stranded genome 
of around 4,7kb [133]. The genome encodes structural proteins of capsid (CAP) 
and replication machinery (REP) flanked by 145 bp inverted terminal repeats (ITRs). 
After cell infection AAV escapes endosomes or lysosomes and the genetic material 
translocates to the nucleus. After entry into the host cell nucleus, AAV can follow 
either one of the two distinct and interchangeable pathways of its life cycle: the lytic 
and the lysogenic. The lytic cycle develops in cells infected with a helper virus such 
as adenovirus or in response to DNA damage. When only AAV infects a human cell 
the lysogenic program is executed and the virus integrates preferentially into the long 
arm of chromosome 19 (referred as AAVS1) and less frequently into chromosome 5 
or chromosome 3 [134,135]. This process is mediated by the REP proteins. During the 
latency, virus gene expression program is repressed [136]. When a latently infected 
cell is super-infected with a helper virus or DNA repair machinery is activated, the 
AAV gene expression program is activated leading to the excision of the provirus DNA 
from the host cell chromosome, followed by replication and packaging of the viral 
genome [137,138]. Finally infected cells are lysed and viruses are released. By replacing 
endogenous AAV genome with gene of interest flanked by ITRs and delivering in 
trans components for REP and CAP production, recombinant AAVs (rAAV) can be 
produced. Removal of CAP and REP genes alters AAV ability to specifically integrate in 
genome; instead the AAV genome forms concatamers which remain episomal [139]. 
However, recent research shows that integration of rAAV may occur at a very low level 
[140]. AAV has several advantages over other viral vectors [141]. AAV naturally infects 
humans and primates - up to 80% are thought to be seropositive for AAV2 [142] but 
importantly, AAV is not known to cause any disease. AAV vectors induce mild (cellular 
as well as humoral) immune responses, which are an important aspect of AAV-based 
gene therapy which will be discussed in more detail later. Based on cross-reactivity of 
neutralizing antibodies, different AAV serotypes can be distinguished [143]. A new 
AAV serotype is described when neutralizing antibodies for other virus types cannot 




however some of the serotypes fail to meet the cross-reactivity requirement i.e. AAV6 
can cross-react with AAV1 while AAV10 and AAV11 are not fully characterized [143]. 
Furthermore there are number of AAV variants for which serological data are not 
available. Each AAV serotype has diverse tissue tropism and therefore specific tissues 
can be targeted by using a particular AAV serotype. Another interesting approach is 
to generate hybrid viruses or create new serotypes in order to change tissue tropism 
or overcome pre-existing or acquired antibody response [144]. Tissue specificity is 
determined by the capsid composition and expression of AAV receptors, however 
apart from AAV2 all other serotypes’ receptors are not very well characterized. 
The most common organ transduced by AAV following tail-vein injection in 
mice is liver. Biodistribution studies of different AAV serotypes vectors demonstrated 
superiority of some AAV serotypes in the context of liver targeting [145]. AAV 
serotypes that preferentially target mice hepatocytes after tail-vein injection are 
serotypes 1, 2, 5, 6, 7, and 8 [145]. Among them AAV7 has the strongest tropism 
to the liver, followed by AAV6. AAV1, 2, and 5 transduce also preferentially the 
liver, however with lower efficiency compared to AAV7 and AAV6. Additionally AAV8 
and AAV9 demonstrate robust expression in the liver; however they also transduce 
other tissues more ubiquitously [145]. It is extremely important to understand that 
tissue specificity is species-specific and vectors which transducer murine liver do not 
necessary transduce human liver with the same efficiency. 
Immune response to AAV capsid or the transgene
Side effects associated with gene therapy can originate from different sources and in the 
case of gene silencing; the outcome may be a combination of toxicity resulting from both 
RNAi and the delivery vehicle. rAAV has been shown to stably express many genes in vivo 
[146]. Surprisingly initial studies in humans led to identification of immune responses 
not to the transgene but to the AAV capsid [102]. A complete understanding of the 
interactions of rAAV with the immune system is pivotal for all gene therapy applications 
and both innate and adaptative immune responses should be taken into account.
In contrast to dsRNA, AAV does not appear to be recognized by any pattern 
recognitions receptors such as TLR [147] and AAV does not activate the classical 
complement reaction [148]. Nonetheless AAV virus interacts with complement and it 
is likely that it can be coated with serum opsonins [148]. AAV capsid has been shown 
to co-precipitate with factors H and C3b of the complement and it is likely that the 
mechanism by which AAV abrogates innate response involves conversion C3b into 
iC3b. AAV particles opsonized with iC3b are subject to adherence to other immune 
cells such as B-cells, which enhances their response and neutralizing antibody 
production. Most humans display naturally acquired neutralizing antibodies to AAV 




Another important aspect is the cellular response to AAV [142], which is mounted 
after the presentation of AAV derived antigen by mature presenting cells in lymph 
nodes to T cells. The manner in which the antigen is presented and the nature of the 
antigen itself determines the activation of antigen specific T cells. Antigen presentation 
can occur in two distinct manners: Antigens that are endogenously generated by the 
cellular machinery are presented on the Major histocompatibility complex (MHC) class I 
molecules which are present on all nucleated cells. Proteins exogenous to the cells are 
presented in context of MHC class II molecules exclusively on APC after phagocytosis or 
endocytosis of the pathogen [149]. During AAV infection, virus-derived antigens can be 
presented by APCs on both MHC class molecules. Opsonized AAVs can be phagocyted by 
APCs [150] and antigens will presented on MHC class II molecules. However it does not 
lead to CTL response as the iC3b and factor H influence APC chemokines and cytokies 
microenvironment. Additionally APCs are not natural targets of AAV which minimizes 
presentation of AAV derived antigens on MHC class I molecules. However, exogenous 
antigen can also be presented on MHC class I molecules via cross-presentation. Cross-
presentation is the predominant mechanism by which AAV induces T cell immune 
response. Co-administration of an immunosuppressive regimen with AAV injection can 
be a good option to impede immune response to AAV [151,152]. It was shown that 
short-term immunosuppression did not lead to toxicity and does not interfere with AAV 
transduction of hepatocytes [152]. Application of immunosuppression prior injection 
may provide a solution for patients with pre-existing antibody response to AAV or for 
re-injecting patients with the same rAAV serotype as this strategy has already been 
validated in animal models [153,154]. 
Overview
Safe and long-term expression of siRNA is necessary for the treatment of patients with 
liver diseases that fail to respond to conventional treatment. This thesis addresses 
important questions about delivery of RNAi therapeutics to the liver, the efficacy 
of gene silencing and possible side effects. These aspects were considered in terms 
of constitutive and inducible expression of RNAi therapeutics in liver (Fig. 4). First, 
we show that ApoB can be inhibited in vivo using AAV vectors delivering shRNA 
expressed from pol III promoters. By inhibiting ApoB, a stable reduction of total plasma 
cholesterol and LDL-C was achieved. To minimize possible toxic effects caused by 
shRNA overexpression pol II-driven expression of shRNA was optimized and compared 
to artificial miRNA expression in vitro. As the latter appeared to be more potent, an 
artificial miRNA construct targeting ApoB was developed, allowing expression from 
the weaker liver-specific LP1 promoter. Subsequently the long-term efficacy and safety 
of shApoB and miApoB was assessed in vivo. Initially both shApoB and miApoB were 





































































































































































































of total cholesterol. Surprisingly, the effect diminished over the time over the course 
of 27 weeks and the loss was associated with virally delivered DNA loss. To address 
this issue we investigated liver function and morphology 8 weeks post injection with 
AAV encoding shApoB or miApoB. We showed differences in processing of shApoB 
and miApoB, which may have serious implications for RNAi therapy of liver diseases.
A second part of this thesis was to investigate the possibility of regulated 
expression using two separate approaches: inducible expression of artificial miRNA 
and transgene regulation using endogenous miRNA. We have shown expression of 
miRNA targeting ApoB using the GeneSwitch inducible system which allowed time-
dependent expression of siApoB when the inducer was administered and no expression 
in its absence. A detailed analysis of the inducible promoter was performed in order 
to optimize induction rate and minimize leakiness. We also optimized an expression 
cassette for inducible expression of miRNA, combining two structural components 
of the GeneSwitch system. This is important safety measure to avoid possible side-
effects resulting from miRNA overexpression.
In this thesis we discuss future developments of RNAi-based gene therapy strategies 
for liver diseases and their potential for clinical applications. Particular emphasis is put 
on safety issues of the different strategies for RNAi induction in cells. Some of these 
topics including tissue specific expression of artificial miRNA and in a detailed analysis 
of in vitro processing have never been previously investigated, but can have serious 
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Abstract
Serum low-density lipoprotein cholesterol (LDL-C) levels are proportionate to the risk 
of atherosclerotic cardiovascular disease. In order to reduce serum total cholesterol and 
LDL-C levels in mice, RNA interference was used to inhibit expression of the structural 
protein of LDL-C, apolipoprotein B100 (ApoB). We developed and screened 19 short 
hairpin RNAs targeting conserved sequences in human, mouse, and macaque ApoB 
mRNAs (shApoB) and subsequently narrowed our focus to one candidate for in vivo 
testing. Self-complementary adeno-associated virus serotype 8 (scAAV8) was used 
for long-term transduction of murine liver with shApoB. A strong dose-dependent 
knockdown of ApoB mRNA and protein was observed, which correlated with a 
reduction in total cholesterol levels, without obvious signs of toxicity. Furthermore, 
shApoB was found to specifically reduce LDL-C in diet-induced dyslipidemic mice, 
while high-density lipoprotein cholesterol (HDL-C) remained unaffected. Finally, 
elevated lipid accumulation was shown in murine liver transduced with shApoB, a 
known phenotypic side effect of lowering ApoB levels. These results demonstrate a 
robust dose-dependent knockdown of ApoB by AAV-delivered shRNA in murine liver, 
thus providing an excellent candidate for development of RNAi-based gene therapy 
for the treatment of hypercholesterolemia. 
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Introduction
Elevated levels of serum total cholesterol and low-density lipoprotein cholesterol (LDL-C) 
are major risk factors and contributors to the development of atherosclerosis and 
cardiovascular disease (CVD). Currently, hydroxymethylglutaryl coenzyme A reductase 
inhibitors (statins) are the preferred pharmacologic agents for hypercholesterolemia 
treatment due to their superior efficacy in lowering LDL-C, proven ability to reduce 
CVD morbidity and mortality, and a low incidence of adverse events. However, statins 
are not uniformly effective in all patients and some patients can be relatively refractory 
to treatment due to absent or diminished LDL-C receptor activity [1]. Furthermore, 
ten to fifteen percent of patients are unable to take statins due to intolerable 
muscle symptoms like myalgias, myositis, or mitochondrial injury [2]. Thus, effective 
therapeutic alternatives with a different mechanism of action are needed. 
Apolipoprotein B (ApoB) is required for the assembly of lipoprotein particles and 
is a constituent of all classes of lipoproteins that are considered atherogenic [3]. 
ApoB exists in two isoforms, ApoB100 and ApoB48, which are transcribed from a 
single gene. ApoB100 is the full-length ApoB protein and is synthesized by the liver. 
It forms the structural protein in very low-density lipoprotein cholesterol (VLDL-C) and 
LDL-C particles, which are essential for the transport and metabolism of cholesterol. 
ApoB48 contains the amino-terminal 2152 amino acids of ApoB100 as a result of 
ApoB mRNA editing which yields an early stop codon. In humans, ApoB is edited 
solely in the small intestine where ApoB48 plays a role in dietary fat absorption as 
part of chylomicrons. By contrast, some species such as mice and rats also edit ApoB 
in their liver and hence synthesize both ApoB100 and ApoB48 [4]. 
Elevated ApoB levels correlate with increased risk of coronary artery disease [5]. 
As a large, lipid-associated protein, ApoB belongs to the so-called “non-druggable” 
targets, which are not amenable to conventional therapies. However, ApoB is a highly 
validated target for treatment of increased LDL-C levels and subsequent CVD [6]. 
An approach targeting ApoB with second-generation antisense oligonucleotides 
(ASO) has progressed into Phase III clinical trials for treatment of homozygous familial 
hypercholesterolemia [6]. Another therapeutic approach that holds great promise for 
silencing ApoB is based on RNA interference (RNAi). 
RNAi is an evolutionary conserved sequence-specific post-transcriptional gene 
silencing mechanism in eukaryotes that results in the degradation of mRNA and 
subsequently in decrease of protein synthesis [7]. Therapeutic RNAi can be induced 
by synthetic small interfering RNAs (siRNA) or by intracellular expression of short 
hairpin RNAs (shRNAs) and artificial microRNAs (miRNA) that target a disease-causing 
gene [8,9,10]. shRNAs are typically expressed from a constitutive strong polymerase 
III (pol III) promoter, and are processed intracellularly by Dicer, rendering a mature 
siRNA which interacts with the cytosolic multiprotein RNA-induced silencing complex 
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(RISC). The RISC-incorporated siRNA binds to the complementary mRNA sequence 
and mediates its sequence-specific degradation [11]. 
The largest obstacle in using synthetic siRNAs as therapeutics in vivo is the need 
for efficient and specific delivery to target cells and organs. Chemical modifications 
and conjugations resulting in lower effective dose and longer half-life of the siRNA 
have improved their efficacy [12,13]. Chemically modified ApoB-specific siRNAs, when 
delivered systemically, can silence ApoB expression up to 90% in murine liver [8,14,15]. 
Inclusion of siApoB in liposomal formulations is another highly effective approach for 
ApoB silencing in the liver [16]. However, even with current improvements, siRNAs 
need to be delivered monthly or bi-monthly, which is not achievable for many diseases, 
especially in the brain, eye, heart, or other internal organs. An alternative for delivery 
of small RNAs is administration of a single dose of recombinant viral vectors based on 
lentivirus or adeno-associated virus (AAV), which yield long-term expression [17,18]. 
The latter holds a unique set of advantages over other vector systems, including the 
complete lack of pathogenicity and low immunogenicity [19]. AAV induces efficient 
and long-term transduction of non-dividing cells, an important facet for liver-based 
gene therapeutic strategies [20]. Unlike the use of synthetic siRNA molecules, AAV 
gene therapy allows long-term efficacy with a single dose. 
In this study, we evaluated the potential of AAV-delivered shRNA for long-term 
silencing of ApoB in murine liver. A single intravenous injection of AAV-shA10 resulted 
in prolonged ApoB knockdown with no obvious signs of toxicity, concomitant with a 
reduction in plasma cholesterol levels. In addition, in mice fed on an atherogenic diet 
there was a significant reduction of LDL-C, while high density lipoprotein cholesterol 
(HDL-C) levels remained unchanged. 
Results
Design and validation of shRNAs targeting conserved ApoB sequences 
Three conserved regions in the last exon of the human, macaque, and mouse ApoB 
mRNA sequences were selected to design 19 anti-ApoB shRNAs. shApoB expression 
plasmids (A1-A19) were constructed with the H1 pol III promoter based on a 
19-nucleotide target sequence (Table S1). Some of the shRNAs were targeting partly 
overlapping sequences. For example, shRNAs A9 to A14 were designed by sliding 
the ApoB target sequence with one nucleotide. All shRNA sequences had identical 
five-nucleotide loop sequences and the top two basepairs of the pSuper system, and 
ended with a 3’ UU overhang derived from the pol III termination signal. 
To evaluate the suppressive activities of the 19 shApoB constructs in vitro, we 
co-transfected them in HEK293T cells with renilla luciferase reporter constructs 
containing the last ApoB exon in the 3’UTR (Luc-ApoB). An shRNA construct targeting 
GFP was included as a negative control and firefly luciferase expression was measured 
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to control for transfection efficiency. Firefly and renilla luciferase expression were 
measured two days post-transfection and their ratio was used to calculate the relative 
luciferase activity. The renilla/firefly ratio in the presence of shGFP was set at 100% 
(Fig. 1a). Four shApoB constructs (A9, A10, A14, and A15) were highly effective 
and inhibited relative Luc-ApoB expression more than 75%. Ten shApoB constructs 
(A4, A5, A6, A7, A11, A12, A16, A17, A18, and A19) showed moderate activity 
and induced 50-75% inhibition of Luc-ApoB. The remaining shApoB constructs were 
not active. Interestingly, A13 was inactive, whereas the following shRNA construct 
A14 was highly active, indicating that a single nucleotide shift can render an shRNA 
ineffective. In total, one out of five tested shApoB constructs was highly active against 
the Luc-ApoB reporter.
The ability of several shApoB constructs to knockdown endogenous ApoB was 
assessed in vitro. The mouse hepatoma Hepa 1-6 and human hepatoma Huh7 cell 
lines were transfected with the highly active shApoB constructs A9, A10, A14, 
and the intermediately active A4, A5, A17, and A18 constructs. As a negative 
control the shGFP construct was transfected. The three highly active shApoB 
constructs inhibited murine endogenous ApoB mRNA by approximately 60% while 
the others were less effective (Fig. 1b). Similar results were obtained for human 
ApoB knockdown in the Huh7 cell line (data not shown). Generally, the inhibitory 
effect of the shApoB constructs on endogenous ApoB showed a similar trend to the 
Luc-ApoB knockdown results. 
The highly active shApoB construct A10 (shA10) was selected for further analysis, 
and siRNA expression from this construct (siA10) was determined in vitro. HEK293T 
cells were transfected with increasing amounts of shA10 plasmid, and two days 
post-transfection total RNA was isolated and siA10-specific small RNA Taqman assay 
was performed (Fig. 1c). To calculate the copy number per cell, we used a standard 
line based on serial dilutions of the guide strand from a synthetic siA10 RNA oligo. 
Increasing the amount of transfected shA10 construct clearly correlated with an 
increase in expression of siA10 (Fig. 1c). For example, transfection with 5 ng and 
100 ng shA10 construct resulted in approximately 125 and 970 siA10 copies per cell, 
respectively. Having established a good correlation between shA10 activity and siA10 
expression in vitro, we proceeded to test the in vivo efficacy of this shRNA construct. 
Efficient shRNA-mediated knockdown of ApoB and decrease of cholesterol 
in vivo 
To test the in vivo efficacy of shA10, self-complementary AAV serotype 8 (scAAV8) viral 
vectors were produced encoding anti-ApoB shA10 or a control shScramble (shScr). 
C57BL/6 mice were injected via the tail vein with scAAV8-shA10 (AAV-shA10) or the 
control vector scAAV8-shScramble (AAV-shScr) at four different concentrations: 108, 
109, 1010, and 1011 genome copies (gc) per animal. Two weeks after injection, mice 
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Figure 1. Inhibition of Luc-ApoB reporter and endogenous ApoB mRNA by shApoB constructs 
in vitro. (a) Luc-ApoB knockdown efficiency of anti-ApoB shRNAs expressed from the H1 promoter. 
HEK293T cells were co-transfected with 10 ng Luc-ApoB reporter and 50 ng different shApoB 
constructs (A1-A19). The shGFP construct was used as a negative control. Two days post-transfection, 
firefly and renilla luciferase expression was measured. Renilla luciferase expression was normalized 
to firefly luciferase expression and shGFP-treated cells were set at 100%. (b) Endogenous ApoB 
mRNA knockdown by shApoB constructs A4, A5, A9, A10, A14, A17, and A18. The shGFP construct 
was used as a negative control. Hepa 1-6 cells were transfected with 1 µg shApoB construct. Two 
days post-transfection, RNA was isolated and qRT-PCR was performed with ApoB- and actin-specific 
primers. ApoB mRNA levels were calculated relative to actin mRNA and shGFP-treated cells were 
set at 100%. (c) Small RNA Taqman detection of siA10 expression from shA10. HEK293T cells were 
transfected with 1, 5, 10, 50, 100, and 250 ng A10 expression construct. Two days post-transfection, 
RNA was isolated and siA10 Taqman was performed. The transfected amount shA10 correlates well 
with siA10 expression (R2=0.997). Data are represented as mean values ±SD from a representative 
experiment conducted with three technical replicates. Luc, luciferase; ApoB, apolipoprotein B100; 
shApoB, short hairpin RNA against apolipoprotein B100; shGFP, short hairpin RNA against green 
fluorescent protein; Hepa 1-6, hepatoma; siA10, small interfering RNA against apolipoprotein B100. 










































































































































































































































































were sacrificed and liver and plasma were analyzed for ApoB knockdown. A dose-
dependent increase in AAV transduction efficiency was demonstrated by monitoring 
GFP fluorescence intensity and GFP mRNA expression in the liver (Figs. 2a and S1), 
and this correlated with a dose-dependent increase in siA10 and siScr expression 
(Fig. 2b and data not shown). ApoB mRNA expression in the liver was strongly 
reduced by administration of increasing doses of AAV-shA10 and reached up to 95% 
knockdown compared to PBS-injected controls at the highest administered AAV dose 
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(Fig. 2c). In contrast, the AAV-shScr control vector did not affect ApoB mRNA levels, 
apart from an unexpected inhibitory effect at the highest dose of 1011 gc. 
To compare the effect of AAV-shA10 on ApoB mRNA with changes in ApoB 
protein levels, we assayed plasma and liver ApoB protein levels by Western blot at 
two weeks post-transduction. AAV-shA10 strongly reduced secreted ApoB100 in a 
dose-dependent manner, while AAV-shScr did not affect ApoB100 protein expression 
(Fig. 2d). Similar results were observed for liver ApoB100 protein knockdown (data 
not shown). In mice, unlike humans, 60-70% of hepatic ApoB mRNA is edited 
to form truncated ApoB48. Similar to ApoB100, we found that ApoB48 protein 
levels in plasma and liver were reduced (Fig. 2d and data not shown).These results 
indicate that a single AAV-shA10 dose achieves a potent knockdown of ApoB mRNA 
and protein in murine liver and plasma. Furthermore, knockdown of ApoB was 
associated with changes in total cholesterol levels. Being the structural protein of 
LDL-C, lowering of ApoB is expected to reduce cholesterol levels. Indeed, dose-
dependent ApoB knockdown correlated tightly with reduction in total cholesterol 
levels, resulting in a maximal cholesterol decrease of 79% compared to PBS-treated 
controls (Fig. 2e). Profiling of cholesterol distribution over the lipoprotein subclasses 
revealed a major reduction in HDL-C by AAV-shA10, concomitant with a decrease in 
VLDL-C and LDL-C levels (Fig. 2f). 
AAV-shA10 administration does not cause severe toxicity in mice
It has been reported that high levels of shRNA expression can lead to severe liver 
toxicity symptoms like weight loss, activation of liver-specific transaminases, changes 
in liver morphology, or oversaturation of the cellular miRNA machinery [21]. We 
monitored alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
levels two weeks post-transduction with AAV-shA10 and AAV-shScr and observed no 
significant increase in liver transaminases for the lower viral doses of 108, 109, and 
1010 gc per animal. However, the group injected with 1011 gc AAV-shScr per animal 
showed a ten- to thirty-fold increase in ALT and AST levels, indicating liver damage 
(Fig. 3a). AAV-shA10 injection at a dose of 1011 gc per animal gave rise to a two- to 
five-fold increase in liver transaminases (Fig. 3a). Histological analysis of liver sections 
revealed no gross changes in liver morphology except for the 1011 gc AAV-shScr dose 
where abnormal morphology was observed (Fig. S2). 
shRNAs and miRNAs share the same processing pathway and nuclear export 
machinery and overexpression of shRNAs can modify the processing of cellular 
miRNA transcripts [22]. We investigated whether high expression of shRNA in the 
liver competes with the intracellular processing of miRNAs. mir-122 was selected 
because it represents 70% of all liver miRNAs and is expressed almost exclusively 
in the liver [23]. mir-122-specific Taqman analysis was performed on RNA samples 
isolated from mice two weeks after administration of increasing doses of AAV-shScr 
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Figure 2. AAV-delivered shA10 strongly inhibits ApoB and plasma cholesterol levels two 
weeks post-transduction. Mice were intravenously injected with 108, 109, 1010, and 1011 gc 
AAV-shA10 or control AAV-shScr per animal. Two weeks after transduction, animals were sacrificed 
and liver and plasma were collected for analysis. (a) Representative image of GFP fluorescence in 
picric-acid fixed liver, which was transduced with 108, 109, 1010, or 1011 gc AAV-shA10 per animal, 
co-expressing GFP under control of the liver-specific LP1 promoter. Nuclei were visualized in blue 
by staining with Hoechst. Photos were taken using the same exposure and magnification settings. 
Scale bar=10 μm. (b) Small RNA Taqman detection of siA10 expression from liver transduced with 
108, 109, 1010, or 1011 gc AAV-shA10 per animal. Total RNA was isolated from snap-frozen livers 
and siA10-specific Taqman was performed. (c) Relative ApoB mRNA expression in transduced liver. 
Total RNA was isolated from snap-frozen liver tissue and qRT-PCR was performed with ApoB- and 
actin-specific primers. ApoB mRNA levels were calculated relative to actin mRNA and the PBS-treated 
group was set at 100%. (d) Western blot analysis of secreted ApoB100 and ApoB48 protein in 0.1 
μL plasma. ApoB protein was detected using a polyclonal anti-ApoB antibody, and antibody binding 
was visualized by a chemiluminescence detection kit. (e) Total cholesterol levels in plasma collected 
from fasted mice. Cholesterol levels were analyzed on the automated clinical chemistry analyzer 
Modular Analytics P800 from Roche. (f) Plasma cholesterol distribution over lipoprotein subclasses in 
FPLC-separated pooled plasma from mice injected with 1011 gc AAV-shA10 or AAV-shScr per animal. 
Data are represented as mean ±SE, treatment groups are n=5. gc, genome copies; AAV-shA10, 
adeno-associated virus expressing short hairpin RNA against apolipoprotein B100; AAV-shScr, adeno-
associated virus expressing short hairpin RNA scramble; GFP, green fluorescent protein; LP1, liver-
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and AAV-shA10. Expression profiles revealed that there was no significant decrease in 
mir-122 expression except for the group transduced with 1011 gc AAV-shScr per animal 
(Fig. 3b). In this group, mir-122 expression decreased more than 50%. Therefore, 
we analysed for increased expression levels of AldoA, Bckdk, and Ndrg3, because 
these genes have been reported as target genes of mir-122 [24]. Gene expression 
was not significantly affected in murine liver transduced with 1011 gc AAV-shScr 
or AAV-shA10 (Fig. S3). We further monitored the expression of the less abundant 
liver miRNAs let-7a and mir-29a (Fig. 3b). The expression profile of these miRNAs 
was similar to mir-122, indicating that there were no severe toxic effects induced by 
AAV-shA10 or AAV-shScr. Finally, the level of induction of markers of the interferon 
response (STAT1, TNFα, IFNβ, IFNγ) was examined by qRT-PCR on RNA isolated from 
murine white blood cells one week after viral administration. No significant induction 
of the interferon-pathway genes was observed upon viral administration indicating 
lack of shRNA toxicity at this time-point (data not shown).
ApoB knockdown results in fat accumulation in murine liver
ApoB suppression results in decreased cholesterol levels due to impairment of 
VLDL-C and LDL-C assembly, but can also lead to hepatic triglyceride accumulation. 
Triglycerides are normally incorporated into VLDL-C, and hepatic accumulation 
of these lipids can potentially cause steatosis [14]. To assess the effect of ApoB 
knockdown on hepatic lipid accumulation, we performed Oil red O staining on liver 
sections obtained from mice injected with 108, 109, 1010, or 1011 gc AAV-shScr and 
AAV-shA10 per animal at two weeks post-administration (Fig. 3c). Analysis of the liver 
sections revealed increased accumulation of hepatic lipid content at the effective 109, 
1010, and 1011 gc AAV-shA10 doses compared with PBS- and AAV-shScr-injected mice 
(Fig. 3c). In addition, plasma triglyceride levels were also decreased after AAV-shA10 
transduction, demonstrating diminished hepatic triglyceride export capacity in these 
mice (data not shown). These results indicate that a single AAV-shA10 administration 
in mice results in a dramatically decreased ApoB expression in murine liver with 
expected phenotypic side effects. 
Long-term efficacy of AAV-shA10 in murine liver
In order to monitor the viral persistence and robustness of ApoB knockdown by 
AAV-shA10, a second group of mice was injected with 109 and 1011 gc AAV-shA10 
or control AAV-shScr and sacrificed at eight weeks post-injection. At this time-point, 
we observed a significant reduction in ApoB mRNA for both AAV-shA10 viral doses 
confirming stable transduction of scAAV8 in murine liver (Fig. 4a). However, maximum 
ApoB mRNA knockdown was slightly less than at two weeks post-transduction (Figs. 2c 
and 4a). Similarly, GFP and siA10 expression was lower at the eight-week time-point, 
compared to two weeks post-injection. This effect was most pronounced in the group 
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Figure 3. Effect of AAV-delivered shA10 on liver transaminases, cellular miRNA expression, 
and hepatic fat accumulation. Mice were intravenously injected with 108, 109, 1010, and 1011 gc 
AAV-shA10 or control AAV-shScr per animal. Two weeks after transduction, animals were sacrificed 
and liver and plasma were collected for analysis. (a) Liver transaminases ALT and AST at two weeks 
post-injection. Transaminases were analyzed on the automated clinical chemistry analyzer Modular 
Analytics P800 from Roche. (b) Relative expression of liver-specific mir-122, let-7a, and mir-29a. 
Total RNA was isolated from snap-frozen livers and miRNA-specific Taqmans were performed. miRNA 
expression levels were calculated relative to actin mRNA and the PBS-treated group was set at 100%. 
Data are represented as mean ±SE, treatment groups are n=5. (c) Representative image of hepatic 
lipid accumulation. Frozen liver sections were stained with Oil red O for lipids, and nuclei were 
counterstained with hematoxylin solution. Fat accumulation was visible starting at a dose of 109 gc 
AAV-shA10. Photos were taken using the same exposure and magnification settings. Scale bar=10 
μm. gc, genome copies; AAV-shA10, adeno-associated virus expressing short hairpin RNA against 
apolipoprotein B100; AAV-shScr, adeno-associated virus expressing short hairpin RNA scramble; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; mir-122, microRNA 122; let-7a, 
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of animals injected with the 1011 dose (Figs. S4a,b). Nevertheless, AAV-shA10 was still 
effective at lowering ApoB100 and ApoB48 protein and cholesterol levels (Figs 4b 
and S4c). AAV-shA10 injection at a dose of 1011 gc per animal gave rise to a two- to 
five-fold increase in liver transaminases, which was most pronounced for ALT levels 
at three weeks post-injection and transaminases were still above baseline after eight 
weeks (Fig. 4c). During the eight week period the highest dose of 1011 gc AAV-shScr 
did not induce a dramatic increase in ALT and AST levels, as was observed in the 
group of animals sacrificed at two weeks post-injection (Figs. 3b and 4c). We next 
tested for altered expression of mir-122, mir-29a, let-7a, and mir-122 target genes 
at eight weeks post-injection. No significant changes were measured in liver miRNA 
or mir-122 target gene expression, although a trend was observed for lower miRNA 
levels in the animals injected with 1011 gc AAV-shA10 (Figs. S4 d,e). 
a b
c
Figure 4. ApoB mRNA and cholesterol decrease eight weeks post-transduction with AAV-
shA10. Mice were intravenously injected with 109 and 1011 gc AAV-shA10 or control AAV-shScr per 
animal. Eight weeks after transduction, animals were sacrificed and liver and plasma were collected 
for analysis. (a) Relative ApoB mRNA expression in liver. Total RNA was isolated from snap-frozen liver 
tissue and qRT-PCR was performed with ApoB- and actin-specific primers. ApoB mRNA levels were 
calculated relative to actin mRNA and the PBS-treated group was set at 100%. (b) Total cholesterol 
levels in plasma collected from fasted mice. Cholesterol levels were analyzed on the automated clinical 
chemistry analyzer Modular Analytics P800 from Roche. (c) Plasma ALT (left panel) and AST (right 
panel) levels at 1, 3, 6, and 8 weeks post-injection. Transaminases were analyzed on the automated 
clinical chemistry analyzer Modular Analytics P800 from Roche. Data are represented as mean ±SE, 
treatment groups are n=5. gc, genome copies; AAV-shA10, adeno-associated virus expressing short 
hairpin RNA against apolipoprotein B100; AAV-shScr, adeno-associated virus expressing short hairpin 
RNA scramble; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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AAV-shA10 specifically reduces LDL-C in mice fed on an atherogenic diet
Mice are refractory to atherosclerosis because they have small amounts of VLDL-C 
and LDL-C, while HDL-C is their major lipoprotein [25]. To specifically elevate VLDL-C 
and LDL-C levels, mice were fed on an atherogenic diet. Nine weeks after starting 
on the atherogenic diet, murine livers were grossly enlarged and pale in color, and 
liver transaminases were elevated compared to lean control animals, as described 
previously [26] (data not shown). In addition, total cholesterol, VLDL-C, and LDL-C 
levels increased substantially compared to lean controls (Figs. 2e, 5a-b, S5a). Seven 
weeks after starting on the atherogenic diet, animals were injected with the effective 
and non-toxic dose of 1010 gc AAV-shA10 or control AAV-shScr per animal, and 
two weeks later mice were sacrificed and liver and plasma were analyzed for ApoB 
knockdown. Transduction efficiency in liver cells was lower in atherogenic diet-fed 
mice compared to lean animals, since GFP mRNA and siA10 expression was respectively 
hundred- and eight-fold lower (Figs. S5b,c). Nonetheless, AAV-shA10 reduced 
ApoB mRNA levels by 62% compared to PBS-injected controls, concomitant with 
a reduction in secreted ApoB100 and ApoB48 protein, whereas AAV-shScr had no 
effect (Figs. 4d and S5d). Furthermore, ApoB knockdown correlated with a significant 
reduction in plasma total cholesterol (Fig. 5a). More importantly, AAV-shA10 reduced 
only VLDL-C and LDL-C levels significantly, while HDL-C concentrations remained 
unaffected (Figs. 5b-c and S5a). 
Discussion
The major challenge for RNAi-based therapies is the delivery of siRNAs to the target 
tissue or organ. In the last few years much progress has been made in optimizing 
the specificity and tissue-tropism of AAV viral vectors. AAV vectors mediating 
expression of shRNAs have proven to be valuable vehicles for RNAi research and 
therapy of various diseases in the liver, brain, and the eye [9]. However, detailed 
studies analyzing the dynamics and putative side effects of AAV-shRNA-mediated 
knockdown of ApoB in vivo have not been carried out. To address this issue, we have 
employed self-complementary AAV serotype 8 that expresses shApoB (AAV-shA10) 
and have studied prolonged inhibition of ApoB in murine liver. With a single injection 
of 1010 gc per animal of this vector, ApoB expression was inhibited dramatically for up 
to eight weeks without inducing severe toxicity or disturbance of miRNA processing. 
Murine liver was transduced with increasing doses of AAV-shA10 and a good 
correlation between the administered viral dose and expression of siA10 and GFP 
mRNA was observed. ApoB knockdown occurred in a dose-dependent fashion and 
was already detected at a low dose of 109 gc AAV-shA10 per animal, demonstrating 
the potency of this shRNA construct. Maximal suppression of ApoB led to 95% 
inhibition of ApoB mRNA and undetectable ApoB100 protein levels, concomitant 
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with a 79% reduction in plasma total cholesterol. Protein levels of ApoB48 were 
also reduced by AAV-shA10 in murine plasma and liver. Inhibition of ApoB48 can 
potentially affect dietary fat absorption in the small intestine. However, AAV-shA10 
is not expected to reduce murine intestinal ApoB48, as AAV8 has a manifold higher 
tropism for liver than intestine [27,28]. Moreover, 85% of intestinal human ApoB 
transcripts have been shown to terminate after the edited stop codon, which excludes 
the shA10 target sequence [29]. Hence, AAV-shA10 is not likely to affect the uptake 
of dietary fats in humans. 
We observed a strong reduction in the major lipoprotein in mice, HDL-C, along 
with a decrease in VLDL-C and LDL-C. The reduction of HDL-C has been attributed 
to the requirement of components from VLDL-C and LDL-C for the formation of 
mature HDL-C; hence a significant loss of VLDL-C and LDL-C should result in a similar 
reduction of HDL-C [30]. There is a debate on to what extent LDL-C levels need to 
be lowered to achieve optimal cardiovascular risk reduction. It is argued that the 
Figure 5. AAV-delivered shA10 specifically lowers total cholesterol and LDL-C levels in mice fed 
on an atherogenic diet. Mice were fed on an atherogenic diet for seven weeks, before intravenously 
receiving 1010 gc AAV-shA10 or control AAV-shScr per animal. Animals continued feeding on the 
atherogenic diet and were sacrificed at two weeks post-transduction. (a) Total cholesterol levels 
in plasma collected from fasted mice. (b) LDL-C levels in plasma collected from fasted mice. LDL-C 
levels were calculated using the Friedewald formula. AAV-shA10 significantly reduces LDL-C levels 
compared with PBS (p=0.001) and AAV-shScr (p=0.039) injected animals. (c) HDL-C levels in plasma 
collected from fasted mice. Cholesterol and HDL-C levels were analyzed on the automated clinical 
chemistry analyzer Modular Analytics P800 from Roche. (d) Relative ApoB mRNA expression in liver. 
Total RNA was isolated from snap-frozen liver tissue and qRT-PCR was performed with ApoB- and 
actin-specific primers. ApoB mRNA levels were calculated relative to actin mRNA and the PBS-treated 
group was set at 100%. Data are represented as mean ±SE, treatment groups are n=5. gc, genome 
copies; AAV-shA10, adeno-associated virus expressing short hairpin RNA against apolipoprotein 
B100; AAV-shScr, adeno-associated virus expressing short hairpin RNA scramble; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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most effective LDL-C intervention is a reduction of at least 30% from baseline, rather 
than reaching a predefined low LDL-C concentration [31]. Our data show a 32% 
reduction of plasma total cholesterol after a single intravenous injection with a low 
dose of 109 gc AAV-shA10 per animal, thus signifying potential therapeutic benefit 
for reducing cardiovascular risk by using this shRNA. To study the specific effect of 
AAV-shA10 on VLDL-C and LDL-C levels, C57BL/6 mice were fed an atherogenic 
diet. These mice had elevated levels of plasma total cholesterol, VLDL-C, and LDL-C 
compared with lean animals. A single administration of 1010 gc AAV-shA10 per 
animal specifically reduced total cholesterol, VLDL-C, and LDL-C levels, while HDL-C 
remained unaffected, demonstrating the specificity of our approach since ApoB 
participates only in the formation of VLDL-C and LDL-C, and not HDL-C particles. 
Similar data have been obtained from human subjects with mild dyslipidemia that 
were treated with an ApoB ASO [32].
The initial excitement around RNAi as a therapeutic of chronic diseases has been 
tempered by skepticism related to off-targeting and toxic effects of the shRNA. 
Recently, it was reported that AAV-expressed shRNAs, when administered to mice, 
can result in profound liver toxicity, presumably by saturation of the cellular miRNA-
processing factors exportin-5 and RISC [21]. shRNA-mediated toxic effects were marked 
by reductions in cytoplasmic levels of mature miRNA, and were independent of the 
shRNA sequence. However, toxic effects were due to the injected viral vector dose of 
1011 and 1012 gc per animal, which led to accumulation of extremely high cytoplasmic 
concentration of the shRNA. The authors discovered that ~10-fold lower viral dose 
and subsequently lower levels of shRNA expression was effective and well-tolerated, 
and had no adverse effects [21]. In our study, we were able to achieve a 90% ApoB 
knockdown at 1010 gc AAV-shA10 per animal. At this effective viral dose we did not 
observe any signs of toxic effects or disturbance of liver mir-122 expression. Similar to 
the previously published observations of Grimm et al. [21], we were able to reach toxic 
levels of shRNA expression with 1011 gc AAV-shScr per animal that was associated with 
ten to thirty times higher ALT and AST levels, decrease in cellular mir-122 expression, 
and changes in liver morphology. This strong liver toxicity was probably dependent on 
the shScr sequence because there was not such a dramatic toxic effect when 1011 gc 
AAV-shA10 per animal was used. The latter induced milder, but persistent ALT and AST 
activation within the eight-week period, which might be a consequence of the almost 
complete ApoB inhibition and hepatic fat accumulation at this viral dose. For both 
AAV-shA10 and AAV-shScr we observed a gradual loss of GFP expression following 
transduction with the high 1011 gc dose, while at 109 gc GFP expression persisted more 
stably within the eight-week study period. These results match previous observations 
that describe a reduction in transgene expression after transduction with over-expressing 
shRNAs due to hepatocyte death and subsequent liver repopulation by non-transduced 
52
AAV-mediated knockdown of ApoB
2
cells [21,33]. An alternative strategy to avoid shRNA toxicity with no sacrifice in gene-
silencing efficacy is to incorporate the siRNA into an artificial miRNA scaffold [34]. It has 
been suggested that miRNAs are better substrates for Dicer and RISC and therefore get 
processed more efficiently than shRNAs [10]. Furthermore, they are more amenable to 
tissue-specific or inducible expression systems than pol III-expressed shRNAs [35]. We 
are currently testing this hypothesis in vivo by incorporating the shA10 sequence in a 
miRNA backbone (miA10) and correlating the efficacy of miA10 with the concentration 
of siA10 molecules in mouse livers. 
Individuals with the autosomal dominant disorder familial hypobetalipoproteinemia 
(FHBL) have very low plasma levels of LDL-C and ApoB that are <30% of the normal, 
and approximately 50% of FHBL subjects carry mutations that result in truncated 
forms of ApoB. Although these subjects are often clinically asymptomatic, non-
alcoholic fatty liver disease (NAFLD) is common due to reduced capacity for hepatic 
triglyceride export [36,37]. Reduction of ApoB by AAV-shA10 was found to increase 
the accumulation of hepatic fat content, as determined by Oil red O staining of frozen 
liver sections, which already occurred at the lowest effective dose of 109 gc AAV-shA10 
per animal. These results corroborate studies that demonstrated an increase in hepatic 
lipid content concomitant with ApoB knockdown [14,38,39]. Steatosis was not 
observed in murine studies with an ApoB ASO [30]. However, treatment of subjects 
with familial hypercholesterolemia with the human ApoB ASO did reveal a trend 
toward an increase in intra-hepatic triglyceride content [40]. The clinical relevance of 
increased hepatic fat content has not been fully elucidated, since follow-up data is 
lacking on the progression of NAFLD in FHBL patients toward more severe chronic liver 
diseases, such as steatohepatitis, fibrosis, and cirrhosis [37]. Careful consideration and 
investigation of this potential consequence of lowering ApoB is warranted. A possible 
solution to prevent fat accumulation in the liver as a consequence of ApoB knockdown 
is the use of inducible shRNA expression, for example by the tetracycline inducible 
(tetO) promoter [41]. Expression of the shApoB can be temporarily “switched on” by 
addition of doxycycline and when sufficient cholesterol decrease is achieved due to 
ApoB knockdown, the shRNA expression can be again “switched off”. This approach 
may prevent accumulation of fat in the liver while maintaining the effectiveness of the 
shApoB in lowering plasma cholesterol levels.
In summary, we showed that ApoB can be almost completely silenced in murine 
liver by AAV-delivered shRNA. A single injection of 1010 gc per animal AAV-shA10 
rendered prolonged gene silencing of ApoB that was associated with clear decrease 
in total plasma cholesterol levels without signs of severe toxicity. Optimization of 
the shA10 RNA structure by inserting the sequences in a miRNA backbone and 
obtaining an inducible expression system will be further steps towards a successful 
gene therapeutic approach for the treatment of hypercholesterolemia. 
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Nineteen shRNA constructs simultaneously targeting mouse, macaque, and human 
ApoB, and an shRNA targeting eGFP were made by annealing of complementary 
oligonucleotides and ligation into the BglII and XhoI site of the pSuper vector 
(OligoEngine, Seattle, WA). The sequence for constructing the negative control hairpin 
shScr has been described previously [42]. The sequences of the oligonucleotides 
used in this study are listed in Table S1. Luciferase reporter Luc-ApoB containing 
in the 3’UTR 1851 nucleotides of the last exon from human ApoB (NM_000384, 
12255-14105) was made by cloning of the ApoB sequence, that was PCR amplified 
with primers LucApoBf and LucApoBr (Table S1), in the NotI and XhoI sites of the 
renilla luciferase gene in the psiCHECK-2 vector (Promega, Madison, WI). The Mfold 
program [43] was used to determine the secondary structure of the RNA transcripts.
For cloning in the AAV backbone, the H1-shRNA expression cassettes were subcloned 
in pCR-Blunt II-TOPO vector (Invitrogen, Carlsbad, CA), digested with SpeI and XbaI and 
ligated in the SpeI site of the pVD287 vector. pVD287 contains the eGFP gene under the 
control of the liver-specific LP1 promoter and generates scAAV due to a mutation in one 
terminal repeat [44]. Sense orientation of the shRNA cassette was verified by sequencing 
and the presence of the two ITRs was verified by restriction digestion with SmaI. 
Cell culture and transfections
The human embryonic kidney (HEK) 293T, human hepatoma (Huh7), and mouse 
hepatoma (Hepa1-6) cell lines were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA) containing 10% fetal calf serum, 100 U/ml penicillin 
and 100 U/ml streptomycin, at 37°C and 5% CO2. For luciferase assays, endogenous 
ApoB knockdown assays, and siRNA expression analysis, cells were seeded in 96- or 
24-well plates at a density of 6 x 104 or 1.5 x 105 cells per well, respectively, in DMEM 
one day prior transfection. Transfections were performed with Lipofectamine 2000 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
Luciferase assays
For luciferase assays, cells were co-transfected with 10 ng Luc-ApoB that contains 
both firefly and renilla luciferase genes, and 50 ng shApoB expression constructs. 
Transfected cells were assayed at 48 hr post-transfection in 20 ml 1 x passive lysis 
buffer (Promega, Madison, WI) by gentle rocking for 15 min at room temperature. 
The cell lysates were centrifuged for 5 min at 4000 rpm and 10 ml of the supernatant 
was used to measure firefly and renilla luciferase activities with the Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI). The relative luciferase activity was 
calculated as the ratio between the renilla and firefly luciferase activities. 
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RNA isolation and quantitative real-time RT-PCR 
To determine endogenous ApoB mRNA knockdown by the shApoB hairpins in vitro, 
Huh7 and Hepa1-6 cells were transfected with 1 µg shApoB-expressing constructs 
using Lipofectamine 2000 reagent and total RNA was isolated from cells 48 hr post-
transfection using the Nucleospin kit (Clontech, Mountain View, CA). To determine 
ApoB mRNA knockdown and mir-122 target gene expression in vivo, total RNA was 
isolated from frozen liver sections at two and eight weeks post-transduction with 
AAV-shA10 using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. Genomic DNA was removed by DNase treatment using TURBO DNase 
(Ambion, Austin, TX). First strand cDNA was reverse transcribed using random hexamer 
primers with the Dynamo kit (Finnzymes, Espoo, Finland) and 700 ng of total RNA. 
Real time PCR amplification was performed with ApoB-, AldoA (Aldolase A)-, Bckdk 
(Branched-chain α-ketoacid dehydrogenase kinase)-, Ndrg3 (N-myc downstream 
regulated gene 3)-, and beta actin-specific primers (Table S1). PCR reaction conditions 
were: 95°C for 10 min, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. 
The assays were performed on ABI 7000 or ABI 7500 (Applied Biosystems, Foster City, 
CA). ApoB, AldoA, Bckdk, and Ndrg3 expression levels were normalized to beta actin, 
and the relative gene expression 2-DDCt method of Livak and Schmittgen was used for 
analysis of PCR data [45]. 
siRNA and miRNA detection by small RNA Taqman assay
RT reactions for siA10, mir-122, mir-29a, and let-7a expression were performed with the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) using 
10 ng RNA and 3 ml custom-made specific RT-stem-loop primer (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions. The Taqman assay was 
done in 20 ml using 1 ml cDNA (15x diluted), 1 ml custom-made siRNA-specific primer with 
FAM-labelled fluorogenic probe (Applied Biosystems, Foster City, CA) and 10 ml Taqman 
2x Universal PCR Master Mix (Applied Biosystems, Foster City, CA). Amplification of the 
beta actin gene was used as a RNA quality and loading control. siRNA copy number per 
cell was calculated based on the amplification plot of a dilution series of synthetic siA10 
RNA standard (IDT, Coralville, IA). Ten-fold dilutions (100 pg – 1 fg) of the guide strand 
of a synthetic siA10 RNA oligo were used to create a standard line. The copy number of 
each dilution was calculated according to the formula 1 mole = 6.02 x 1023 molecules. 
The trend line value of the standard line was used to calculate the siA10 copy number 
cell, assuming 15 pg RNA per cell [46]. mir-122, mir-29a, and let-7a expression levels 
were normalized to beta actin, and the relative gene expression 2-DDCt method of Livak 
and Schmittgen was used for analysis of PCR data [45]. 
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Western blot analysis for detection of ApoB100 and ApoB48 protein
Murine plasma proteins (0.1 µL) were separated by electrophoresis on a 3-8% Tris-
Actetate gel (Invitrogen, Carlsbad, CA) and blotted onto a 0.45 µm nitrocellulose 
membrane (Invitrogen, Carlsbad, CA). The blot was incubated with a 1:2000 
dilution of a rabbit polyclonal anti-ApoB antibody (ab31992, Abcam, Cambrigde, 
UK), followed by incubation with a 1:2000 dilution of goat anti-rabbit antibody 
conjugated to horseradish peroxidase (P0448, Dako, Glostrup, Denmark). Antibody 
binding was detected by the Lumi-LightPLUS chemiluminescent detection kit (Roche 
Diagnostics, Basel, Switzerland). Equal loading of protein samples was confirmed by 
Ponceau S staining (Sigma, St. Louis, MO).
AAV vector production 
AAV viral vectors were produced encoding shA10 or control shScr and co-expressing 
the GFP reporter gene under control of the liver-specific LP1 promoter [47]. To 
maximize efficacy in the murine liver, AAV serotype 8 was employed because it can 
transduce 100% of hepatocytes in mice when delivered peripherally at high doses 
[48]. Secondly, a self-complementary AAV (scAAV) vector was used because it shows 
faster onset of gene expression and 10- to 100-fold higher expression levels than 
conventional single-stranded vectors [44]. In addition, the scAAV vector is well-suited 
for expression of short pol III shRNA cassettes, since it cannot accommodate inserts 
longer than ~2 kb. Self-complementary AAV serotype 8 vectors were produced by 
calcium phosphate-mediated co-transfection in HEK293T cells, using the three-
plasmid based system described by Gao et al. [49]. The cells were lysed 48 hr after 
transfection and virus was released by addition of Tris lysis buffer. Crude lysate from 
all batches was treated with Benzonase (50 U/mL) (Merck, Darmstadt, Germany) 
for 1 hr at 37°C. AAV vector particles were purified by iodixanol (Sigma, St. Louis, 
MO) gradient centrifugation as described previously [50]. Purified batches were 
concentrated by passage through Vivaspin 15R tubes (Sartorius Stedim, Aubagne, 
France) to a final concentration of 8-11x1011 genome copies (gc) per mL as determined 
by quantitative PCR with LP1f and LP1r primers amplifying a 95-bp fragment from the 
LP1 promoter region (Table S1). 
In vivo experiments
All animal experiments were conducted according to the guidelines of the local animal 
welfare committee. Six-to-eight-week-old male C57BL/6 mice received 108, 109, 
1010, or 1011 gc AAV-shScr or AAV-shApoB per animal intravenously via the tail vein, 
corresponding to approximately 4x109, 4x1010, 4x1011, or 4x1012 gc/kg. Heparinized 
blood samples were taken at 1, 2, 3, 6, and 8 weeks post-injection from fasted mice for 
plasma analysis. Mice were sacrificed at two and eight weeks post-injection and livers 
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and plasma were examined for ApoB knockdown. Feeding was performed ad libitum 
with either regular chow or the atherogenic Paigen diet (TD.88051, Harlan, Madison, 
WI). Plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), cholesterol, and high-density lipoprotein cholesterol (HDL-C) were analyzed on 
the automated clinical chemistry analyzer Modular Analytics P800 (Roche Diagnostics, 
Basel, Switzerland) at the Academic Medical Center (Amsterdam, the Netherlands). 
Lipoprotein profiling using FPLC separation of pooled plasma was carried out at the 
Academic Medical Center (Amsterdam, the Netherlands). GFP expression was analyzed 
in liver sections that were fixed with 4% formalin, 7% picric acid, and 10% sucrose in 
PBS. Livers were cryosectioned at 5 μm and eGFP signal was visualized using standard 
fluorescence microscopy on a Leica fluorescent microscope (Leica Microsystems GmbH, 
Wetzlar, Germany). Nuclei were visualized by staining with Hoechst. For analysis of 
liver fat accumulation, snap-frozen liver sections were cryosectioned at 5 μm, fixed in 
10% formalin and stained for 25 min in filtered 0.3 % Oil red O (Sigma, St. Louis, MO) 
solution in 60% isopropanol. Nuclei were counterstained for 5 min in hematoxylin 
solution (Sigma, St. Louis, MO). Liver histology was assessed by hematoxylin-eosin 
(H&E) staining of frozen liver sections. Statistical analysis was performed by ANOVA 
testing and p<0.05 was considered significant.
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Figure S1 GFP mRNA expression in liver transduced with AAV-shA10 and AAV-shScr  









AAV-shA10 or control AAV-shScr per animal. Two weeks post-transduction, RNA was isolated 
from snap-frozen liver tissue and qRT-PCR was performed with GFP- and actin-specific primers. 
GFP mRNA levels were calculated relative to actin mRNA and the PBS-treated group was set at 
1. Data are represented as mean +SE, treatment groups are n=5.  
 
 
Figure S1. GFP mRNA expression in 
liver transduced with AAV-shA10 
and AAV-shScr. Relative GFP mRNA 
expression in mice intravenously 
injected with 108, 109, 1010, and 1011 
gc AAV-shA10 or control AAV-shScr per 
animal. Two weeks post-transduction, 
RNA was isolated from snap-frozen 
liver tissue and qRT-PCR was performed 
with GFP- and actin-specific primers. 
GFP mRNA levels were calculated 
relative to actin mRNA and the PBS-
treated group was set at 1. Data are 
represented as mean ±SE, treatment 
groups are n=5. 
 
 
Figure S2 Transduction with 10
11
 gc AAV-shScr results in abnormal liver tissue 
morphology, as determined by H&E staining 
Figure S2. Transduction with 
1011 gc AAV-shScr results in 
abnormal liver tissue morphology, 
as determined by H&E staining. 
Representative image of liver sections 
from mice transduced with 108, 109, 
1010, and 1011 gc AAV-shA10 or 
control AAV-shScr per animal. Animals 
were sacrificed at two weeks post-
transduction and frozen liver tissue was 
cryosectioned at 5 μm and used for 
hematoxylin and eosin (H&E) staining. 
Photos were taken using the same 
exposure and magnification settings. 
Scale bar = 10 μm. 
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Figure S3 Expression of mir-122 target genes at two weeks post-transduction 
Relative expression of mir-122 target genes AldoA, Bckdk, and Ndrg3 in mice transduced with 
10
11
 gc AAV-shA10 or control AAV-shScr per animal. Two weeks post-transduction, RNA was 
isolated from snap-frozen liver tissue and qRT-PCR was performed with AldoA-, Bckdk-, Ndrg3-, 
and actin-specific primers. AldoA, Bckdk, and Ndrg3 mRNA levels were calculated relative to 
actin mRNA. Data are represented as individual measurements with median plotted, treatment 









Figure S3 Expression of mir-122 target genes  two w eks post-tr nsduction 
Relative expression of mir-122 target genes AldoA, Bckdk, and Ndrg3 in mice transduced with 
10
11
 gc AAV-shA10 or control AAV-shScr per animal. Two weeks post-transduction, RNA was 
isolated from snap-frozen liver tissue and qRT-PCR was performed with AldoA-, Bckdk-, Ndrg3-, 
and actin-specific primers. AldoA, Bckdk, and Ndrg3 mRNA levels were calculated relative to 
actin mRNA. Data are represented as individual measurements with median plotted, treatment 









Figure S3 Expression of mir-122 target genes at two we ks post-tr nsduction 
Relative expression of mir-122 target genes AldoA, Bckdk, and Ndrg3 in mice transduced with 
10
11
 gc AAV-shA10 or control AAV-shScr per animal. Two weeks post-transduction, RNA was 
isolated from snap-frozen liver tissue and qRT-PCR was performed with AldoA-, Bckdk-, Ndrg3-, 
and actin-specific primers. AldoA, Bckdk, and Ndrg3 mRNA levels were calculated relative to 
actin mRNA. Data are represented as individual measurements with median plotted, treatment 
groups are n=5.  
 
Figure S3. Expression of mir-122 target genes at two weeks post-transduction. Relative 
expression of mir-122 target genes AldoA, Bckdk, and Ndrg3 in mice transduced with 1011 gc 
AAV-shA10 or control AAV-shScr per animal. Two weeks post-transduction, RNA was isolated from 
snap-frozen liver tissue and qRT-PCR was performed with AldoA-, Bckdk-, Ndrg3-, and actin-specific 
primers. AldoA, Bckdk, and Ndrg3 mRNA levels were calculated relative to actin mRNA. Data are 
represented as individual measurements with median plotted, treatment groups are n=5. 
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Figure S4. AAV-shA10 persistence, robustness of ApoB knockdown, and off-target effects 
at eight weeks post-transduction. (a) Comparison of GFP expression in murine liver at two (black 
bars) and eight (white bars) weeks post-transduction with 109 and 1011 gc AAV-shA10 or control 
AAV-shScr per animal. Both viruses co-express the GFP reporter gene under control of a liver-specific 
LP1 promoter. RNA was isolated from snap-frozen liver tissue, followed by qRT-PCR with GFP- and 
actin-specific primers. GFP mRNA levels were calculated relative to actin mRNA and the groups injected 
with 109 gc were set at 100%. (b) Comparison of siA10 expression in murine liver at two (black bars) 
and eight (white bars) weeks post-transduction with 109 and 1011 gc AAV-shA10 per animal. Total 
RNA was isolated from snap-frozen livers and siA10-specific small RNA Taqman was performed. 
The copy number siA10 per cell was calculated as described in Fig. 1c. (c) Western blot analysis of 
secreted ApoB100 and ApoB48 protein in 0.1 μL plasma eight weeks post-transduction with 109 and 
1011 gc AAV-shA10 or control AAV-shScr per animal. ApoB100 and ApoB48 protein was detected 
using a polyclonal anti-ApoB antibody, and antibody binding was visualized by a chemiluminescence 
detection kit. (d) Relative expression of mir-122, let-7a, and mir-29a in murine liver eight weeks post-
transduction with 109 and 1011 gc AAV-shA10 or control AAV-shScr. miRNA-specific Taqmans were 
performed on RNA isolated from snap-frozen livers, and miRNA expression levels were calculated 
relative to actin mRNA and the PBS-treated group was set at 100%. Data are represented as mean 
±SE, treatment groups are n=5. (e) Relative expression of mir-122 target genes AldoA, Bckdk, and 
Ndrg3 in mice transduced with 1011 gc AAV-shA10 or control AAV-shScr per animal. Eight weeks 
post-transduction, RNA was isolated from snap-frozen liver tissue and qRT-PCR was performed with 
AldoA-, Bckdk-, Ndrg3-, and actin-specific primers. AldoA, Bckdk, and Ndrg3 mRNA levels were 
calculated relative to actin mRNA. Data are represented as individual measurements with median 
plotted, treatment groups are n=5. 
 
 
Figure S4 AAV-shA10 persistence, robustness of ApoB knock-down, and off-target effects 
at eight weeks post-transduction 
(a) Comparison of GFP expression in murine liver at two (black bars) and eight (white bars) 




 gc AAV-shA10 or control AAV-shScr per animal. Both 
viruses co-express the GFP reporter gene under control of a liver-specific LP-1 promoter. RNA 
was isolated from snap-frozen liver tissue, followed by qRT-PCR with GFP- and actin-specific 
primers. GFP mRNA levels were calculated relative to actin mRNA and the groups injected with 
10
9 
gc were set at 100%. (b) Comparison of siA10 expression in murine liver at two (bl ck bars) 
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Figure S5. AAV-shA10 persistence and robustness of ApoB knockdown in mice fed on an 
atherogenic diet. Mice were fed on regular chow (lean) or on an atherogenic diet (fat) containing 
approximately 15.8% fat, 1.25% cholesterol, and 0.5% sodium cholate for seven weeks, before being 
injected via the tail vein with 1010 gc AAV-shA10 or control AAV-shScr per animal. Animals continued 
feeding on the atherogenic diet and were sacrificed at two weeks post-transduction. (a) Plasma 
cholesterol distribution over lipoprotein subclasses in FPLC-separated pooled plasma. (b) Comparison 
of GFP expression in liver from AAV-transduced mice fed on a regular (lean) or atherogenic (fat) diet. 
Both AAV-shA10 and AAV-shScr co-express the GFP reporter gene under control of a liver-specific 
LP1 promoter. Total RNA was isolated from snap-frozen liver tissue and qRT-PCR was performed with 
GFP- and actin-specific primers. GFP mRNA levels were calculated relative to actin mRNA and the 
groups of lean mice were set at 100%. (c) Comparison of siA10 expression in liver from AAV-shA10 
transduced mice fed on a regular (lean) or atherogenic (fat) diet. Total RNA was isolated from snap-
frozen livers and siA10-specific small RNA Taqman assay was performed. The copy number siA10 per 
cell was calculated as described in Fig. 1c. (d) Western blot analysis of secreted ApoB100 and ApoB48 
protein in 0.1 μL plasma from mice that were fed on an atherogenic diet and transduced with 1010 gc 
AAV-shA10 or control AAV-shScr. ApoB100 and ApoB48 protein was detected using a polyclonal 
anti-ApoB antibody, and antibody binding was visualized by a chemiluminescence detection kit. Data 
are represented as mean ±SE, treatment groups are n=5. 
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Comparison of GFP expression in liver from AAV-transduced mice fed on a regular (lean) or 
atherogenic (fat) diet. Both AAV-shA10 and AAV-shScr co-express the GFP reporter gene under 
control of a liver-specific LP-1 promoter. Total RNA was isolated from snap-frozen liver tissue and 
qRT-PCR was performed with GFP- and actin-specific primers. GFP mRNA levels were 
calculated relative to actin mRNA and the groups of lean mice were set at 100%. (c) Comparison 
of siA10 expression in liver from AAV-shA10 transduced mice fed on a regular (lean) or 
atherogenic (fat) diet. Total RNA was isolated from snap-frozen livers and siA10-specific small 
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Abstract
Controlling and limiting the expression of short hairpin RNA (shRNA) by using constitutive 
or tissue-specific polymerase II (pol II) expression can be a promising strategy to avoid 
RNAi toxicity. However, to date detailed studies on requirements for effective pol II shRNA 
expression and processing are not available. We investigated the optimal structural 
configuration of shRNA molecules, namely: hairpin location, stem length and termination 
signal required for effective pol II expression and compared it with an alternative strategy 
of avoiding toxicity by using artificial microRNA (miRNA) scaffolds.
Highly effective shRNAs targeting luciferase (shLuc) or Apolipoprotein B100 (shApoB1 
and shApoB2) were placed under the control of the pol II CMV promoter and expressed 
at +5 or +6 nucleotides (nt) with reference to the transcription start site (TSS). Different 
transcription termination signals (TTS), namely minimal polyadenylation (pA), poly T 
(T5) and U1 were also used. All pol II-expressed shRNA variants induced mild inhibition 
of Luciferase reporters carrying specific targets and none of them showed comparable 
efficacy to their polymerase III-expressed H1-shRNA controls, regardless of hairpin 
position and termination signal used. Extending hairpin stem length from 20 basepairs 
(bp) to 21, 25 or 29 nt yielded only slight improvement in the overall efficacy. When 
shLuc, shApoB1 and shApoB2 were placed in an artificial miRNA scaffold, two out of 
three were as potent as the H1-shRNA controls. Quantification of small interfering RNA 
(siRNA) molecules showed that the artificial miRNA constructs expressed less molecules 
than H1-shRNAs and that CMV-shRNA expressed the lowest siRNA molecules suggesting 
that RNAi processing in this case is least effective. Furthermore, CMV-miApoB1 and 
CMV-miApoB2 were as effective as the corresponding H1-shApoB1 and H1-shApoB2 
in inhibiting endogenous ApoB mRNA. 
Our results demonstrate that artificial miRNA have a better efficacy profile than 
shRNA expressed either from H1 or CMV promoter and will be used in the future for 
RNAi therapeutic development.
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Introduction
RNA interference (RNAi) is an evolutionary conserved mechanism for regulating gene 
expression. It plays an important role in defense against viruses but also in development 
and in normal functioning of the cell [1,2]. The natural RNAi mechanism functions by 
endogenous microRNA (miRNA) molecules, which are synthesized in cells as part of 
longer primary RNA transcripts (pri-miRNAs). Pri-miRNAs are cleaved by the nuclear 
Drosha-DGCR8 complex to produce miRNA precursors (pre-miRNAs) of 70 nucleotides 
(nt), which are then transported by Exportin 5 to the cytoplasm and processed by the 
RNAse III endonuclease family enzyme Dicer to produce a mature miRNA duplex of 
~21,22 basepairs (bp). The guide strand of the miRNA enters a multiprotein RNA-
induced silencing complex (RISC) where it is used for sequence-specific recognition 
of target messenger RNA (mRNA). RISC binding to complementary sequences on the 
target mRNA results in transcript degradation or translational repression [3].
By introducing molecules that constitute substrates for the endogenous RNAi 
pathway disease-related mRNA and thus protein translation can be inhibited. RNAi 
in cells can be induced in different ways. Generally this is achieved by delivery of 
20-25 bp-long small interfering RNAs (siRNAs) [4] which serve as substrates for the 
RISC complex. Alternatively, siRNAs can be generated by expressing short hairpin RNA 
(shRNA) [5] or artificial microRNA (miRNA) structures [6]. Both enter the endogenous 
RNAi pathway and are processed into mature siRNAs. The crucial difference between 
shRNAs and artificial miRNAs is in their secondary structure and processing in the RNAi 
pathway. shRNAs are normally expressed from polymerase III (pol III) promoters and 
directly generate a mature product which is exported and processed by Dicer, while 
miRNAs require an additional step of excision from the longer pre-miRNA sequence by 
the Drosha-DGCR8 complex. Moreover, miRNAs are expressed from polymerase II (pol 
II) promoters that allow for the use of tissue-specific or regulated expression systems. 
To date, shRNA expression from pol III promoters is the most common way to 
induce RNAi in cells, which provides potent and stable target inhibition. Several 
pol III promoters are being used for expression of shRNAs, such as H1 or U6, and 
transcription initiation and termination sites together with the structural requirements 
for effective expression of the hairpins are well described [7,8]. However, there are 
serious disadvantages of pol III expression systems which question their possible 
application as therapeutic agents. There are cases reporting severe toxicity after 
administration of high doses of vectors encoding shRNA [9,10]. Toxicity was shown 
to be associated with oversaturation of the cellular RNAi machinery and changes in 
endogenous miRNA expression. 
This toxicity problem may be circumvented by using weaker pol II promoter to 
express shRNAs or by embedding siRNA into artificial miRNA scaffolds. The CMV 
promoter has been the first pol II promoter shown to express active shRNA and 
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initial requirements for this approach have been established: the shRNA has to be 
juxtaposed to the transcription start site (TSS) (within 6 nt) and followed by the minimal 
polyadenylation signal (pA) [11]. When these two conditions were not met, the shRNA 
was found to be inactive. Additionally, to limit toxicity tissue-specific pol II promoters 
which restrict expression to the target tissue can be applied. This approach has been 
used to safely express shRNAs targeting JNK1, JNK2, and PI3 under the control of 
the prostate-specific antigen pol II promoter in androgen-responsive cancer cells [12]. 
Furthermore, in vivo toxicity related to high shRNA expression levels from a pol III 
promoter was abolished when the shRNA was expressed from the liver-specific pol 
II hAAT promoter and U1 termination signal was used [13]. Incorporation of a siRNA 
sequence in an artificial miRNA scaffold has been shown to abolish shRNA-induced 
neuronal cell death and to avoid disruption of the endogenous RNAi pathway [14,15].
In the current study we focused on the structural requirements to determine 
the optimal configuration for pol II shRNA expression and compared it to the pol II 
expression of artificial miRNA. To date, no detailed studies on the hairpin positions, 
transcription termination signal (TTS) and shRNA stem length requirements for 
efficient pol II shRNA expression have been performed. Varying positions of the 
hairpin relative to the TSS +5 or +6, stem length of 20, 21, 25, 29 bp, and different 
TTS (pA, U1 and T5) have been tested for a shRNA targeting luciferase (shLuc) and 
expressed from the pol II CMV promoter. shLuc at +6 location relative to TSS, with 
stem length of 20 nt with either pA or U1 termination signal was found to yield 
optimal results. However, the average luciferase inhibition of 40% was still lower 
than the control pol III H1-shRNA, which inhibited luciferase up to 90%. Additionally, 
two shRNAs targeting ApoB (shApoB1 and shApoB2) were found inactive when 
expressed from CMV using the same configuration. In contrast, when the three 
shRNAs were incorporated in an artificial miRNA scaffold, two were equally active to 
their respective H1-shRNA controls while expressing much less siRNA molecules. This 
indicates that using artificial miRNA scaffolds has a greater therapeutic potential than 
direct expression of shRNAs from pol II promoters.
Results
Design and knockdown efficacy of CMV-shLuc with different transcription 
start and transcription termination signals
Previously, we have identified a highly effective siRNA potent in knocking down 
luciferase when expressed as shLuc from the pol III H1 promoter [16]. To minimize 
the risk of inducing toxic effects due to siRNA overexpression we wanted to express 
the same shLuc sequence under the control of the pol II CMV promoter. In contrast 
to pol III, most pol II transcripts undergo posttranscriptional modification at the 5’ 
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and 3’ ends, which enhances their stability and protects them from degradation 
[17]. However, both 5’ and 3’ overhangs of the shRNA are important for correct 
recognition and processing by Dicer [18] therefore these sequences needed to be 
optimized. A panel of shLuc constructs with perfect complementary 20-bp shRNA 
stem and 9-nt loop was expressed from the pol II CMV promoter (Fig. 1a). Initially, 
shLuc was placed behind the CMV promoter, followed by a minimal pA signal. The 
beginning of the passenger strand of the shLuc sequence was placed at positions 
+5 or +6 relative to the TSS generating CMV+5shLuc-pA and CMV+6shLuc-
pA, respectively (Fig. 1a). It has been reported that T5 TTS can be used instead 
of pA signal in a CMV-shRNA expression cassette [19]. Therefore, this termination 
signal was used in the +5shLuc and +6shLuc constructs instead of pA, resulting 
in CMV+5shLuc-T5 and CMV+6shLuc-T5. Finally, the U1 termination signal was 
cloned behind +6shLuc, resulting in CMV+6shLuc-U1. To compare their inhibitory 
effect, HEK293T cells were co-transfected with the different variants of CMV-shLuc 
together with the firefly luciferase reporter. shRNA targeting GFP (shGFP) was 
included as a negative control and renilla luciferase expression was measured to 
correct for experimental conditions. The ratio firefly/renilla in the negative control 
was set as 100% and relative inhibition of the luciferase reporter was calculated. All 
CMV-shLuc constructs appeared less effective in inhibiting luciferase compared to the 
pol III H1-shLuc control (Fig. 1b). The maximum inhibition of luciferase achieved was 
22% and 36% for CMV+5shLuc-pA and CMV+6shLuc-pA constructs, respectively. 
CMV+6shLuc-U1 inhibited luciferase expression with only 18%. CMV+5shLuc-T5 
and CMV+6shLuc-T5 constructs were not effective at all. 
Design and knockdown efficacy of CMV-shLuc with different hairpin stem 
length 
The length of the stem in the shRNA has been found to be important for Dicer 
processing resulting in enhancement of the silencing potential of a given hairpin 
[20]. Dicer recognizes double-stranded RNA and cleaves 21-22 nt to produce mature 
siRNA. To check whether extending stem length of shLuc would improve its efficacy 
as a result of better Dicer processing, constructs with 20, 21, 25, and 29 bp stem were 
designed by extending the 5’ end of the guide strand, resulting in shLuc20, shLuc21, 
shLuc25, and shLuc29 variants (Fig. 2a). Based on our previous findings shLuc was 
placed at +6 site and followed by pA or U1 termination signal. Luciferase knockdown 
was measured to determine the efficacy of the extended stem length constructs 
(Fig. 2b,c). Improved efficacy was observed when extending hairpin stem to 21 nt for 
both pA (Fig. 2b) and U1 TTS (Fig. 2c). This improvement was statistically significant 
for pA TTS (p < 0,05) while change for U1 TTS was not significant (p >0,05). Further 
lengthening of the shLuc hairpin stem to 25 and 29 bp did not change the inhibitory 
effect of these constructs (Fig. 2b,c).
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Design and knockdown efficacy of CMV-shRNA and artificial miRNA 
targeting luciferase or apolipoprotein B100 (ApoB)
Previously, H1-shApoB1 and H1-shApoB2 have been used to inhibit in vitro and 
in vivo the expression of ApoB that is the structural protein of low density lipoprotein 
cholesterol (LDL-C) [21](and data not shown). To evaluate whether the structural 
requirements for expression of shRNA from the CMV promoter, +6 TSS and pA TTS 
apply not only to luciferase-targeting constructs, two CMV-shRNAs targeting ApoB 
were designed and named CMV-shApoB1 and CMV-shApoB2, respectively. As an 



































































































Figure 1. Structure and knockdown efficacy of short hairpins targeting luciferase (shLuc) 
with TSS and TTS. (a) Schematic representation of shLuc constructs expressed from H1 and CMV 
promoters. Different TTS (pA, T5 and U1) are presented. Hairpin location (+5 or +6) is shown with 
reference to the TSS (set as +1). The shLuc consists of 20 nt perfectly complementary hairpin structure 
and a loop of 9 nt. (b) Luciferase knockdown by CMV-shLuc with different TSS and different TTS. 
Renilla and firefly luciferase were measured two days post-transfection with 2,5 ng Firefly luciferase 
reporter, 0,5 ng Renilla luciferase and 100 ng shLuc expressing plasmids. Firefly luciferase expression 
was normalized to Renilla luciferase expression. H1-shLuc was used as a positive control, H1-shGFP 
and CMV-shGFP served as negative controls and were set at 100%. Data are represented as mean 
values ±SD from three independent experiments analyzed with the factor correction method [35]. 
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incorporating siRNA targeting luciferase or ApoB were designed by substituting the 
mature miRNA sequence with luciferase and ApoB target sequences, resulting in 
CMV-miLuc, CMV-miApoB1 and CMV-miApoB2 (Fig. 3a,b,c). The pri-miRNA structure 
contains additional flanking sequences at the 5’ and 3’ ends of the hairpin, which 
enables correct recognition and processing by the RNAi pathway enzymes Drosha and 
Dicer. The 5’ and 3’ flanking sequences of pri-mir155 were used, therefore design and 
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Figure 2. Structure and knockdown efficacy of CMV-shLuc with different stem length and 
polyadenylation (pA) or U1 transcription termination signals (U1). (a) Predicted stem-loop 
structure of CMV-shLuc with different stem lengths (20, 21, 25 and 29 nt). Guide strand is highlighted 
in grey (b) Luciferase knockdown by CMV-shLuc20, CMV-shLuc21, CMv-shLuc25, CMV-shLuc29 with 
pA transcription termination signal. (c) Luciferase knockdown by CMV-shLuc20, CMV-shLuc21, CMV-
shLuc25, CMV-shLuc29 with U1 transcription termination signal. Renilla and firefly luciferase were 
measured two days post-transfection with 2,5 ng Firefly luciferase reporter, 0,5 ng Renilla luciferase 
and 100 ng short hairpin expressing plasmid. Firefly luciferase expression was normalized to Renilla 
luciferase expression. H1-shLuc was used as a positive control. H1-shScr and CMV-shScr served as 
negative controls and were set at 100%. Data are represented as mean values ±SD from three 
independent experiments analyzed with the factor correction method [35]. *p < 0.05, **p < 0.01 
versus negative control (One-way ANOVA test with Bonferroni post test).
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for effective knockdown. Knockdown efficacy of CMV-shRNAs and CMV-miRNAs was 
determined on their specific luciferase reporters, containing ApoB target sequences in 
case of shApoB and miApoB constructs. H1-shLuc, H1-shApoB1 and H1-shApoB2 were 
used as positive controls and H1-shScr, CMV-shScr and CMV-miScr, not targeting any 
sequence in the human genome, were used as negative controls. Luciferase expression 
in the negative controls was set at 100% and the relative inhibition of luciferase 
reporters was calculated (Fig. 3d,e,f). CMV-shApoB1 and CMV-shApoB2 inhibited 
luciferase reporters by 22% and 8% respectively (Fig. 3e,f), which is similar to the 
knockdown observed with CMV+6shLuc20-pA (Fig. 3d). By contrast, CMV-miApoB1 
and CMV-miApoB2 were found to inhibit luciferase reporters up to 57% and 75% 
respectively (Fig. 3e,f). CMV-miLuc was not more active than CMV+6shLuc20-pA even 
though it was designed the same way as CMV-miApoB1 and CMV-miApoB2 (Fig. 3d). 
Quantification of siRNA molecules processed from the different shRNA  
and miRNA scaffolds 
Next, we wanted to determine if the inhibitory effect of the shRNA and artificial 
miRNA constructs correlates with the amount of processed siRNA molecules in the 
cell. For siLuc, siApoB1 and siApoB2 sequences, small RNA specific Taqman assay was 
designed for detecting the guide strand (Table S1). Ten-fold dilutions (100 pg – 1 fg) 
of the guide strand of each synthetic siRNA oligo were used to create a standard 
line (Fig. 4a). All siRNA assays showed a clear exponential correlation between the 
amplification pattern and the amount of siRNA standard. The small RNA Taqman 
assay relies on the hybridization of stem-loop RT primers to the mature guide strand 
and in some cases the method could show insufficient specificity, amplifying the 
precursor shRNA hairpin or nonspecifically binding to another siRNA molecule. To 
Figure 3. Structure and knockdown efficacy of shRNA and miRNA hairpin constructs 
targeting luciferase and Apolipoprotein B100 (ApoB). (a,b,c) Predicted stem-loop structures of 
shRNA and miRNA targeting luciferase: shLuc or miLuc and ApoB: shApoB or miApoB with guide 
strand highlighted in grey. shRNA structure is described in Fig. 1. miApoB consists of pri-mir-155 
precursor sequence, where the mature mir-155 sequence was replaced with the target sequence for 
luciferase or ApoB. ApoB1 and ApoB2 target different sequences in the ApoB gene. (d) Luciferase 
knockdown by CMV-shLuc and CMV-miLuc. Renilla and firefly luciferase were measured two days 
post-transfection with 100 ng shRNA or miRNA expressing plasmid and 2,5 ng Firefly luciferase and 
0,5 ng Renilla luciferase. H1-shLuc was used as a positive control. shScr and miScr served as negative 
controls and were set at 100%. Firefly luciferase expression was normalized to Renilla luciferase 
expression. Data are represented as mean values ±SD from three independent experiments analyzed 
with the factor correction method [35] (e) Knockdown of Luc-ApoB1 reporter, containing in its 3’ UTR 
ApoB1 target sequence, by CMV-shApoB1 and CMV-miApoB1. Experimental setup was as described 
in (d) H1-shApoB1 was used as a positive control. (f) Knockdown of Luc-ApoB2 reporter, containing 
in its 3’ UTR ApoB2 target sequence, by CMV-shApoB2 and CMV-miApoB2. Experimental setup was 
as described in (d) with the exception that in this Renilla luciferase contained target sequence for 
ApoB2 and its expression was normalized to Firefly luciferase expression H1-shApoB2 was used as a 
positive control. **p < 0.01 versus negative control (One-way ANOVA test with Bonferroni post test).
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exclude this possibility, we investigated the ability of the siApoB1 and siApoB2 assays 
to differentiate between the mature siRNA molecules, their shApoB1 or shApoB2 
hairpin precursors and expression plasmids by performing additional Taqman 
experiments. The primers and probes specifically amplified only the corresponding 
synthetic siRNA standard and no aspecific amplification was detected for the shRNA 
hairpin oligo or expression plasmid suggesting that the small RNA Taqman assays 
were highly specific for the mature siApoB1 or siApoB2 (Tables S2 and S3). Having 
confirmed that properly processed siRNA molecules can be specifically detected, 
we proceeded with detection and quantification of the siRNA molecules per cell for 
H1-shRNA, CMV-shRNA and CMV-miRNA constructs (Fig. 4b,c,d). For all constructs 
an amplification chart was created and the amount of molecules was calculated. The 
exponential amplification for H1-shLuc began at 25 cycles, while it began later for 
both CMV-shLuc and CMV-miLuc (32 and 29 cycles respectively) (Fig. 4b left panel). 
The expression of siLuc molecules was 125-fold lower when expressed as CMV-shLuc 
and 10-fold lower when expressed as CMV-miLuc compared to H1-shLuc, which 
resulted in 16686 siRNA molecules per cell (Fig. 4b right panel). The exponential 
amplification for H1-shApoB1 began at 26 cycles, at cycles 32 for CMV-shApoB1 
and at 27 cycles for CMV-miApoB1 (Fig. 4c left panel). This represents 12-fold 
less molecules expressed with CMV-shApoB1 and 2-fold less for CMV-miApoB1 
compared to H1-shApoB1, which resulted in 14838 siRNA molecules (Fig. 4c right 
panel). siApoB2 molecules were not detected as efficiently as siLuc and siApoB1 thus 
the exponential amplification started later: for H1-shApoB2, it began at 29 cycles, at 
36 cycles for CMV-shApoB2 and at 34 cycles for CMV-miApoB2 (Fig. 4d left panel). 
This represented 49-fold less molecules expressed with CMV-shApoB2 and 32-fold 
less for CMV-miApoB2 compared to H1-shApoB2, which resulted in 1764 molecules 
per cell (Fig. 4d right panel).
Figure 4. Quantification of siRNA molecules expressed from H1-shRNA, CMV-shRNA and 
CMV-miRNA targeting luciferase and Apolipoprotein B100. (a) Synthetic siRNA standard lines. 
siRNA- specific small RNA Taqman was performed with dilution series of synthetic siLuc, siApoB1 or 
siApoB2 molecules. Based on molecular weight of the synthetic siLuc, siApoB1 and siApoB2, the 
amount of molecules for each point of standard line was calculated and plotted against CT value. 
Data are represented as mean values from 2 independent experiments conducted with two technical 
replicates. (b) siLuc amplification plot (left panel) and expression in HEK293T cells (right panel). RNA 
was isolated two days post-transfection with 1 μg H1-shLuc, CMV-shLuc or CMV-miLuc expressing 
constructs and siLuc-specific small RNA TaqMan was performed. siRNA copy number was calculated 
using the synthetic RNA oligo standard line as described in (a) Data are presented from representative 
experiment from two independent experiments conducted with two technical replicates (c) siApoB1 
amplification plot (left panel) and expression in HEK293T cells (right panel) after transfection with 
1 μg H1-shApoB1, CMV-shApoB1 or CMV-miApoB1 expressing constructs. Experimental set up as 
described in (b) (d) siApoB2 amplification plot (left panel) and expression in HEK293T cells (right panel) 
after transfection with 1 μg H1-shApoB2, CMV-shApoB2 or CMV-miApoB2 expressing constructs. 
Experimental set up as described in (b). Data are represented as mean values from 2 independent 
experiments conducted with two technical replicates.
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Endogenous ApoB mRNA knockdown
In order to assess the inhibitory effect of shApoB1, shApoB2, miApoB1 and miApoB2 
constructs on endogenous ApoB expression the mouse hepatoma Hepa1-6 cell line 
was selected. Cells were transfected with H1-shApoB1, CMV-shApoB1 and CMV-
miApoB1 or with their equivalent constructs having ApoB2 as a target. Two days 
post transfection RNA was isolated and ApoB mRNA expression was determined by 
RT-qPCR. Both H1-shApoB1 and CMV-miApoB1 efficiently inhibited ApoB mRNA up 
to 70% and 50% respectively (Fig. 5a). An even stronger effect was observed for H1-
shApoB2 and CMV-miApoB2 which inhibited ApoB mRNA both up to 85% (Fig. 5b). 
CMV-shApoB1 and CMV-shApoB2 showed no inhibition of endogenous ApoB 
expression, which confirms the results on luciferase reporters inhibition (Fig. 3e,f) 
and shows the specificity of the designed constructs.
Discussion
There are few examples of successful shRNA expression using pol II promoters. 
Although several requirements for pol II shRNA expression have been established, 
optimization and direct assessment of different hairpin stem lengths, TSS and TTS 
have not been performed. In the current study we evaluated the relevance of these 
factors by positioning shRNAs targeting luciferase or ApoB at +5 or +6 relative to the 
CMV TSS and added the T5, pA or U1 TTS at the 3’ end of the hairpins. Additionally, 


























































Figure 5. Comparison of endogenous ApoB mRNA knockdown by shApoB1, shApoB2, 
miApoB1 and miApoB2in Hepa1-6 cells. (a) Endogenous ApoB mRNA knockdown by H1-
shApoB1, CMV-shApoB1 and CMV-miApoB1 constructs (b) Endogenous ApoB mRNA knockdown 
by H1-shApoB2, CMV-shApoB2 and CMV-miApoB2 constructs qRT-PCR was performed two days 
post-transfection with 1 μg of shRNA or miRNA expressing constructs and ApoB mRNA levels were 
calculated relative to actin mRNA. H1-shApoB1 and H1-ApoB1 served as positive control. shScr and 
miScr served as negative controls and were set at 100%. Data are represented as mean values ±SD 
from three independent experiments analyzed with factor correction method [35]. **p < 0.01 versus 
negative control (One-way ANOVA test with Bonferroni post test).
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evaluation between the silencing efficacy and processing of pol II-expressed shRNA 
and miRNA was performed. 
The nucleotide distance between the promoter, the shRNA structure and the 
TTS determines the length and sequence composition of the 5’ and 3’ overhangs of 
the expressed hairpin. Both ends act as reference points for recognition and proper 
processing by Dicer [18]. Initial rules published by Xia et al. include shRNA location 
within 6 nt from the TSS and pA TTS [11]. Later shRNA containing T5 and U1 TTS 
where also found to be active when substituted for pA [13,19]. These settings were 
used in our study to express shRNA from the CMV promoter. The shLuc, shApoB1 
and shApoB2 sequences have been previously validated as potent inhibitors of 
their targets when expressed from the pol III H1 promoter [16,21]. Surprisingly, all 
CMV-shLuc constructs induced only a mild target inhibition when the hairpin was 
placed at +6 TSS and T5 or pA TTS were used. In contrast to previously published 
data, the use of U1 TTS did not improve silencing efficacy. By shifting the hairpin from 
+6 to +5 from TSS, thus minimizing the 5’ overhang, no significant improvement 
was achieved and the effect was not dependent of TTS used. Additionally, the CMV-
shApoB1 and CMV-shApoB2 hairpins were ineffective when the initial settings of +6 
TSS and pA TTS were used, indicating that those settings cannot be used as a general 
rule for pol II-shRNA expression.
The length of the shRNA hairpin stem has been shown to play an important role in 
silencing efficacy as it can lead to differential processing into multiple siRNAs [8,22,23]. 
In the current study we optimized the pol II shRNA expression by testing stem lengths 
of 20, 21, 25, and 29 bp. Slight increase in silencing efficacy was observed only when 
extending hairpin stem from 20 to 21 bp but not when the stem length was further 
extended to 25 or 29 bp. Mcintyre et al. performed a similar study by extending the 
shRNA stem length from 16 to 41 bp and looked at the core placement of the shRNA 
[23]. While the processing of hairpins was clearly dependent on the stem length, the 
activity was primarily dependent on the sequence of processed products. Consistent 
with their data, our results suggest that there is no strict correlation between the 
increase in stem length and better silencing activity of the shRNAs. Here, we focused 
only on pol II expression of shRNA but an alternative approach would be to express 
long hairpin RNA (lhRNA) where the stem length is extended up to 300 bp [24-26]. 
Using lhRNA allows generating multiple siRNA from a single transcript, which can be 
used for viral infections or cancer, where multiple sequences have to be targeted. To 
date, expression of active lhRNA from pol II promoter has not been successful due to 
inefficient processing of the hairpins by the RNAi machinery, and detailed studies on 
TSS, TTS and hairpin location, similar to those for shRNA are lacking.
An alternative to optimizing pol II expression of shRNA is to use pre-miRNA scaffolds 
and replace the mature miRNA sequence with siRNA targeting a gene of interest. 
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Cellular miRNAs are naturally expressed from pol II promoters [1,27]. Therefore, 
when shLuc, shApoB1 and shApoB2 were expressed from the pri-mir-155 scaffold 
the knockdown efficacy was significantly improved. Importantly, artificial miRNA have 
been found to be less toxic in vitro and in vivo compared to shRNA as they do not 
disrupt the endogenous RNAi pathway. McBride et al. used this approach to target 
Huntingtin mRNA and to avoid neurotoxicity caused by overexpression of shRNA 
[15]. Similarly, incorporation of a siRNA against Spinocerebellar ataxia 1 protein into 
an artificial miRNA abolished neuronal cell death observed with a shRNA harboring 
the same siRNA sequence [28]. In a previous study we have provided evidence for 
the efficacy of liver-specific expression of artificial miRNA targeting ApoB in vivo and 
demonstrated its advantages over the pol III-expressed shRNA [29]. In conclusion, we 
and others have shown that pol II expression of artificial miRNA scaffolds is a more 
robust and promising approach than pol II shRNA expression, probably due to the 
specific structural characteristics of the miRNA.
An additional advantage of the use of artificial miRNAs is that several precursors 
can be expressed as clusters from longer transcripts, allowing simultaneous targeting 
of multiple genes [30]. This feature of the miRNA is very important when mutation-
prone viruses, such as HIV-1 or HCV, are targeted or when several disease-related 
genes need to be simultaneously silenced. Moreover, miRNAs can be linked to the 
3’ untranslated region of a therapeutic gene, which is an additional advantage 
for therapeutic applications since it allows co-delivery of a codon-optimized gene 
together with a miRNA targeting the disease-causing version of the same gene. Such 
combinational therapy has been shown for alpha1-antitrypsin (A1AT) deficiency, in 
which a hairpin RNA targeting mutated A1AT transcript was delivered together with 
codon-optimized A1AT gene [31]. 
Quantification of the siRNA molecules expressed from the H1-shRNA, CMV-shRNA 
or CMV-miRNA constructs was highly specific and revealed differences in the amount 
of processed siRNA molecules per cell. As expected, highest siRNA amounts were 
detected when the shRNAs were expressed from the strong H1 promoter. However, 
when the same shRNAs were expressed from the CMV promoter, 12- to 125-fold 
less siRNA molecules were detected indicating that either the shRNA was not 
efficiently transcribed from the CMV promoter or that there was impaired siRNA 
processing by the RNAi machinery. Surprisingly, the amount of processed siRNA from 
the CMV-miRNA constructs did not correlate with efficacy. For example, CMV-miLuc 
yielded 1591 siLuc molecules per cell and was completely ineffective in target 
knockdown while CMV-miApoB2 yielded only 56 siApoB2 molecules per cell and 
was highly efficient. A possible explanation for this discrepancy is that the small RNA 
Taqman assay detects only one variant of the guide strand and although identical 
predicted siRNA sequences were incorporated in the CMV-shRNA and CMV-miRNA 
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scaffolds, they can still be processed differently. Indeed, our newest data based on 
Next Generation Sequencing (NGS) of small RNAs from cells transfected with H1-
shApoB2 and CMV-miApoB2 indicates differential processing and different mature 
sequences from the two scaffolds [29]. The siRNAs originating from the H1-shRNA 
were more heterogeneous in cleavage sites and length compared to the products 
originating from the CMV-miRNA scaffold supporting the notion that Dicer cleavage 
is less precise than the combination of Drosha and Dicer. Unfortunately, NGS data 
from pol II-expressed shRNA, which would allow verifying the processed siRNA 
variants and their abundance, are still not available.
Conclusions
In summary, our results demonstrate that it is currently difficult to draw rules for 
efficient pol II shRNA expression and processing. Optimization of the shRNA stem 
length, TSS and TTS did not result in better silencing efficacy for any of the CMV-
expressed shRNAs. On the other hand, when identical predicted sequences were 
incorporated in miRNA scaffolds, two out of three sequences resulted in potent 
inhibition of luciferase reporters and endogenous mRNA. Our data question the 
application of the previously published rules for pol II shRNA expression as general 
standards. The rules for design of potent shRNA expressed from pol II promoters 
are still far from clear and they can be used rather as reference points. Still detailed 
empirical optimization of hairpin location seems to be required for every target and 
pol II promoter used. We consider that embedding siRNA in artificial miRNA scaffold 
and expression from pol II promoter is a better and approach than direct pol II shRNA 
expression due to the intrinsic characteristics of the miRNA structure rendering it a 
better substrate for the RNAi machinery.
Metherials and methods
DNA constructs
H1-shRNAs were made by annealing complementary oligonucleotides and ligating 
them into the BglII and XhoI sites of the pSuper vector (OligoEngine, Seattle, WA, USA). 
The vector contains a stretch of five thymidines (T5), which acts as the transcription 
termination signal. Panel of shRNAs were designed to act as positive controls: one 
shRNAs was designed that target firefly luciferase (H1-shLuc), two shRNAs were made 
that target different regions of human ApoB gene (H1-shApoB1 and H1-shApoB2). 
Additionally two negative controls shRNA were deigned: one that do not target any 
gene in human and mouse genome (H1-shScr) and one that target the GFP (H1-shGFP). 
All the sequences of oligonucleotides used in this study are listed in Table S1.
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CMV-shRNA with different termination signals were designed as followed. First different 
TTS (T5, pA or U1) were annealed from complementary oligonucleotides and ligated into 
the AccI and SphI sites of pVD23 which includes the CMV promoter. Next, plasmids were 
digested with SacI and NheI and complementary oligonucleotides containing shRNA 
targeting GFP (shGFP) or Luciferase (shLuc) were inserted. shLuc oligonucleotides were 
designed to allow the hairpin transcription to start at +5 or +6 nucleotides after the TSS, 
which was considered as +1. The final constructs were CMV+5shLuc-T5, CMV+6shLuc-T5, 
CMV+5shLuc-pA and CMV+6shLuc-pA. For U1 termination signal only CMV+6shLuc-U1 
was created. As negative controls CMV-shGFP-T5, CMV-shGFP-pA and CMV-shGFP-U1 
were made. GFP oligonucleotides were designed that hairpin started at +6 from the TSS.
CMV-shRNAs with different stem length of the hairpin were designed as followed. 
CMV-shLuc20, CMV-shLuc21, CMV-shLuc25 or CMV-shLuc29 were made by annealing 
complementary oligonucleotides that create the stem-loop structure of 20, 21, 25 and 
29 bp respectively and ligating them into the BamHI and XhoI sites of the pSilencer 4.1 
CMV vector (Life Technologies, Grand Island, NY). Constructs contained either the pA 
or the U1 termination signal. To create the CMV-shApoB1 and CMV-siApoB2, siRNA 
sequences from shApoB1 and shApoB2 were cloned by annealing complementary 
oligonucleotides and ligating them into the BamHI and XhoI sites of the pSilencer 4.1 
CMV vector with pA termination signal. As the negative control, pSilencer 4.1 CMV 
control (Life Technologies, Grand Island, NY) plasmid was used, named CMV-shScr.
To create the artificial miRNA expressing vectors, siRNA sequences from shLuc, 
shApoB1 and shApoB2 were cloned into the pri-mir-155 backbone of pcDNA6.2-
GW/EmGFP-miR (Life Technologies, Grand Island, NY) by annealing complementary 
oligonucleotides and ligation into BamHI- and XhoI-digested pcDNA6.2 plasmid and 
named respectively CMV-miLuc, CMV-miApoB1and CMV-miApoB2. As the negative 
control pcDNA6.2-GW/EmGFP-miR-neg control (Life Technologies, Grand Island, 
NY) was used, named CMV-miScr. The Mfold program was used to determine the 
secondary structure of all RNA transcripts [32].
Reporter constructs that were used for luciferase knockdown are Firefly luciferase 
pGL4 (Promega, Madison, WI) and pRL Renilla (Promega, Madison, WI) under control 
of the CMV promoter. Luc-ApoB1 reporter, containing in its 3’ UTR a fragment of 
239 nucleotides of human ApoB (NM_000384, 9362-9600) sequence was made, 
by cloning of the ApoB sequence, that was PCR amplified with primers pr565f and 
pr566r in the XhoI and NheI sites of pGL4 plasmid. For The Luc-ApoB2 containing in 
the 3’UTR of siCheck2 vector (Promega, Madison, WI) 1851 nucleotides of the last 
exon from the human ApoB has been described previously. 
Cell culture and transfections
The human embryonic kidney (HEK)293T and mouse hepatoma Hepa1-6 cell lines 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, 
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Grand Island, NY) containing 10% fetal calf serum, 100 U/ml penicillin and 
100 U/ml streptomycin, at 37°C and 5% CO2. For luciferase assays, endogenous ApoB 
knockdown assays, and siRNA expression analysis, cells were seeded in 96- or 24-well 
plates at a density of 3×104 or 1.2×105 cells per well, respectively, in DMEM one day 
prior transfection. Transfections were performed with Lipofectamine 2000 reagent 
(Life Technologies, Grand Island, NY) according to the manufacturer’s instructions.
Luciferase assays
Cells were co-transfected with 100 ng shRNA or miRNA expressing plasmid and 
respectively 2,5 ng Firefly luciferase or Luc-ApoB1 and 0,5 ng Renilla or 50 ng 
Luc-ApoB2 reporter.Transfected cells were assayed at 48 hr post-transfection in 20 µl 
1x passive lysis buffer (Promega, Madison, WI) firefly and renilla were measured 
luciferase activities with the Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI). For luciferase knockdown calculations, H1-shLuc was used as a positive 
control. CMV-shScr, CMV-shGFP or CMV-miScr served as negative controls and 
were set at 100%. For luciferase- and ApoB1-targeting constructs Firefly luciferase 
expression was normalized to Renilla luciferase expression. For ApoB2-targeting 
constructs Renilla luciferase expression was normalized to Firefly luciferase expression 
since the siCheck2 plasmid was used.
RNA isolation and quantitative real-time RT-PCR 
To determine endogenous ApoB mRNA knockdown by shApoB and miApoB constructs 
in vitro, Hepa1-6 cells were transfected with 1 µg shApoB1, shApoB2, miApoB1 or 
miApoB2 and total RNA was isolated from cells 48 hr post-transfection using the 
Nucleospin kit (Clontech, Mountain View, CA). Genomic DNA (gDNA) was removed 
by DNase treatment using TURBO DNase (Ambion, Austin, TX). First strand cDNA was 
reverse transcribed using random hexamer primers with the Dynamo kit (Finnzymes, 
Espoo, Finland). Real time PCR amplification was performed with ApoB- and beta 
actin-specific primers (Table S1). PCR reaction conditions were: 95°C for 10 min, 
followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. The assays were performed 
on ABI 7000 or ABI 7500 (Applied Biosystems, Foster City, CA). ApoB expression levels 
were normalized to beta actin as an internal control, and the relative gene expression 
2-ΔΔCt method of Livak and Schmittgen was used for analysis of PCR data [33]. 
siRNA detection by Small RNA Taqman assay
RT reactions for siLuc, siApoB1 and siApoB2 expression were performed with the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) 
using 10 ng RNA isolated from cells transfected with shRNA or miRNA expression 
plasmids and 3 µl custom-made specific RT-stem-loop primers (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions. The TaqMan assay was 
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done in 20 µl using 1,33 µl cDNA , 1 µl custom-made siRNA-specific primer with 
FAM-labeled fluorogenic probe (Applied Biosystems) and 10 µl TaqMan 2× Universal 
PCR Master Mix (Applied Biosystems). For determining the assay specificity, 10 ng 
of the indicated oligo or expression plasmid was added to the Taqman reaction. 
Amplification of the beta actin gene was used as a RNA quality and loading control. 
siRNA copy number per cell was calculated based on the amplification plot of a 
dilution series of synthetic siRNA standards (IDT, Coralville, IA). Tenfold dilutions 
(100 pg – 1 fg) of the guide strand of the synthetic siRNA oligo were used to create 
a standard line. The copy number of each dilution was calculated according to the 
formula 1 mol = 6.02 × 1023 molecules. The trend line value of the standard line was 
used to calculate the siRNA copy number per cell, assuming 15 pg RNA per cell [34].
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Table S2. Determination of siApoB1 RT primers and Taqman probe specificity on siApoB1, shApoB1 
hairpin precursor, shApoB1- and miApoB1-expression plasmid and siApoB2





siApoB1 synthetic standard 10 pg ApoB1 ApoB1 15,1 1,23E+05
siApoB1 synthetic standard 1 pg ApoB1 ApoB1 17,2 1,23E+04
siApoB1 synthetic standard 0,1 pg ApoB1 ApoB1 21,5 1,23E+03
siApoB1 synthetic standard 0,01 pg ApoB1 ApoB1 24,9 1,23E+02
siApoB1 synthetic standard 0,001pg ApoB1 ApoB1 29,0 1,23E+01
siApoB1 synthetic standard 10 pg ApoB2 ApoB1 ND ND
siApoB1 synthetic standard 1 pg ApoB2 ApoB1 ND ND
siApoB1 synthetic standard 0,1 pg ApoB2 ApoB1 ND ND
siApoB1 synthetic standard 0,01 pg ApoB2 ApoB1 ND ND
siApoB1 synthetic standard 0,001pg ApoB2 ApoB1 ND ND
siApoB2 synthetic standard 10 pg ApoB1 ApoB1 ND ND
siApoB2 synthetic standard 1 pg ApoB1 ApoB1 ND ND
siApoB2 synthetic standard 0,1 pg ApoB1 ApoB1 ND ND
siApoB2 synthetic standard 0,01 pg ApoB1 ApoB1 ND ND
siApoB2 synthetic standard 0,001pg ApoB1 ApoB1 ND ND
H1-shApoB1 plasmid 10 ng - ApoB1 ND ND
CMV-shApoB1 plasmid 10 ng - ApoB1 ND ND
CMV-miApoB1 plasmid 10 ng - ApoB1 ND ND
shApoB1 oligo 10 ng - ApoB1 ND ND
miApoB1 oligo 10 ng - ApoB1 ND ND
siApoB1- specific assay was tested against synthetic RNA standards, shApoB1-expression plasmids and 
shApoB1 hairpin oligonucleotides using different configuration of RT primer and Taqman probe. Average 
CT values lower than 40 cycles are presented. The amount of molecules per cell was calculated, assuming 
that 15 pg RNA was isolated per cell [34]. Data are presented from one representative experiment from 
two independent experiments conducted with two technical replicates. ND, not detected
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Table S3. Determination of siApoB2 RT primers and Taqman probe specificity on siApoB2, shApoB2 
hairpin precursor, shApoB2- and miApoB2-expression plasmid and siApoB1





siApoB2 synthetic standard 10 pg ApoB2 ApoB2 12,7 1,28E+05
siApoB2 synthetic standard 1 pg ApoB2 ApoB2 16,2 1,28E+04
siApoB2 synthetic standard 0,1 pg ApoB2 ApoB2 19,4 1,28E+03
siApoB2 synthetic standard 0,01 pg ApoB2 ApoB2 23,2 1,28E+02
siApoB2 synthetic standard 0,001pg ApoB2 ApoB2 23,7 1,28E+01
siApoB2 synthetic standard 10 pg ApoB1 ApoB2 28,7 7,13E+00
siApoB2 synthetic standard 1 pg ApoB1 ApoB2 32,0 5,26E-01
siApoB2 synthetic standard 0,1 pg ApoB1 ApoB2 36,4 1,72E-02
siApoB2 synthetic standard 0,01 pg ApoB1 ApoB2 ND ND
siApoB2 synthetic standard 0,001pg ApoB1 ApoB2 ND ND
siApoB2 synthetic standard 10 pg ApoB2 ApoB1 ND ND
siApoB2 synthetic standard 1 pg ApoB2 ApoB1 ND ND
siApoB2 synthetic standard 0,1 pg ApoB2 ApoB1 ND ND
siApoB2 synthetic standard 0,01 pg ApoB2 ApoB1 ND ND
siApoB2 synthetic standard 0,001pg ApoB2 ApoB1 ND ND
H1-shApoB2 plasmid 10 ng - ApoB2 ND ND
CMV-shApoB2 plasmid 10 ng - ApoB2 ND ND
CMV-miApoB2 plasmid 10 ng - ApoB2 ND ND
shApoB2 oligo 10 ng - ApoB2 ND ND
miApoB2 oligo 10 ng - ApoB2 ND ND
siApoB2- specific assay was tested against synthetic RNA standards, shApoB2-expression plasmids and 
shApoB1 hairpin oligonucleotides using different configuration of RT primer and Taqman probe. Average 
CT values lower than 40 cycles are presented. The amount of molecules per cell was calculated, assuming 
that 15 pg RNA was isolated per cell [34]. Data are presented from one representative experiment from 
two independent experiments conducted with two technical replicates. ND, not detected
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Abstract
Overexpression of short hairpin RNA (shRNA) often causes cytotoxicity and using 
microRNA (miRNA) scaffolds can circumvent this problem. In the current study 
identical predicted small interfering RNA (siRNA) sequences targeting Apolipoprotein 
B100 (siApoB) were embedded in shRNA (shApoB) or miRNA (miApoB) scaffolds and 
a direct comparison of the processing and long-term in vivo efficacy was performed. 
Next generation sequencing (NGS) of small RNAs originating from shApoB- or 
miApoB-transfected cells revealed substantial differences in processing, resulting 
in different siApoB length, 5’ and 3’ cleavage sites and abundance of the guide 
or passenger strands. Murine liver transduction with adeno-associated virus (AAV) 
vectors expressing shApoB or miApoB resulted in high levels of siApoB expression 
associated with strong decrease of plasma ApoB protein and cholesterol. Expression 
of miApoB from the liver-specific LP1 promoter was restricted to the liver, while the 
H1 promoter-expressed shApoB was ectopically present. Delivery of 1×1011 genome 
copies AAV-shApoB or AAV-miApoB led to a gradual loss of ApoB and plasma 
cholesterol inhibition, which was circumvented by delivering a 20-fold lower vector 
dose. In conclusion, incorporating identical siRNA sequences in shRNA or miRNA 
scaffolds results in differential processing patterns and in vivo efficacy that may have 
serious consequences for future RNAi-based therapeutics.
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Introduction
RNA interference (RNAi) is an evolutionary conserved mechanism for post-transcriptional 
regulation of gene expression. It plays an important role in defense against viruses but 
also in development and in normal functioning of the cell [1,2]. Since its discovery 
RNAi has become a valuable research tool for functional analysis of gene expression 
and a promising therapeutic approach for treatment of many disorders by silencing 
disease-related genes [3]. Significant progress has been made towards improving the 
specificity of RNAi-mediated target inhibition and minimizing its potential side-effects, 
yet more insight is needed on the exact small interfering RNA (siRNA) processing 
pattern when identical predicted sequences are incorporated in a short-hairpin RNA 
(shRNA) or artificial microRNA (miRNA) scaffold for therapeutic applications. 
Processing of miRNA by RNAse III family endonucleases plays a central role in 
their proper functioning in the cell [4]. In the nucleus, Drosha cleaves primary miRNA 
precursors (pri-miRNAs) to produce ~70 nucleotides (nt) miRNA precursors (pre-
miRNAs) with 2 nt 3’ overhang [5]. Pre-miRNAs are transported by Exportin 5 to the 
cytoplasm where Dicer, another member of the RNAse III endonuclease family produces 
a mature miRNA duplex of ~21-28 nt basepairs (bp) [6]. Dicer also recognizes and 
processes shRNAs, which resemble the pre-miRNA structure. shRNAs with 19 bp or 
shorter stem may also be processed independently from Dicer cleavage, however the 
detailed mechanism has not been described [7-9]. The ~21-28 nt cleavage products 
enter a multiprotein RNA-induced silencing complex (RISC) where one of the strands 
is used for the sequence-specific recognition of target messenger RNA (mRNA) [10]. 
Drosha and Dicer cleavage is determined by certain RNA structures like a terminal loop 
region, a central stem bulge and single-stranded RNA (ssRNA) flanking sequences, 
which are recognized and serve as reference points for endonuclease digestions 
[5,6,11-13]. In the case of miRNA processing by Drosha, the stem-ssRNA junction is 
recognized by the Drosha cofactor DGCRG8 and cleavage occurs ~11 nt away from 
this structure [13]. Dicer anchors to both 5’ and 3’ ends of processed molecules and 
cleaves ~21-28 nt measured from one of the termini of the pre-miRNA or shRNA [11]. 
For Dicer cleavage mainly, the 5’ counting rules apply, meaning that the 5’ end acts 
as the primary reference point for the cleavage. The terminal loop is important as 
its disruption inhibits Drosha pri-miRNA processing as well as pre-miRNA and shRNA 
processing by Dicer [13]. Precise cleavage is critical for shRNA and miRNA functions 
because alterations in cleavage sites can change the abundance and thermodynamic 
stability of the shRNA and miRNA duplex, which is important for RISC loading [14].
shRNAs are generally expressed from polymerase III (pol III) promoters, which 
provide constitutive high expression levels necessary for potent knockdown of 
target mRNA. Although these features are valuable for research purposes, they 
can be disadvantageous for therapeutic applications. It has been reported that pol 
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III-expressed shRNA can lead to severe toxicity when high doses are used [15-17]. 
Grimm et al. observed liver failure and mortality in mice injected with different AAV-
expressed shRNAs irrespective of hairpin length, sequence and target [17]. Toxic side-
effects were associated with saturation of the cellular RNAi machinery and changes 
in endogenous miRNA expression. Toxicity may be circumvented by using lower 
doses of vectors encoding shRNA. However, this approach may result in loss of RNAi 
silencing efficacy and therapeutic effect [18]. Alternatively, toxicity resulting from 
shRNA overexpression can be resolved by embedding the siRNA sequence into an 
artificial miRNA scaffold and expressing it from weaker polymerase II (pol II) promoters 
[19,20]. Incorporation of a siRNA sequence in an artificial miRNA scaffold has been 
shown to abolish shRNA-induced neuronal cell death and to avoid disruption of the 
endogenous RNAi pathway [18,21]. However, in some cases miRNAs were found to 
be less potent compared to shRNAs [22]. 
Another disadvantage of pol III-expressed shRNAs is their constitutive expression in 
all cell types and organs. In order to limit their expression to target organs, the use of 
tissue-specific promoters has been applied for shRNAs [23,24]. However, this has been 
achieved with limited success as the rules for efficient transcription of shRNAs from 
poll II promoters are poorly understood and these constructs show only mild knockdown 
efficacy. Others have used inducible systems regulated by tetracycline or by ecdysone 
for expression of shRNAs or artificial miRNAs, which allows time- and dose-dependent 
expression when the inducer is administered and no expression in its absence [25-29]. 
Proof of concept has been established in transgenic mice enabling inducible and reversible 
suppression of gene expression by a tetracycline-regulated shRNA which also resulted 
in phenotypic changes [27]. However, the use of such systems in preclinical and clinical 
studies is limited because they include two additional components; elements encoding 
regulatory proteins that often induce an immune response and inducer molecules which 
need to be safe for long-term applications.
To date, no detailed analyses have been performed on the processing of identical 
predicted siRNA sequences embedded in shRNA or artificial miRNA scaffolds and the 
consequences for in vivo applications. Moreover, long-term efficacy in vivo and the 
use of miRNA expressed from a tissue-specific promoter have not been described. 
We addressed these issues by incorporating identical predicted siRNA targeting 
Apolipoprotein B (ApoB) in a shRNA (shApoB) or artificial miRNA scaffold (miApoB) 
and performed Next Generation Sequencing (NGS) analysis of the processed small 
RNAs. Additionally, aspecific off-target effects of shApoB and miApoB in vivo were 
investigated using NGS transcriptome analysis of the murine livers. ApoB is a constituent 
of all classes of lipoproteins that are considered atherogenic and elevated ApoB levels 
have been demonstrated to correlate with increased risk of cardiovascular disease 
(CVD) [30]. Therefore, ApoB is a highly validated target for treatment of increased low-
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density lipoprotein cholesterol levels and subsequent CVD [31,32]. Injection of AAV-
shApoB and AAV-miApoB yielded a long-term strong reduction of total cholesterol 
and ApoB expression. However, AAV-miApoB expressed from the liver-specific LP1 
promoter induced stronger knockdown and its expression was restricted to the 
targeted hepatocytes in contrast to AAV-shApoB, which was ubiquitously expressed. 
Our results demonstrate that incorporation of identical predicted siRNA sequences in a 
shRNA or miRNA scaffolds yields differential processing and long-term efficacy in vivo 
that might have implications for future therapeutic applications. 
Results
In vitro efficacy of shApoB and miApoB
Previously, we have reported that AAV delivery of shApoB expressed from the H1 
pol III promoter is highly effective in knocking down ApoB and in reducing plasma 
cholesterol in mice [33]. However, the AAV-shApoB effect measured at 8 weeks p.i. 
decreased compared to week 2 p.i., which was associated with lower expression of 
anti-ApoB siRNA (siApoB) [33]. For clinical applications, stringent control of shRNA 
expression and restriction to the target organs is desirable. Therefore, the 21 nt-long 
siApoB guide sequence was embedded in an artificial miRNA scaffold using pri-
mir-155 (miApoB, Fig. 1a) and expressed from the liver-specific LP1 promoter. The 
mature miApoB sequence was predicted to be identical as the one expressed from 
the shApoB scaffold (Fig. 1a). 
Initially, the efficacy of miApoB was tested in vitro using the CMV promoter 
instead of the liver-specific LP1 promoter since the latter has low activity in vitro [34] 
The inhibitory effect of shApoB and miApoB was compared by co-transfecting human 
embryonic kidney 293T (HEK 293T) cells with a reporter expressing renilla luciferase 
that contained the ApoB target sequence in its 3’UTR (Luc-ApoB). Scrambled controls 
for both shRNA and miRNA (shScr and miScr) were included as negative controls and 
firefly luciferase expression was measured to correct for transfection efficiency. The 
renilla/firefly luciferase ratio in the negative controls was set at 100% and relative 
inhibition of the Luc-ApoB reporter was calculated. Both shApoB and miApoB showed 
similar efficacy and reduced luciferase expression by approximately 80% (Fig. 1b).
Since the identical predicted siApoB sequence was embedded in the shApoB or 
miApoB scaffold the number of processed molecules per cell was determined by small 
RNA Taqman assay (Fig. 1c). HEK 293T cells were transfected with either shApoB- or 
miApoB-expression constructs and two days post-transfection total RNA was isolated 
and siApoB copies were measured. Processing of siApoB from the miApoB scaffold 
was ~30-fold lower compared to shApoB (Fig. 1c). In order to assess the effect of the 
inhibitory constructs on endogenous ApoB expression, the mouse hepatoma Hepa1-6 
cell line was transfected with shApoB or miApoB and ApoB mRNA knockdown was 
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measured two days post transfection (Fig. 1d). Both shApoB and miApoB efficiently 
inhibited ApoB mRNA up to 80% confirming the efficacy and specificity of the hairpin 
constructs. Our results indicate that shApoB and miApoB are equally effective in 
inhibiting Luc-ApoB and endogenous ApoB mRNA expression in vitro. 
NGS analysis of siApoB processed from shApoB or miApoB scaffolds reveals 
guide and passenger strand heterogeneity 
So far, the “golden standard” for siRNA detection has been the small RNA Taqman 
assay that relies on amplification of the predicted processed guide strand, which is 
normally 21 nt long. In the current research we investigated whether exactly identical 
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Figure 1. Structure and knockdown efficacy of shApoB and miApoB in vitro. (a) Predicted 
stem-loop structure for shApoB and miApoB with the guide strand shown in grey. (b) Knockdown 
of Luc-ApoB by shApoB and miApoB in HEK293T cells. Renilla and firefly luciferase were measured 
two days post-transfection with 50 ng Luc-ApoB reporter and 50 ng shApoB or miApoB, and renilla 
luciferase expression was normalized to firefly luciferase expression. shScr and miScr served as 
negative controls and were set at 100%. Data are represented as mean values ±SD from three 
independent experiments analyzed with factor correction [52] **p < 0.01 versus shScr or miScr. (c) 
siApoB expression from shApoB and miApoB in HEK293T cells. RNA was isolated two days post-
transfection with 1, 5, 10, 50, 100 and 250 ng of shApoB or miApoB and siApoB-specific small RNA 
TaqMan was performed. siApoB copy number was calculated using a siApoB synthetic RNA oligo 
standard line. Data are represented as mean values from two independent experiments conducted 
with two technical replicates. (d) Endogenous ApoB mRNA knockdown by shApoB and miApoB in 
Hepa1-6 cells. qRT-PCR was performed two days post-transfection with 1 μg shApoB or miApoB 
and ApoB mRNA levels were calculated relative to actin mRNA. shScr and miScr served as negative 
controls and were set at 100%. Data are represented as mean values ±SD from a representative 
experiment conducted with three technical replicates. **p < 0.01 versus shScr or miScr.
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miRNA scaffolds. This is an important issue since it may have serious implications 
for future therapeutic development. NGS sequencing was performed on small RNAs 
isolated from HEK 293T cells transfected with shApoB or miApoB. A total of ~ 16 mln 
reads were obtained for each sample, which were further processed by applying the 
selection criteria described in Materials and Methods. For the NGS data analysis, all 
reads smaller than 15 nt or larger than 55 nt and all reads that were read less than 
10 times were excluded from the analysis. Cellular miRNA expression pattern were 
compared between the miApoB and shApoB samples and are shown in Table S2. The 
small RNAs were aligned against their reference sequence resulting in 541.939 reads 
matching shApoB and 1.525.211 reads matching miApoB (Fig. S1 and S2). Analysis 
of the length distribution of the reads indicated that siApoB guide strand originating 
from shApoB ranged between 19 and 23 nt, with the most abundant one being 21 
nt-long (Fig. 2a). Surprisingly, siApoB guide from miApoB scaffold ranged from 23 
to 25 nt with the 24 nt-long strand being the predominant variant. This finding was 
rather unexpected considering that the predicted guide strand of siApoB was 21 nt 
long for both shApoB and miApoB scaffolds. Analysis of the processed 5’ ends of the 
siApoB guide strand indicated that most of the reads matched position +1 relative 
to the predicted cleavage site for shApoB, while all the reads matched position 0 for 
miApoB (Fig. 2b). The 3’ ends of the siApoB guide strand had a more heterogeneous 
pattern and ranged from -1 to +3 for shApoB and +1 to +4 for miApoB (Fig. 2c). 
Next, we looked at the sequence distribution and percentage of reads for both the 
guide and passenger siApoB strands originating from the shApoB and miApoB scaffolds 
(Fig. 2d). A substantial difference between the two is that the guide from shApoB is in 
the 3’ arm and hence Dicer [6] or other endonuclease [7-9] defines the cleavage position 
while the guide is present in the 5’ arm of miApoB, where Drosha defines the cleavage 
[5]. Thus, defining the length and exact cleavage position for the guide and passenger 
strands is very important since even single nucleotide differences may result in significant 
changes in the predicted targets of the siRNAs. Moreover, the passenger siRNA* strand, 
if not degraded efficiently, may bind to unanticipated targets and cause off-target effects. 
As expected, 44.4% of the reads originating from shApoB matched the siApoB guide 
strand but processing was shifted at position +1 (Fig. 2d, upper panel). Surprisingly only 
12.1% of the reads matched perfectly the predicted siApoB guide strand of 21 nt and 
starting at position 0. The reads matching the passenger siApoB* strand were represented 
in much lower percentage with the predominant one being only 5.3%. 
Analysis of the guide strand from the siApoB reads originating from the miApoB 
scaffold indicated that they all started at the predicted cleavage site (Fig. 2d, lower 
panel). Surprisingly, the predominant, 22.3% of reads were 24 nt-long. Furthermore 
5.1% reads were 23 nt- and 1.9% were 25 nt-long. A substantial number of 62% 
of the reads was found matching the passenger siApoB* strand and ranged between 
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Figure 2. Small RNA NGS analysis reveals differential siApoB guide and siApoB* passenger 
strand processing from shApoB and miApoB scaffolds. (a) Sequence length distribution of the 
siApoB guide strand recovered from small RNA NGS of HEK293T cells transfected with shApoB- 
or miApoB-expression plasmids. The frequency on the y axis represents the reads per million. (b) 
Sequence variation in the 5’ end of the mature siApoB guide strand. Nucleotide position 0 was 
designated as the 5’ end of the predicted siApoB guide and other forms are numbered accordingly. 
(c) Sequence variation in the 3’ end of the mature siApoB guide strand. Nucleotide position 0 was 
designated as the 3’ end of the predicted siApoB guide and other forms are numbered accordingly. 
(d) Sequence distribution and percentage of reads from siApoB guide and siApoB* passenger strands 
aligned to the reference shApoB (upper panel) or miApoB (lower panel) sequence. ApoB sequences 
are presented in upper case, the loop and flanking sequences are in lower case, the predicted 21 nt 
siApoB guide strand is shaded in grey. The percentage of reads was calculated based on the total 
number of reads matching the reference shApoB or miApoB sequence. Sequences represented with 
less than 1% were excluded from the figure and can be found in Figures S1 and S2. 
20 and 22 nt in length. In conclusion, both shApoB and miApoB scaffolds did not 
yield the predicted siApoB guide or siApoB* passenger sequences after processing 
from the cellular RNAi machinery. The guide from miApoB was cleaved much more 
precisely by Drosha at its 5’ end compared to shApoB that gave more heterogeneous 
pools of sequences following processing. Cellular miRNA expression profiles were 
also not identical for cells transfected with shApoB or miApoB (Table S2). 
102
Differential processing and efficacy of shRNA and miRNA
4
Long-term knockdown efficacy of AAV-delivered shApoB and miApoB in 
murine liver
Having shown that CMV-expressed miApoB, although differentially processed, is as 
effective in inhibiting ApoB as shApoB in vitro, we replaced the constitutive CMV promoter 
with the liver-specific LP1 promoter for in vivo applications. The use of LP1 limits miApoB 
expression to hepatocytes, thereby avoiding siApoB accumulation in non-target tissues. 
Male C57Bl/6 mice were injected with 1×1011 gc self-complementary AAV8 (scAAV8) 
per animal encoding shApoB, miApoB, shScr or miScr. All viruses co-expressed enhanced 
green fluorescent protein (eGFP) for monitoring of liver transduction efficacy. At week 27 
p.i. mice were sacrificed and siApoB small RNA Taqman was performed on RNA isolated 
from the liver, spleen, ileum, lung, heart, and kidney. Four times less siApoB molecules 
were detected from the AAV-miApoB-injected animals in the liver compared to AAV-
shApoB-injected animals (1163 vs. 399 copies per cell respectively) (Fig. 3a). In addition, in 
AAV-miApoB-injected animals siApoB expression was restricted to the liver in contrast to 
AAV-shApoB-injected mice where expression was detected in non-target organs (Fig. 3a). 
At week 27 p.i. ApoB mRNA was reduced by 55% in AAV-miApoB-injected animals 
while no mRNA decrease was detected in the AAV-shApoB group (Fig. 3b). The 
inhibitory effect of AAV-shApoB and AAV-miApoB on ApoB protein was determined 
every two weeks up to week 27 p.i. by Western blot (Fig. 3c and data not shown). 
Initially, a strong inhibition of ApoB protein was achieved by both AAV-shApoB and 
AAV-miApoB. However, the effect decreased at week 10 p.i. for AAV-shApoB and 
at week 20 p.i. for AAV-miApoB. At week 27 p.i. ApoB concentrations in plasma 
were decreased by 25% in animals injected with AAV-shApoB and by 60% in mice 
treated with AAV-miApoB (Fig. 3c). Next, the phenotypic effect of ApoB knockdown 
was measured every two weeks by biochemical lipid profiling of cholesterol in 
murine plasma (Fig. 3d). Similar to the ApoB protein knockdown, initially a strong 
~ 70% cholesterol decrease was induced by both AAV-shApoB and AAV-miApoB. 
However, the effect decreased gradually and at week 27 p.i. total cholesterol levels 
were reduced in both groups by only 25% compared to scrambled controls (Fig. 3d). 
Two-way ANOVA analysis revealed that AAV-miApoB performed significantly better 
than AAV-shApoB in reducing plasma cholesterol over the course of the experiment 
(p= 0.0018). In addition, there was a clear trend of a slower loss of plasma ApoB and 
cholesterol inhibition in mice injected with AAV-miApoB compared to AAV-shApoB 
indicating that miApoB had a better long-term efficacy than shApoB (Fig. 3c,d). 
Based on our previous observations that shApoB and miApoB are differentially 
processed and that miApoB has a different passenger, we checked for possible aspecific 
off-target effects in vivo. NGS liver transcriptome analysis was performed 8 weeks p.i. 
for animals injected with 1x1011 gc AAV encoding shScr, shApoB, miScr and miApoB. 
We investigated whether shApoB and miApoB processing differences translate into 
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Figure 3. Long-term reduction of ApoB 
and plasma cholesterol levels by 1×1011 
gc AAV-shApoB and AAV-miApoB. Mice 
were intravenously injected with 1×1011 
gc AAV-shApoB or AAV-miApoB, or their 
respective controls AAV-shScr, AAV-miScr 
or PBS. Plasma was collected every two 
weeks p.i. and animals were sacrificed at 27 
weeks p.i. (a) siApoB expression in murine 
spleen, ileum, lung, heart, kidney, and liver 
27 weeks p.i. Total RNA was isolated from 
snap-frozen tissue and siApoB-specific small 
RNA TaqMan was performed. siApoB copy 
number was calculated using a siApoB 
synthetic RNA oligo standard line. Data are 
represented as mean values ±SE, treatment 
groups are n=4-5 for AAV-shApoB, AAV-
shScr, AAV-miApoB or AAV-miScr and n=2 
for PBS-injected animals. (b) Relative ApoB 
mRNA expression in murine liver 27 weeks 
p.i. Total RNA was isolated from snap-frozen 
liver tissue and qRT-PCR was performed 
using ApoB- and actin-specific primers. ApoB 
mRNA levels were calculated relative to actin 
mRNA and scrambled controls were set at 
100 %. **p < 0.01 versus shScr or miScr (c) 
Western blot analysis of plasma ApoB at 2, 
4, 10, 16, 20, 24, and 27 weeks p.i. ApoB 
protein was detected in 0.1 µl plasma using 
a polyclonal antibody against ApoB. (d) Total 
cholesterol levels in plasma collected from 
fasted mice over the course of 27 weeks 
p.i. Cholesterol levels were analyzed on 
the automated clinical chemistry analyzer 
Modular Analytics P800. 
differences in gene expression in injected animals. A total number of 266 genes were 
significantly changing (p <0,05) in miApoB-injected mice compared to miScr (Table S3). 
Additionally 106 genes were found to be significantly up or down-regulated (p<0,05) 
in the shApoB mice compared to shScr (Table S4). Off-target predictions using Smith-
Waterman algorithm [35] for the most abundant guide and passenger strand variants 
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interactions. None of the changing genes had predicted targets for the guide or 
passenger strands of shApoB or miApoB (Table S3 and S4). 
Decrease of ApoB knockdown is due to gradual AAV vector DNA loss 
To follow up on the loss of ApoB and cholesterol inhibitory effect in vivo, AAV vector 
DNA copies were determined in murine liver at 2, 8, and 27 weeks p.i. from mice 
injected with AAV-shApoB and AAV-shScr. In both animal groups a clear gradual 
decrease in AAV vector DNA was observed over time indicating that the effect was 
not dependent on the shRNA target sequence (Fig. 4a). At week 8 and 27 p.i. the 
amount of AAV vector DNA copies in murine livers from AAV-miApoB and AAV-miScr 
were similar to AAV-shApoB and AAV-shScr indicating similar kinetics of vector loss 
irrespective of the promoter type (pol III or pol II), target sequence (Scr or ApoB), or 
of the shApoB or miApoB scaffolds (Fig. 4b). 
The loss of AAV vector DNA occurs presumably as a result of cell death due to 
liver toxicity. In line with this assumption, transient activation of liver transaminases 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured 
in all AAV-injected animals during the course of the experiment (Fig. S3). To 
explore the mechanism behind the DNA loss in more detail liver morphology was 
examined by hematoxylin and eosin staining. In addition, immunohistochemistry was 
performed to detect markers for apoptosis, T-regulatory cells, cytotoxic T lymphocytes, 
macrophages, and B lymphocytes. With none of those markers obvious differences 
between the treatment and PBS groups were found (data not shown). ELISA assay 
for antibodies against eGFP was performed to explore the possibility that these could 
have contributed to the loss of AAV vector DNA. No immune response against eGFP 
was found in any of the animals (data not shown). Together, these results indicate that 
there was no acute inflammatory effect responsible for the loss of AAV vector DNA. 
A possible reason for the observed AAV vector DNA loss is oversaturation of 
the endogenous RNAi machinery resulting in changes of cellular miRNA processing. 
Previously, we have shown that cellular mir-122, mir-29a and let-7a expression does 
not change in murine livers at 2 and 8 weeks p.i. with 1×1011 gc AAV-shApoB or 
AAV-shScr [33]. To exclude the possibility that the loss of AAV vector DNA is due to 
oversaturation of the endogenous miRNA pathway, we determined the amount of 
the most abundant liver miRNA mir-122 at week 27 p.i. for animals injected with 
AAV-shApoB, AAV-miApoB and the two control viruses. There were no significant 
changes in mir-122 expression between all animal groups indicating that there was 
no oversaturation of the RNAi machinery caused by the injected AAVs (Fig. S4). 
Lower AAV dose results in sustained ApoB and plasma cholesterol decrease
A possible reason for the observed AAV vector DNA loss and decrease in ApoB 
knockdown effect is the use of a too high viral dose. Previously we have shown 
105
Differential processing and efficacy of shRNA and miRNA
4
that when 1×109 gc AAV-shApoB or AAV-shScr was injected in mice, ~90% liver 
transduction can be achieved that was not associated with viral loss at 8 weeks p.i 
[33]. In the current study a 12 week mouse experiment was initiated with a dose 
of 5×109 gc AAV-shApoB, AAV-miApoB, AAV-shScr, AAV-miScr and an additional 
control group AAV-eGFP expressing only eGFP (Fig. 5). The experiment was restricted 
to 12 weeks based on our previous observations [33] and the results presented in 
Figure 3 showing that a 12-week time period is sufficient to observe a significant loss 
of AAV vector DNA and knockdown efficacy.
Inhibition of ApoB mRNA was observed in the groups injected with AAV-shApoB 
or AAV-miApoB at 12 weeks p.i, 57% for AAV-miApoB and 43% for AAV-shApoB, 
respectively (Fig. 5a). Subsequently a decrease in ApoB protein levels was observed at 
week 4 and the effect remained stable during the 12-week course of the experiment 
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Figure 4. Gradual loss of AAV vector DNA in vivo over a time course of 27 weeks p.i. Mice 
were intravenously injected with 1×1011 gc AAV-shApoB or AAV-miApoB, or their respective controls 
AAV-shScr and AAV-miScr and livers were collected at 2, 8 or 27 weeks p.i. Genomic DNA (gDNA) 
was isolated from snap-frozen liver tissue and qPCR was performed using LP1-specific primers. AAV 
copy number was calculated using a LP1 plasmid standard line. (a) AAV copy number per microgram 
gDNA in murine liver of animals injected with AAV-shScr or AAV-shApoB at 2, 8, and 27 weeks p.i. 
*p < 0.05, **p < 0.01 versus shScr wk2 or shApoB wk2. (b) AAV copy number per microgram gDNA 
in murine liver 8 and 27 weeks p.i. with AAV-shScr, AAV-shApoB, AAV-miScr or AAV-miApoB. Data 
are represented as mean values ±SE, treatment groups are n=4-5. 
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the kinetics and longevity of ApoB knockdown (Fig. 5c). Two weeks p.i., plasma 
cholesterol levels were decreased by 53% and 39% for AAV-miApoB- and AAV-
shApoB-injected animals and the effect remained stable until week 12 p.i. Finally, 
equal amounts of AAV vector DNA copies were measured in mice livers for all animal 
groups (Fig. 5d). The animals injected with AAV-eGFP control had similar ApoB, and 
cholesterol levels as well as AAV vector DNA copies as the AAV-shScr or AAV-miScr 
controls indicating that there were no hairpin-related non-specific toxic effects in 
the current study. Importantly, over the 12-week time course, liver transaminases 
were not significantly elevated for all treatment groups (Fig. S5). Again, there was a 
trend for a stronger ApoB and cholesterol decrease in AAV-miApoB injected animals 
compared to AAV-shApoB (Fig. 5 b,c). 
Figure 5. Sustained decrease of ApoB and plasma cholesterol levels by 5×109 gc AAV-shApoB 
and AAV-miApoB. Mice were intravenously injected with 5×109 gc AAV-shApoB, AAV-miApoB, 
AAV-shScr, AAV-miScr, AAV-GFP, or PBS. Plasma was collected every two weeks p.i. and animals were 
sacrificed at 12 weeks p.i. (a) Relative ApoB mRNA expression in murine liver 12 weeks p.i. Total RNA 
was isolated from snap-frozen liver tissue and qRT-PCR was performed using ApoB- and actin-specific 
primers. ApoB mRNA levels were calculated relative to actin mRNA and scrambled controls were set 
at 100%.*p < 0.05, **p < 0.01 versus shScr or miScr (b) Western blot analysis of plasma ApoB at 
0, 4, 8, and 12 weeks p.i. ApoB protein was detected in 0.1 µl plasma using a polyclonal antibody 
against ApoB. (c) Total cholesterol levels in plasma collected from fasted mice over the course of 12 
weeks p.i. Cholesterol levels were analyzed on the automated clinical chemistry analyzer Modular 
Analytics P800. (d) AAV copy number per microgram gDNA in murine liver 12 weeks p.i. gDNA was 
isolated from snap-frozen liver tissue and qPCR was performed using GFP-specific primers. AAV copy 
number was calculated using a GFP plasmid standard line. Data are represented as mean values ±SE, 






Differential processing and efficacy of shRNA and miRNA
4
Discussion
RNAi technology is one of the fastest developing scientific fields and holds a great 
promise for development of therapeutics of various diseases in the liver, brain, and 
the eye [36]. AAV vectors mediating expression of shRNAs or artificial miRNAs have 
proven to be valuable vehicles for RNAi research and therapy. However, induction of 
severe toxicity and/or off-target effects remains a major hurdle to be overcome before 
a long-term inhibition of a disease-related gene in the target tissue or organ can 
be accomplished. So far, detailed studies analyzing the precise processing of siRNA 
molecules expressed from shRNA or miRNA scaffolds and the consequences for in 
vivo applications have not been carried out. To address this issue, we have performed 
detailed NGS analysis of the siRNA processing when identical predicted sequences 
targeting ApoB have been embedded in shRNA or miRNA scaffolds. By using AAV 
delivery, we compared the efficacy and toxicity profiles of a constitutively expressed 
shRNA to tissue-specific expressed artificial miRNA in long-term in vivo studies. 
An unexpected discovery in the current study was that siRNA processing by the 
cellular RNAi machinery did not follow the generally accepted and described cleavage 
sites for both molecules shApoB and miApoB siApoB guide strand originating from 
the shApoB scaffold was more heterogeneous in cleavage sites and length compared 
to the product originating from the miApoB scaffold. Most likely, differential 
cleavage mechanism defined the heterogeneity in the guide and passenger strands. 
Additionally, shRNAs with 19 bp stem or less are not necessarily recognized by Dicer 
and maybe be processed differently [7-9]. The heterogeneity seen with the shApoB 
can also be explained by the potential for 2 or 3 uridines to be added following 
termination of pol III transcription [37]. The main pool of guide sequences originating 
from miApoB was 24 nt-long although we used the scaffold of cellular pri-mir-155 
that produces a 23 nt mature miRNA. However, a 24 nt-long siApoB sequence did not 
compromise efficacy because when placed in the miApoB scaffold, the ApoB target 
sequence was extended at the 3’ end with 4 nt until the loop (Fig. 1a). 
Another important observation is that the siApoB* passenger strand was present in 
a very high percentage of the reads from miApoB. Our results are in accordance with Gu 
et al. [14] who recently reported that mainly the guide siRNA strand of an shRNA was 
pulled down with Ago2 while both guide and passenger strands were detected from a 
miRNA scaffold associated with Ago1/2/3/4 [14]. Moreover, the passenger strand from 
the miRNA scaffold was not cleaved and eliminated as efficiently as from the shRNA. 
However, reporter assays revealed that the passenger siRNA* strand was mainly loaded 
into non-activated Ago complexes rendering those sequences ineffective at inducing 
knockdown. Our findings, together with the previously reported ones indicate that 
differential Ago loading of siRNAs originating from different scaffolds may have serious 
implications for future design of RNAi-based therapeutics. 
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There are important consequences of our findings for the small RNA Taqman 
that is being used for routine detection of siRNA expression. In our opinion this 
assay cannot be directly applied for sequences originating from shRNA or miRNA 
scaffolds because it amplifies only the predicted 21 nt guide strand and conclusions 
based on such data should be drawn with caution. Considering the different siApoB 
processing pattern from shApoB or miApoB scaffolds, the small RNA Taqman that 
was performed in vivo has only an indicative value rather than a precise estimation of 
the number of molecules per cell. 
The use of the liver-specific LP1 promoter for miApoB limited the expression of 
siApoB to hepatocytes, thus providing an additional safety level for future clinical 
applications compared to the ubiquitously expressed shApoB. So far it has been 
suggested that the use of tissue-specific promoters for miRNA expression will not be 
feasible in vivo as the expression would be too low to achieve significant therapeutic 
effect [36]. In the current study we provide evidence for the efficacy of such an 
approach in vivo and demonstrate its advantages over the pol III-expressed shRNA. 
Although it has been reported that expression of shRNA can be achieved from liver-
specific hAAT promoter and tetracycline-inducible promoter [23,27], the rules for 
design of potent shRNA expressed from pol II promoters are still far from clear. An 
additional advantage is that several miRNAs can be expressed as clusters from longer 
transcripts, allowing simultaneous targeting of multiple genes [20,38,39]. This feature 
of the miRNA is very important when mutation-prone viruses, such as HIV-1 or HCV, 
are targeted or when several disease-related genes need to be simultaneously silenced. 
Moreover, miRNAs can be linked to the 3’ untranslated region of a therapeutic gene, 
which is an additional advantage for therapeutic applications since it allows co-
delivery of a codon-optimized gene together with a miRNA targeting the disease-
causing version of the same gene. Such combinational therapy has been shown for 
alpha1-antitrypsin (A1AT) deficiency, in which a hairpin RNA targeting mutated A1AT 
transcript was delivered together with codon-optimized A1AT gene [40,41]. 
In the current study, we have demonstrated a more sustained ApoB target 
knockdown by miApoB over the shApoB in long-term in vivo experiments. Although 
differential processing resulting in different siApoB families from the two scaffolds 
should be kept in mind, this study provides indication that limiting siRNA expression 
to the target cells or organ holds greater promises for future therapeutic applications. 
Oversaturation of the RNAi machinery and competition with cellular miRNA transport 
from nucleus to cytoplasm have been described for both siRNA and shRNA and this 
toxicity problem was circumvented when the siRNA sequence was expressed from 
a miRNA scaffold by the CMV pol II promoter [20,42]. Grimm et al. reported that 
delivery of a high dose of 1×1012 gc per animal scAAV8 expressing shRNA led to 
hepatocyte death, often severe enough to cause liver failure and morbidity [17]. This 
109
Differential processing and efficacy of shRNA and miRNA
4
was associated with accumulation of shRNA precursor, which saturated Exportin 5 
and led to deregulation of the endogenous RNAi pathway. Toxic effects were reduced 
without compromising knockdown efficacy of the shRNA when a 10-fold lower viral 
dose or liver-specific expression of the shRNA were used [23]. Several other studies 
revealed neurotoxicity following AAV delivery of a shRNA targeting Huntingtin 
mRNA [18,21,22]. Subsequently, when siRNA sequences were incorporated in an 
artificial miRNA scaffold and expressed from the U6 pol III promoter neurotoxicity 
was abolished [21]. To our knowledge, no long-term head-to-head comparison 
has been performed to evaluate the processing and efficacy of siRNA sequences 
incorporated as identical predicted guide strand in a pol III-shRNA or liver-specific 
LP1 pol II-miRNA scaffolds. In contrast to the above-mentioned studies, our current 
data demonstrate that LP1-expressed miApoB did not circumvent liver toxicity and 
vector DNA loss when high doses of AAV were injected into mice. In our case AAV-
shApoB and AAV-miApoB delivery initially showed strong inhibition of ApoB protein 
and plasma cholesterol levels in vivo and the effects diminished due to gradual AAV 
vector DNA loss. Interestingly, the NGS small RNA analysis indicated that the number 
of processed siApoB molecules from the shApoB or miApoB scaffolds was almost 
identical indicating that we might have reached a threshold above which no more 
siRNA molecules are being processed. Indeed, it has been calculated that in a typical 
mammalian cell the number of active RISC complexes ranges from 103 to 104 and 
the number of ectopic RNAi triggers should be kept in this range [43]. An important 
observation was that none of the changes in gene expression in AAV-miApoB and 
AAV-shApoB can be explained by possible aspecific down-regulation of non-target 
transcripts. Because of the complexity of sh/miRNA processing and RISC loading, 
off-targeting interactions are difficult to predict and evaluate. Although we could not 
explain the changes in gene expression by off-target prediction with Smith-Waterman 
algorithm, we cannot exclude that other prediction methods like screening 3’ UTRs of 
genes for perfect complementarity to siRNA seed region may be more accurate [44]. 
miRNAs may regulate their targets by translational repression, therefore we might 
speculate that the off-target effects may be stronger at protein level.
By lowering the viral dose 20-fold a stable reduction of ApoB protein and plasma 
cholesterol was achieved by both AAV-shApoB and AAV-miApoB. Ongoing research 
including detailed liver histology to determine liver damage and small RNA NGS from 
murine livers will further investigate the exact cause of loss of RNAi inhibitory effect. 
For example, it is still unclear why after 27 weeks substantial amounts of siApoB can be 
detected from the AAV-shApoB-injected animals without observing ApoB knockdown 
effect. GFP fluorescence microscopy analysis demonstrated that only a few positive cells 
were still present at 27 weeks p.i. Most likely, only those few cells still expressed siApoB, 
which was not enough to achieve overall ApoB inhibition effect since the majority of 
110
Differential processing and efficacy of shRNA and miRNA
4
hepatocytes lost the siApoB due to liver regeneration. AAV itself is not likely to cause 
liver toxicity as it was shown not to be pathogenic or immunogenic in rodents [45] and 
in our studies we could not detect toxicity resulting from GFP expression, therefore 
excluding those two possibilities as reasons for AAV viral DNA loss. 
In summary, our results demonstrate that incorporating identical predicted 
sequences in shRNA or miRNA scaffolds results in differential siRNA processing 
patterns that may have serious consequences for future RNAi-based therapeutic 
applications. However, we consider that tissue-specific expression and embedding 
siRNA in artificial miRNA scaffold can contribute to a better and safer gene therapy 
approach due to the intrinsic characteristics of the miRNA structure rendering it a 
better substrate for the RNAi machinery.
Materials and methods
DNA constructs
Cloning of shApoB constructs (shA10) and shScr in the pSuper and AAV backbone 
has been described previously [33]. To create the miApoB vector, the siRNA sequence 
from shApoB was cloned into the mir-155 backbone of pcDNA6.2-GW/EmGFP-miR 
(Invitrogen, Carlsbad, CA) by annealing complementary oligonucleotides and ligation 
into BamHI- and XhoI-digested pcDNA6.2 plasmid. As a negative control for miApoB 
pcDNA6.2-GW/EmGFP-miR-neg control (Invitrogen, Carlsbad, CA) was used, named 
miScr. The luciferase reporter Luc-ApoB containing in the 3’UTR 1851 nucleotides of 
the last exon from human ApoB has been described previously [33]. The sequences 
of the oligonucleotides used in this study are listed in Table S1.
Cell culture and transfections
The HEK293T and Hepa1-6 cell lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen, Carlsbad, CA) containing 10% fetal calf serum, 100 U/
ml penicillin and 100 U/ml streptomycin, at 37°C and 5% CO2. For luciferase assays, 
endogenous ApoB knockdown assays, siRNA expression analysis, and small RNA NGS 
cells were seeded in 96-, 24- or 6-well plates at a density of 3×104, 1.2×105 or 4.5×105 
cells per well, respectively, in DMEM one day prior transfection. Transfections were 
performed with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions. 
Luciferase assays
Cells were co-transfected with 50 ng Luc-ApoB that contains both firefly and renilla 
luciferase genes, and 50 ng shApoB or miApoB expression constructs. Transfected 
cells were assayed at 48 hr post-transfection in 20 µl 1x passive lysis buffer (Promega, 
Madison, WI) by gentle rocking for 15 min at room temperature. The cell lysates 
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were centrifuged for 5 min at 4000 rpm and 10 µl of the supernatant was used to 
measure firefly and renilla luciferase activities with the Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI). Relative luciferase activity was calculated as the ratio 
between renilla and firefly luciferase activities. 
RNA isolation and quantitative real-time RT-PCR 
To determine endogenous ApoB mRNA knockdown by shApoB and miApoB constructs 
in vitro, Hepa1-6 cells were transfected with 1 µg shApoB- or miApoB-expression 
plasmids using Lipofectamine 2000 reagent and total RNA was isolated from cells 
48 hr post-transfection using the Nucleospin kit (Clontech, Mountain View, CA). 
For NGS analysis and Small RNA Taqman HEK293T cells were transfected with 4 µg 
shApoB- or miApoB-expression plasmids using Lipofectamine 2000 reagent and total 
RNA was isolated from cells 48 hr post-transfection using Trizol (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s protocol. To determine ApoB mRNA knockdown 
in vivo, total RNA was isolated from frozen liver sections at 27 and 12 weeks p.i. 
using Trizol (Invitrogen, Carlsbad, CA). Genomic DNA (gDNA) was removed by DNase 
treatment using TURBO DNase (Ambion, Austin, TX). First strand cDNA was reverse 
transcribed using random hexamer primers with the Dynamo kit (Finnzymes, Espoo, 
Finland). Real time PCR amplification was performed with ApoB- and beta actin-
specific primers (Table S1). PCR reaction conditions were: 95°C for 10 min, followed 
by 40 cycles of 15 sec at 95°C and 1 min at 60°C. The assays were performed on ABI 
7000 or ABI 7500 (Applied Biosystems, Foster City, CA). ApoB expression levels were 
normalized to beta actin as an internal control, and the relative gene expression 2-ΔΔCt 
method of Livak and Schmittgen was used for analysis of PCR data [46]. 
siRNA and miRNA detection by small RNA Taqman assay
RT reactions for siApoB and murine mir-122 expression were performed with the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) using 
10 ng RNA and 3 µl custom-made specific RT-stem-loop primer (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions. Amplification of the 
beta actin gene was used as a RNA quality and loading control.siRNA copy number 
per cell was calculated based on the amplification plot of a dilution series of synthetic 
siApoB RNA standard (IDT, Coralville, IA). The trend line value of the standard line 
was used to calculate the siApoB copy number cell, assuming 15 pg RNA per cell [47].
Next Generation Sequencing (NGS) of small RNA 
Small RNA sequencing libraries were generated using high-quality total RNA as 
input and the NEXTflex Small RNA Sequencing kit (Bioo Scientific, USA). Briefly, 
the small RNA species were subjected to ligation with 3’ and 5’ RNA adapters, 
first strand reverse transcription, and PCR amplification. Sample-specific barcodes 
112
Differential processing and efficacy of shRNA and miRNA
4
were introduced in the PCR step. The PCR products were separated on TBE-PAGE 
electrophoresis and the expected band around 140-160bp was recovered for each 
sample. The resulting sequencing libraries were quantified on a BioAnalyzer (Agilent). 
The libraries were multiplexed, clustered, and sequenced on an Illumina HiSeq 2000 
(TruSeq v3 chemistry) with a single-read 36 cycles sequencing protocol and indexing. 
The sequencing run was analyzed with the Illumina CASAVA pipeline (v1.8.0), 
with demultiplexing based on sample-specific barcodes. The raw sequencing data 
produced was processed removing the sequence reads which were of too low quality 
(only “passing filter” reads were selected), and discarding reads that aligned against 
the PhiX control. In total, we generated 16016701 reads for sample miApoB, and 
15843150 reads for sample shApoB. 
The NGS small RNA raw data set was analyzed using the CLC_bio genomic workbench 
(CLC Bio, Aarhus, Denmark). The obtained reads were adaptor-trimmed, which decreased 
the average read size from ~36bp to ~25bp. The custom adapter sequenced used for 
trimming all the bases extending 5’ was: GTGACTGGAGTTCCTTGGCACCCGAGAATTCCA. 
All reads containing ambiguity N symbols, reads shorter than 15 nt, longer than 55 nt 
in length and reads represented less than 10 times were discarded. Next, both data sets 
from shApoB and miApoB samples were grouped based on the match to the reference 
sequence and the obtained unique small RNAs were aligned to the sequence of pre-
miApoB: GATCCTGGAGGCTTGCTGAAGGCTGTATGCTGATGGACAGGTCAATCAATCT 
TGTTTTGGCCACTGACTGACAAGATTGAGACCTGTCCATCAGGACACAAGGCC 
TGTTACTAGCACTCACATGGAACAAATGGCCCAGATCTGGCCGCAG or shApoB: GA 
TCCCCGATTGATTGACCTGTCCATTTCAAGAGAATGGACAGGTCAATCAATCT 
TTTTCAGCTT sequence, respectively. To relatively represent the expression counts for 
the small RNAs obtained in the experiment, reads per million (rpm) [48] or percentage 
of reads based on the total number of reads matching the reference shApoB or miApoB 
sequence were calculated Finally, to identify the differences in cellular miRNA reads 
between the miApoB and shApoB samples the small RNA data sets were annotated to 
miRBase, Release 18 and grouped based on the mature miRNA sequences, the rpm were 
calculated and the fold change between miApoB and shApoB samples was calculated.
Total RNA sequencing libraries for the Illumina sequencing platform were 
generated using high-quality total RNA as input and the Illumina TrueSeq RNA v2 
Sample preparation kit according to the manufacturer’s protocol. Each read file 
(sample), in the FASTQ format, was individually aligned against the mouse reference 
genome (15 May 2012 NCBI build 38.1) using CLC Bio-Genomic Workbench and the 
expression abundance for each gene (RPKM) was calculated according to Montazavi 
et al. [49]. Smith-Waterman algorithm [35] was used to predict off-target genes in the 
mouse reference genome and mouse RNA Refseq for the most abundant expressed 
passenger and guide strands variants of shApoB and miApoB. 
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The NGS data discussed in this publication have been deposited in NCBI’s Gene 
Expression Omnibus [50] and are accessible through GEO Series accession number 
GSE39187 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39187).
Western blot analysis for detection of ApoB protein
Murine plasma proteins (0.1 µl) were separated by electrophoresis on a 3-8% Tris-
Actetate gel (Invitrogen, Carlsbad, CA) and blotted onto a 0.45 µm nitrocellulose 
membrane (Invitrogen, Carlsbad, CA). The blot was incubated with a 1:2000 
dilution of a rabbit polyclonal anti-ApoB antibody (ab31992, Abcam, Cambrigde, 
UK), followed by incubation with a 1:2000 dilution of goat anti-rabbit antibody 
conjugated to horseradish peroxidase (P0448, Dako, Glostrup, Denmark). Antibody 
binding was detected by the Lumi-LightPLUS chemiluminescent detection kit (Roche 
Diagnostics, Basel, Switzerland). 
AAV vector production 
Production of scAAV8 vectors encoding shApoB and shScr has been described 
previously [33]. The eGFP-expressing scAAV8 vector was created by digestion of a 
pTRCGW vector with XbaI and AflII restriction enzymes, blunting and ligation into 
a pro-AAV vector. The product of this cloning was named pVD287 and contains 
the eGFP gene under the control of the liver-specific LP1 promoter and generates 
scAAV due to a mutation in one terminal repeat For cloning the miRNA constructs, 
expression cassettes were amplified using PCR with specific primers miRf and miRr 
containing respectively EcoRI and PstI restriction sites at the 5’ end. Digested PCR 
product was ligated into EcoRI and PstI sites of pVD287. Constructs were sequence-
verified and the presence of two ITRs was confirmed by restriction digestion with 
SmaI. scAAV8 vectors were produced by calcium phosphate-mediated co-transfection 
in HEK293T cells, using the three-plasmid based system described by Gao et al. [51] 
Cells were lysed 48 hr after transfection and virus was released by addition of Tris 
lysis buffer. Crude lysate from all batches was treated with Benzonase (50 U/ml) 
(Merck, Darmstadt, Germany) for 1 hr at 37°C. AAV vector particles were purified 
by iodixanol (Sigma, St. Louis, MO) gradient centrifugation as described previously 
Purified batches were concentrated by passage through Vivaspin 15R tubes (Sartorius 
Stedim, Aubagne, France) and final concentration was determined by quantitative 
PCR with LP1f and LP1r primers amplifying a 95-bp fragment from the LP1 promoter 
region (Table S1). All viruses used in this study were simultaneously quantified three 
times to ensure that equal amount of gc per animal was injected.
Genomic DNA isolation and PCR
Genomic DNA (gDNA) was isolated using the DNeasy Blood & Tissue Kit (QIAGEN 
Inc., Chatsworth, CA) according to the manufacturer’s protocol. The amount of viral 
114
Differential processing and efficacy of shRNA and miRNA
4
DNA in 250 ng gDNA was quantified using quantitative PCR using Lp1fv and Lp1rv 
primers (Table S1) amplifying 95-bp fragment from LP1 region or primers eGFPf and 
eGFPr (Table S1) amplifying a 101-bp fragment from the eGFP region. As a standard 
line, serial dilutions of plasmid DNA containing LP1 or GFP respectively were used.
In vivo experiments
All animal experiments were conducted according to the guidelines of the local 
animal welfare committee. Six-to-eight-week-old male C57BL/6 mice received 
an intravenous AAV injection of 1×1011 gc per animal (~4×1012 gc/kg) or 5×109 
gc per animal (~2×1010 gc/kg) via the tail vein. Treatment groups were n=4-5 for 
AAV-shRNA and AAV-miRNA and n=2 for PBS-injected animals. In the AAV-shApoB 
group sacrificed at 12 weeks n=4 because one animal died during blood sampling. 
Heparinized blood samples were taken every two weeks p.i. from fasted mice. Mice 
were sacrificed at 2, 8, 12 or 27 weeks p.i. and liver, heart, lung, kidney, ileum, 
spleen, and plasma were collected for analysis. Liver samples from 2 and 8 weeks p.i. 
were obtained from a previous experiment where mice were injected with 1×1011 gc 
of identical preparation of AAV-shScr or AAV-shApoB. Mice were housed 6 per cage 
and feeding was performed ad libitum with regular chow. Plasma levels of ALT, AST, 
and total cholesterol were analyzed on the automated clinical chemistry analyzer 
Modular Analytics P800 (Roche Diagnostics, Basel, Switzerland) at the Academic 
Medical Center (Amsterdam, the Netherlands). Statistical analysis was performed by 
ANOVA testing and p<0.05 was considered significant.
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Figure S1. Sequence annotation of siApoB reads matching shApoB sequences (available 
online). siApoB reads were annotated against shApoB reference sequence with the following 
settings: 2 additional upstream bases, 2 maximum mismatches, 2 missing downstream bases, 2 
missing upstream bases. There were 793 from 26,848 small RNAs sequence variants annotated to 
shApoB sequence (541,939 of 14,491,210 reads). The match type can be exact or a sequence variant 
with mismatches and the numbers represent number of reads for each sequence. For calculating of 
frequency 10e6 (rpm), the numbers of reads have to be multiplied by a factor of 0,690.
Figure S2. Sequence annotation of siApoB reads matching miApoB sequences (available 
online). siApoB reads for miApoB sample were annotated against pre-miApoB reference sequence 
with the following settings: additional 2 additional upstream bases, 2 maximum mismatches, 2 
missing downstream bases, 2 missing upstream bases. There were 741 from 33,164 small RNAs 
sequence variants annotated to miApoB sequence (1,525,211 of 14,524,958 reads). The match type 
can be exact or a sequence variant with mismatches and the numbers represents number of reads 
for each sequence. For calculating of frequency 10e6 (rpm), numbers of reads have to be multiplied 
by a factor of 0,688.
Figure S3. Transient increase in liver transaminases after injection with 1x1011 gc AAV. Liver 
transaminases AST (left) and ALT (right) over the course of 27 weeks p.i. Mice were intravenously 
injected with 1x1011 gc AAV-shApoB or AAV-miApoB, or their respective controls AAV-shScr and 
AAV-miScr or PBS. Plasma was collected every two weeks p.i. and animals were sacrificed at 27 
weeks p.i. Transaminases were analyzed on the automated clinical chemistry analyzer Modular 
Analytics P800 from Roche. Data are represented as mean values ±SE, treatment groups are n=4-5 
for AAV-shRNA or AAV-miRNA and n=2 for PBS-injected animals.
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Figure S4. No significant change in mir-122 expression after injection with AAV-shRNA and 
AAV-miRNA. Relative expression of liver-specific mir-122. Total RNA was isolated from snap-frozen 
livers at 27 weeks p.i. and miRNA-specific Taqman was performed. mir-122 expression level was 
calculated relative to actin mRNA and the PBS control was set at 100%. Data are represented as mean 
±SE, treatment groups are n=4-5 for AAV-shRNA or AAV-miRNA and n=2 for PBS.
Figure S5. Stable liver transaminases after injection with 5x109 gc AAV. Liver transaminases AST 
(left) and ALT (right) over the course of 12 weeks p.i. Mice were intravenously injected with 5x109 
gc AAV-shApoB, AAV-miApoB, AAV-shScr, AAV-miScr, AAV-GFP, or PBS. Plasma was collected every 
two weeks p.i. and animals were sacrificed at 12 weeks p.i. Transaminases were analyzed every 2-4 
weeks p.i. on the automated clinical chemistry analyzer Modular Analytics P800 from Roche. Data are 
represented as mean values ±SE, treatment groups are n=4-5.
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Table S1. Oligonucleotides used in this study


























ApoBf TGGTTACTGCGCTGAGAGG ApoB qRT-PCR 
ApoBr CCACACTGAACCAAGGCTT
m-act-f ACGGCCAGGTCATCACTATTG Mouse actin qRT-PCR 
m-act-r CAAGAAGGAAGGCTGGAAAAGA
LP1f CCCTGTTTGCTCCTCCGATAA LP1 qPCR 
LP1r GTCCGTATTTAAGCAGTGGATCCA
eGFPf GGGCACAAGCTGGAGTACAACTA eGFP qRT-PCR
eGFPr ATGTTGTGGCGGATCTTGAAG
118
Differential processing and efficacy of shRNA and miRNA
4
Table S2. Changes in miRNA expression in shApoB versus miApoB samples (available online). 
Cellular small RNA data sets were annotated to miRBase (release 18, November 2011) and grouped 
based on the mature miRNA sequences and reads per million (rpm) were calculated. For each miRNA, 
proportion of the reads and the fold change between shApoB and miApoB samples were calculated. 
If the proportion of the given miRNA from the shApoB sample was lower than proportion of the 
same miRNA in the miApoB sample then this was represented by the negative value. All miRNAs with 
sequential numerical identifiers up to 500 and fold change more than two were included in statistical 
comparison. Kal’s test (Z-test) with Bonferroni correction was used to compare the proportions of 
miRNAs in the miApoB versus shApoB sample. *p < 0.05, **p < 0.01.
Table S3. Expression changes in miApoB versus miScr murine liver samples (available online). 
Total RNA from murine livers was isolated 8 wk p.i. with 1×1011 gc AAV encoding miScr and miApoB 
and NGS analysis was performed for a representative animal of each group. Data sets were annotated 
to mouse reference genome (15 May 2012 NCBI build 38.1) and the expression abundance was 
quantified using the Reads per kilobase of exon model per million mapped reads (RPKM) measure: 
RPKM of (i) gene = 109 x Ci/(Ni x Li), where i is the gene, Ci is the sum of short read counts mapped 
to exons and Ni represents all mapped read counts in the lane, and Li is the sum of exon lengths [47]. 
For each entry the fold change between miApoB and miScr samples were calculated. If expression of 
given gene (RPKM) in the miApoB sample was lower than expression of the same gene in the miScr 
sample then this was represented by a negative value. Kal’s test (Z-test) with Bonferroni correction 
was used to compare the RPKM value in the miApoB versus miScr sample. *p < 0.05, **p < 0.01.
Table S4. Expression changes in shApoB versus shScr murine liver samples (available online). 
Total RNA from livers was isolated 8 wk p.i. with 1×1011 gc AAV encoding shScr or shApoB and 
NGS analysis was performed for one representative animal of each group. Data sets were annotated 
to mouse reference genome (15 May 2012 NCBI build 38.1) and the expression abundance was 
quantified using the Reads per kilobase of exon model per million mapped reads (RPKM) measure: 
RPKM of (i) gene = 109 x Ci/(Ni x Li), where i is the gene, Ci is the sum of short read counts mapped 
to exons and Ni represents all mapped read counts in the lane, and Li is the sum of exon lengths [47]. 
For each entry the fold change between shApoB and shScr samples were calculated. If expression of 
given gene (RPKM) in the shApoB sample was lower than expression of the same gene in the shScr 
sample then this was represented by the negative value. Kal’s test (Z-test) with Bonferroni correction 
was used to compare the RPKM value in the shApoB versus shScr sample. *p < 0.05, **p < 0.01.
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Abstract
Constitutive expression of short-hairpin RNAs (shRNAs) may cause cellular toxicity 
in vivo and using microRNA (miRNA) scaffolds can circumvent this problem. Here 
we show that embedding siRNA sequences targeting Apolipoprotein B100 (ApoB) in 
shRNA (shApoB) or miRNA (miApoB) scaffolds resulted in differential processing and 
efficacy, leading to changes in liver morphology, cellular miRNA and gene expression. 
Adeno-associated virus (AAV)-shApoB- or AAV-miApoB-mediated ApoB knockdown 
induced differential expression of 37 cellular miRNAs and significant deregulation of 
106 and 266 genes, respectively. Overall, our data indicate that therapeutic expression 
of shApoB and miApoB results in alterations of different lipid metabolism genes 
despite the same phenotypic effect of plasma cholesterol reduction. Surprisingly, only 
in AAV-shApoB-injected animals, genes involved in immune system activation or cell 
growth and death were affected, which was represented with increased hepatocyte 
proliferation in this group. Subsequently, in AAV-miApoB-injected animals, changes 
of genes involved in oxidoreductase activity, oxidative phosphorylation and nucleic 
bases biosynthetic processes were observed indicating that shApoB and miApoB have 
a distinct side effect profile. Deregulation of cellular miRNA and liver transcriptome 
may have serious consequences for future RNAi therapeutics as it may result in 
cytotoxicity and loss of gene silencing.
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Introduction
RNAi is an evolutionary conserved sequence-specific post-transcriptional gene silencing 
mechanism in eukaryotes that results in the degradation of mRNA and subsequently 
in decrease of protein synthesis [1]. Therapeutic RNAi can be induced by delivering 
synthetic small interfering RNAs (siRNAs) or by intracellular expression of short hairpin 
RNAs (shRNAs) and artificial microRNAs (miRNAs) that target a disease-causing gene 
[2,3,4]. shRNAs and miRNAs are typically expressed in the cell from pol III or pol II 
promoters, respectively and are processed by the RNAi machinery, rendering a mature 
siRNA, which interacts with the cytosolic multiprotein RNA-induced silencing complex 
(RISC). The RISC-incorporated siRNA binds to the complementary mRNA sequence and 
mediates its sequence-specific degradation or translational repression [5,6].
Because RNAi can interfere with normal functioning of the cells, the safety of RNAi 
therapeutics is a major issue. Non-specific effects resulting from the RNAi induction 
appear to have several main causes: oversaturation of the RNAi pathway, aspecific 
activation of the immune response and off-target effects due to miRNA-like binding 
[7-12]. These side effects are often associated with severe toxicity, which can be even 
fatal. High expression levels of therapeutic shRNA can saturate the endogenous RNAi 
machinery and in consequence lead to deregulation of the entire miRNA network. 
For example, mice injected with AAV expressing shRNAs against different targets, 
developed liver failure irrespective of hairpin length, sequence, and target [10]. Toxicity 
could be circumvented by using lower vector doses, but this approach in some cases 
resulted in loss of RNAi silencing efficacy and therapeutic effect [13]. Alternatively, 
toxicity resulting from shRNA overexpression can be resolved by embedding the 
siRNA sequence into an artificial miRNA scaffold and expressing it from weaker pol II 
promoters [4,14,15]. By using miRNA scaffolds disruption of the endogenous RNAi 
pathway is avoided and shRNA-induced cell death can be prevented. However, in 
some cases miRNA were found to be less potent compared to shRNA [13]. 
A second source of toxicity is immune system activation. Characteristically, the 
interferon (IFN) response to foreign double-stranded RNAs (dsRNAs) is either mediated 
by phosphorylation of the dsRNA-dependent protein kinase R (PKR) leading to a global 
inhibition of protein synthesis [16] or via Toll-like receptor (TLR) activation [17]. Recent 
studies showed that RNAi therapeutics, in particular siRNAs can be potent inducers 
of IFN and inflammatory cytokines both in vivo and in vitro [9,11]. Administration 
of siRNA for treatment of neovascular age-related macular degeneration (AMD) has 
been reported to induce retinal degeneration via non-specific activation of immune 
response, which was independent of siRNA or target sequence [18]. Although 
intracellulary expressed shRNAs are less prone to IFN activation because they can 
evade activation of TLR, several reports indicated immune reactions against vector 
delivered shRNA. For example, adenoviral delivery of shRNA targeting Fatty acid 
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binding protein 5 (Fabp5) activated IFN response in liver [19] and lentiviral vector 
delivery of shRNA targeting Cyclophilin resulted in IFN activation in vitro [20]. 
Another source of RNAi toxicity is aspecific deregulation of gene expression, when 
non-targeted transcripts are down-regulated based on sequence complimentarily to 
the shRNA or miRNA “seed” sequence [12,21]. Because of the complexity of shRNA 
and miRNA processing and RISC loading, these unanticipated interactions are difficult 
to predict and evaluate. Off-targeting can be minimized by adopting a stringent 
design filter both for sense and antisense strands of the RNAi efector molecules. This 
approach has been validated for siRNA targeting Huntingtin, where off-targeting 
effect was significantly minimized by avoiding complementarity of siRNA “seed” to 
3’UTR, while a high silencing potential was maintained [22]. Additionally significant 
reduction of off-target effects can be achieved by reducing the dose of siRNA or by 
chemical modification which impairs siRNA binding to possible off-targets [23].
Previously we have identified differences in processing and efficacy of shRNA and 
artificial miRNA targeting Apolipoprotein B100 (ApoB) that resulted in differences 
in long-term gene silencing in vivo when delivered with self-complementary adeno-
associated virus serotype 8 (AAV) [24]. In the present study we investigated the effect 
of AAV-shApoB and AAV-miApoB expression on liver morphology, cell proliferation, 
cellular miRNA and transcriptome changes. Using both approaches, a strong decrease 
of plasma cholesterol was observed in vivo without signs of serious side-effects. 
Although biochemical analysis showed no acute toxicity, the AAV-shApoB and AAV-
miApoB induced differential changes in liver histology, miRNA and transcriptome 
profiles. Hepatic steatosis, which is known side-effect of ApoB inhibition, was 
observed with both molecules. However in AAV-shApoB-injected animals increased 
proliferation of hepatocytes was observed as compared to AAV-miApoB and only in 
AAV-shApoB-injected animals, genes involved in immune response, cell growth and 
death were found to be affected. 
Results
Knockdown efficacy of AAV-delivered shApoB and miApoB in murine liver
We have previously reported that identical AAV-delivered siApoB sequences in 
shApoB and miApoB scaffolds (Fig. 1a) are differently processed and have a dissimilar 
knockdown efficacy in vivo [24]. miApoB had a better long-term efficacy and resulted 
in a more sustained reduction of plasma ApoB and cholesterol in mice. The reduction 
of therapeutic efficacy was associated with a loss of virally-delivered DNA, but no 
obvious signs of RNAi toxicity were observed. To directly compare the safety profile of 
shApoB and miApoB, male C57Bl/6 mice were injected with 1×1011 gc AAV per animal 
encoding shApoB, miApoB, shScr and miScr. All viruses co-expressed enhanced green 
fluorescent protein (eGFP) for monitoring of liver transduction efficacy and eGFP only 
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expressing virus (AAV-GFP) was used as an additional control. Mice were sacrificed 
at week 8 post injection (p.i.) and liver samples were collected for histological and 
molecular analysis. According to eGFP fluorescence intensity liver transduction efficacy 
was ~50% (Fig. 1b), and at week 8 ApoB mRNA was reduced by 80% in AAV-
shApoB and 87% in AAV-miApoB-injected animals (Fig. 1c). This resulted in 60% and 
70% inhibition of plasma cholesterol, respectively (Fig. 1d). Quantification of siApoB 
molecules expressed from both shApoB and miApoB showed that the knockdown 
effect correlated to siRNA expression in the liver and AAV-miApoB transduction 
resulted in significantly less siApoB molecules (Fig. 1e).
It has been reported that expression of shRNA may lead to severe liver toxicity 
symptoms that is associated with an increase of plasma levels of the transaminases 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Mice injected 
with AAV-miScr eshowed a mild increase in ALT levels at weeks 4 and 6 p.i., which 
returned to baseline at week 8 p.i. (Fig. 1f). AAV-miApoB injection gave rise to a 
two- to three- fold increase in ALT at week 4 p.i. and AST at week 6 p.i. (Fig. 1f). 
In contrast, no significant increase in liver transaminases for the AAV-shScr, AAV-
shApoB and AAV-GFP-injected animals was observed (Fig. 1f). Mouse body weight 
did not change in any groups and none of the animals displayed any signs of illness 
or discomfort (data not shown).
Expression of shApoB increases hepatocyte proliferation in vivo
A histological analysis was performed to evaluate the effect of stable expression of 
shApoB and miApoB on liver morphology. ApoB suppression results in decreased 
cholesterol levels due to impairment of VLDL-C and LDL-C assembly [25] but can also 
lead to hepatic triglyceride accumulation [26-28]. Triglycerides are normally incorporated 
into VLDL-C and hepatic accumulation of these lipids can potentially cause steatosis. To 
investigate the effect of ApoB knockdown on liver morphology, a scoring system was 
developed and was used to score hematoxylin and eosin (H&E) liver sections (Table S1). 
Histological analysis revealed no gross changes in liver morphology and no signs of 
lobular or portal inflammation or parenchymal necrosis were detected in any group 
(Fig. 2a). However in AAV-shApoB- and AAV-miApoB-injected animals, microvesicular 
steatosis affecting more than 67% of the liver tissue was apparent (Table 1 and Fig. 2a). 
In addition, an increase in the hepatocellular mitosis rate was found in AAV-shApoB-
injected animals (Table 1). To confirm the scoring results and assess the effect of ApoB 
knockdown on hepatic lipid accumulation, Oil red O staining was performed on liver 
sections. Increased accumulation of hepatic lipid content in AAV-shApoB- and AAV-
miApoB-injected animals compared to control groups was detected (Fig. 2b).
Previously we have demonstrated that the silencing effect of AAV-shApoB and 
AAV-miApoB waned over time and this was associated with a loss of virally delivered 
DNA [24]. We hypothesized that the loss of the (non-integrated) silencing construct 
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Figure 1. Structure, knockdown efficacy of AAV-shApoB and AAV-miApoB, siApoB expression 
and ALT/AST levels in vivo. Male C57BL/6 mice were intravenously injected with 1x1011 gc AAV-
shApoB, AAV-miApoB, AAV-shScr, AAV-miScr, AAV-GFP or PBS. Plasma was collected every two 
weeks p.i., animals were sacrificed at 8 weeks p.i. and liver samples were collected for analysis 
(a) Predicted stem-loop structure for shApoB and miApoB with the guide strand shown in grey. 
(b) Representative image of GFP fluorescence in snap-frozen livers, transduced with 1011 gc of the 
indicated viruses. Photos were taken using the same exposure and magnification settings. (c) Relative 
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could have resulted from either cell division or cell death. Histological scoring showed 
an increase of proliferating hepatocytes in AAV-shApoB-injected animals, but no 
increase of apoptotic cells was observed in any of the groups (Table 1). To confirm 
these histological findings, we first examined whether AAV-shApoB or AAV-miApoB 
administration enhances the proliferative state of the liver cells. Two major types 
of cells populate the liver lobes: parenchymal referred as hepatocytes and non-
parenchymal cells-sinusoidal cells. To distinguish between proliferating hepatocytes 
and sinusoidal cells slides were simultaneously stained with antibodies against 
cytokeratine 18 (CK18), which is a marker for hepatocytes, anti-CD31, a known 
marker for sinusoidal cells, and the Ki67 antigen, a known marker for cell proliferation 
(Fig. 2c). Surprisingly the number of proliferating hepatocytes was increased ~2 fold 
in AAV-shApoB animals compared to AAV-miApoB and control groups (Fig. 2d). 
When livers were stained for cleaved caspase 3, no increased apoptosis was detected 
in any of the animal groups (Fig. 2e). 
Table 1. Histological scoring of H&E liver sections. Mice were intravenously injected with 1x1011 
gc AAV-shApoB or AAV-miApoB, or their respective controls AAV-shScr, AAV-miScr, AAV-GFP and 
PBS. Animals were sacrificed at 8 weeks p.i. and liver samples were collected for analysis Paraffin 
embedded liver sections were stained with H&E and blind histological scoring was performed. 
Detailed information about the the scoring system used can be found in Table S1. *p<0,05 One-way 
ANOVA with Bonferroni post test against PBS.
ITEM
AVERAGE SCORE
shScr shApoB miScr miApoB shGFP PBS
Macrovesicular steatosis 0 0 0 0 0 0
Microvesicular steatosis 1 3* 0 3* 0 0
Ballooning 0 0 0 0 0 0
Lobular inflammation 1 1 1 1 1 1
Portal inflammation 1 0 0 1 0 1
Sinusoidal dilatation 0 0 0 0 0 0
Parenchymal necrosis 0 0 0 0 0 0
Hepatocellular mitosis 1 2* 0 0 0 0
Councilman bodies 0 0 1 1 1 1
tissues and qRT-PCR was performed using ApoB- and actin-specific primers. ApoB mRNA levels were 
calculated relative to actin mRNA. ApoB mRNA levels in the PBS group was set at 100 %. Data are 
represented as mean values ±SE (d) Total cholesterol levels in plasma collected from fasted mice 
over the course of 8 weeks p.i. Cholesterol levels were analyzed on the automated clinical chemistry 
analyzer Modular Analytics P800. (e) siRNA expression in murine liver 8 weeks p.i. Total RNA was 
isolated from snap-frozen tissues and siApoB-specific small RNA TaqMan was performed. siApoB copy 
number was calculated using a siApoB synthetic RNA oligo standard line. Data are represented as 
mean values ±SE. (f) Plasma ALT (left panel) and AST (right panel) levels at 0, 2, 4, 6 and 8 weeks p.i. 
Transaminases were analyzed on the automated clinical chemistry analyzer Modular Analytics P800. 
Data are represented as mean ±SE, treatment groups are n = 5.
▶
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Figure 2. Effect of AAV-delivered shApoB and miApoB on liver morphology, proliferation 
and hepatic fat accumulation. Mice were intravenously injected with 1x1011 gc AAV-shApoB or 
AAV-miApoB, or their respective controls AAV-shScr, AAV-miScr, AAV-GFP and PBS. Animals were 
sacrificed at 8 weeks p.i. and liver samples were collected for analysis. (a) Representative image 
of H&E liver morphology staining. Paraffin embedded liver sections were stained with eosin for 
cytoplasm visualization, and nuclei were counterstained with hematoxylin solution. (b) Representative 
image of hepatic lipid accumulation. Frozen liver sections were stained with Oil Red O for lipids, and 
nuclei were counterstained with hematoxylin solution. (c) Representative image of liver proliferation. 
Paraffin embedded liver sections were simultaneously stained in red for hepatocytes (Rabbit anti-
mouse CK18), in brown for sinusoidal cells (rabbit anti-mouse CD31) and in blue for antigen Ki67 
(Rabbit ant-mouse Ki67). A nuclei counterstaining with hematoxylin was performed. (d) Representative 
image of liver apoptosis. Paraffin embedded liver sections were stained in blue for cleaved-Caspase 
3 (Rabbit anti-mouse). Nuclei counterstaining with hematoxylin was performed. (e) Quantification 
of proliferating hepatocytes staining described in c). Spectral decomposition was done using inForm 
software v1.4 and the amount of proliferating hepatocytes (CK18+, Ki67+) was calculated for each 
animal in 5 different visual fields. Data are represented as mean values of 5 animals ±SE. ***p < 
0.001 One-way ANOVA with Bonferroni post test against PBS. Bar = 5 µm
▶
shApoB and miApoB expression induces differential cellular miRNA expression
Overexpression of therapeutic shRNAs and miRNAs can modify the processing of 
cellular miRNA transcripts since they share the same processing pathway and 
nuclear export machinery. We investigated whether high expression of shApoB and 
miApoB competes with the intracellular processing of miRNAs in vitro and in vivo. 
Next generation sequencing (NGS) of small RNAs was performed on HEK293T cells 
transfected with shApoB- or miApoB-expression constructs. Expression of endogenous 
miRNAs was normalized to mir-92 and expressed as number of reads per million 
(rpm). All conserved mammalian miRNAs with more than a 2-fold change between 
miApoB and shApoB were included in the statistical comparison. Kal’s test (Z-test) 
with Bonferroni correction was used to compare the expression values of the cellular 
miRNAs in the miApoB- versus shApoB-transfected cells. A total of 37 cellular miRNAs, 
were found to be differentially expressed (Fig. 3a). A complete list of the differentially 
expressed miRNAs in the miApoB- versus shApoB-transfected cells can be found in 
Supplementary Table 2.
To determine whether shApoB and miApoB expression in vivo also results in 
different cellular miRNA profiles, endogenous levels of 7 miRNAs that are expressed 
in liver were measured in vivo 8 wk p.i. for all animal groups (Fig. 3b). The levels of 
the liver-specific mir-122 and the broadly expressed miRNAs let-7a, let-7e, mir-26a 
and mir-221 were not significantly changed in any of the groups expressing shApoB 
or miApoB. Expression levels for all miRNAs tested were in the range of 80% to 200% 
of the levels measured in PBS-treated animals. Mir-133a and mir-199a expression 
was 2-3 fold upregulated in AAV-miApoB-injected animals compared to PBS-injected 
animals. Importantly, mir-133a expression was significantly different in AAV-miApoB 
group compared to AAV-shApoB.
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Figure 3. Effect of shApoB and miApoB expression on cellular miRNA levels in vitro and 
in vivo. (a) Cellular miRNA changes in miApoB vs. shApoB transfected cells. NGS analysis was 
performed on RNA isolated two days post-transfection with 1 μg shApoB or miApoB expression 
constructs. Cellular small RNA data sets were annotated to miRBase (release 18, November 2011) and 
grouped based on the mature miRNA sequences and reads per million (rpm) were calculated. For each 
miRNA, proportion of the reads and the fold change between shApoB and miApoB samples were 
calculated using Kal’s test (Z-test) with Bonferroni correction. All miRNAs with sequential numerical 
identifiers up to 500 that are significantly changing are represented in the graph. (b) Verification of 
the NGS data in vivo. Relative expression of let-7a, let-7e, mir-26a, mir-122, mir-133a, mir-199b and 
mir-221 in vivo was measured by miRNA TaqMan. Mice were intravenously injected with 1×1011 gc 
AAV-shApoB or AAV-miApoB, or their respective controls AAV-shScr, AAV-miScr, AAV-GFP and PBS. 
Total RNA was isolated from snap-frozen livers. miRNA expression levels were calculated relative 
to actin mRNA and the PBS-treated group was set at 100%. Data are represented as mean ±SE, 
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NGS of liver transcriptome reveals differential gene expression  
in AAV-shApoB- and miApoB-injected animals
The differential siRNA processing from shRNA or miRNA scaffolds may have different 
consequences for induction of aspecific off-target effects. Therefore we investigated 
the effect of AAV-shApoB, AAV-shScr, AAV-miApoB, AAV-miScr or PBS on the liver 
transcriptome by performing NGS analysis. The expression abundance for each 
gene, represented in reads per kilobase of exon model per million mapped reads 
(RPKM) was calculated and Kal’s test (Z-test) with Bonferroni correction was used 
to compare the RPKM values. We further focused on gene changes that are specific 
results of shApoB and miApoB expression, therefore we compared their profiles to 
the negative controls AAV-shScr and AAV-miScr. All AAV viruses co-expressed GFP 
therefore AAV-GFP sample was excluded from the NGS analysis. In the AAV-shApoB 
sample 106 genes were found to be significantly changed (68 were upregulated 
and 38 were downregulated; p<0,05) compared to AAV-shScr (Fig. 4a and 4b). A 
total of 266 genes were significantly changed (p <0,05) in AAV-miApoB-treated mice 
compared to AAV-miScr (Fig. 4a). Among them 154 genes were upregulated and 
112 genes were found to be downregulated (Fig. 4b). Additionally gene expression 
of AAV-shApoB and AAV-miApoB samples was compared to the PBS and there was 
no significant difference in the amount of genes affected compared to shScr or miScr 
controls (Fig 4a). The number of genes affected in AAV-shApoB and AAV-miApoB 
samples when compared to PBS was 124 and 289, respectively (Fig. 4a). To confirm 
the changes observed in the NGS analysis, ApoB knockdown as measured with 
NGS, qRT-PCR and Western blot were compared (Fig. 4c). For both AAV-shApoB and 
AAV-miApoB animal groups ApoB knockdown detected with NGS correlated with 
qRT-PCR and Western blot data indicating that the NGS analysis is a reliable method 
for comparing gene expression between the different animal groups.
Next, we focused on genes that are specific results of ApoB inhibition in AAV-
shApoB and AAV-miApoB-injected animals. Therefore we compared the expression of 
genes that are predicted to functionally interact with ApoB (Fig. 4d). Several consistently 
changing genes were observed like: Apobec2, Bgn and Lpl. However the majority of 
the ApoB-interacting genes were differentially changing between AAV-shApoB and 
AAV-miApoB and the expression of a number of genes remained unaltered.
Functional categorization of the NGS data
To generate a full functional profile for all genes altered by the in vivo expression of 
shScr, shApoB, miScr and miApoB, a web-based tool DAVID was used for the ontological 
analysis of large lists of genes (see Materials and Methods). Analysis of the 106 genes 
that were significantly changed in the AAV-shApoB group indicated that the most 
significant functional alterations were related to genes involved in lipid metabolism and 
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Figure 4. NGS transcriptome analysis indicates differential gene expression profiles between 
AAV-shApoB- and AAV-miApoB-injected animals. To analyze liver transcriptome, total RNA was 
isolated from a representative animal 8 wk p.i. and NGS analysis was performed. The expression 
abundance for all genes was quantified using the reads per kilobase of exon model per million mapped 
reads (RPKM) measure. Expression data was compared using Kal’s Z-test with Bonferroni correction. 
Genes significantly altered (p<0,05) were used in further analysis (a) Genes significantly altered (p<0,05) 
in AAV-shApoB- and AAV-miApoB-injected animals. Grey bars represent gene changes compared to 
PBS group and black bars represent gene changes compared to AAV-shScr or AAV-miScr controls 
(b) Genes significantly upregulated or downregulated in AAV-shApoB and AAV-miApoB injected 
animals. Grey and black bars represent number of genes upregulated and downregulated respectively 
compared to AAV-shScr or AAV-miScr controls (p<0,05) (c) Comparison of ApoB knockdown in vivo by 
NGS, qRT-PCR and protein Western blot. In all assays ApoB expression levels were calculated relative 
to AAV-shScr or AAV-miScr, which served as negative controls and were set at 100%. (d) Prediction 
of ApoB functional interactions was performed with STING software. Upregulated genes (fold 
change > 1,5) were marked in green and downregulated (fold change < -1,5) were marked in red.
transport and response to stimuli (Fig. 5a). In addition, expression of genes involved 
in drug metabolism, inflammation, cell growth and death and the MAPK signaling 
pathway were altered. In the AAV-miApoB animal group, the 266 significantly altered 
genes corresponded mainly to genes involved in drug metabolism, oxidoreductase 
activity and processes (Fig 5b). Other relevant pathways include lipid metabolism and 
transport, ion binding, response to stimuli and nucleobase, nucleoside and nucleotide 
biosynthetic process. A complete list of genes functionally annotated with DAVID 
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Figure 5. Functional categorization of gene expression changes in AAV-shApoB and AAV-
miApoB injected animals. (a) Percentage and functional categorization of genes significantly 
changing in AAV-shApoB and AAV-miApoB animal groups. Genes significantly altered in AAV-
shApoB and AAV-miApoB groups (p<0,05) were annotated to Gene Ontology (GOTERM_BP_FAT and 
GOTERM_MF_FAT) and KEGG (KEGG_PATHWAY) using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) v6.7 (National Institute of Allergy and Infectious Diseases (NIAID), 
NIH). Significant annotations (p<0,05) were grouped in 8 categories and the percentage of genes 
in each category was calculated with reference to all genes annotated in the DAVID analysis.(b) 
Outline of cholesterol pathway changes in AAV-miApoB and AAV-shApoB injected animals. There 
are several types of lipoproteins within blood: chylomicrons, very-low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein 
(HDL). ApoB100 protein is synthesized in the liver and it forms the structural protein in VLDL and 
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for miApoB and shApoB samples can be found in Supplementary Tables 3 and 4, 
respectively. Although both shApoB and miApoB resulted in the same phenotypic effect 
as result of ApoB knockdown, the changes exerted on other lipid metabolism genes 
were rather dissimilar (Fig. 5c). Inhibition of ApoB in AAV-shApoB-injected mice resulted 
in a decrease of LDL-C and HDL-C associated genes: ApoA2, ApoE, ApoC1, ApoC3 
and ApoC4. By contrast the same genes were upregulared in AAV-miApoB-injected 
samples. Furthermore miApoB was associated with downregulation of ApoA4, Ldlr, 
Pcsk9 and Scarb1, which are key components in cholesterol homeostasis. By contrast, 
ApoA4 and Scrab1 genes were upregulated in the AAV-shApoB sample. In both AAV-
shApoB- and AAV-miApoB-injected animals Apobec2 gene was downregulated while 
Lpl gene was significantly upregulated (Fig 5c).
Although both shApoB and miApoB were found to affect response to stimuli and 
drug metabolism, only the serine protease inhibitors Serpina1b, Serpina1c, Serpina1d 
and Serpina3k were simultaneously affected in both groups. Serpins compose a large 
family of the functional diverse proteins which are involved in numerous intracellular 
and extracellular functions: blood clotting, inflammation, storage, hormone carriage 
and tumor suppression [29-31]. Only AAV-shApoB injection was found to upregulate 
genes involved in inflammatory response such as Serpina 8N which is induced during 
inflammation and Serum amyloid A1 (Saa1), a major acute phase reactant. shApoB 
but not miApoB expression also upregulated components of the MAPK signaling 
pathway: Fos, Jun, Nr4a1, Dusp1 and Dusp6. Fos, Jun, Nr4a1 are transcription factors 
involved a number of cellular processes including differentiation, proliferation, and 
apoptosis [32] and Nr4a1 plays a key role in mediating inflammatory responses in 
macrophages [33]. Dusp1 and Dusp6 negatively regulate the members of the MAPK 
family pathways JNK and p38, which results in cell apoptosis [34].
miApoB expression downregulated genes involved in drug metabolism such as 
members of alpha-glutathione-S-transferase Gsta1, Gsta2, Gsta4 and glutathione-
S-transferase mu genes Gstm1, Gstm2, Gstm3 and Gstm3. By contrast, expression 
of those genes was upregulated in the AAV-shApoB-injected animal. Other genes 
that were upregulated in AAV-miApoB-injected animal are involved in oxidoreductase 
activity, oxidative phosphorylation and nucleic bases biosynthetic processes. Most 
of these are structural components of mitochondrial oxidative phosphorylation 
system: NADH-coenzyme Q oxidoreductase (complex I), Cytochrome bc1 complex 
metabolism of triglyceride-rich lipoproteins. Therefore inhibition of ApoB affects VLDL-C, LDL-C and 
HDL levels-C. Genes significantly altered in the AAV-shApoB and AAV-miApoB groups were used 
(p<0,05) for toxicology prediction using Metacore software (Thomson Reuters) and the top scored 
map was generated. Experimental data from AAV-shApoB and AAV-miApoB groups are linked to and 
visualized on the image as thermometer-like figures place in the top right of respective gene or group 
of genes. Upward red colored thermometers indicate up-regulated components and downward blue 
thermometers indicate down-regulated components of the pathway. 
▶
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(complex III), Cytochrome c oxidase (complex IV) and ATP synthase (complex V). Finally, 
genes involved in lipid metabolism and transport that encode alcohol dehydrogenase 
(Adh1), Acetyl-Coenzyme A acyltransferase (Acaa1b, Acaa1a, Acaa2), Aldehyde 
dehydrogenase 3 family (Aldh3a2) and Cytochrome P450 family members (Cyp4a10, 
Cyp3a11, Cyp2c29, Cyp4a14) were upregulated in the AAV-miApoB sample. 
shApoB and miApoB do not affect the expression of predicted off-target genes 
A common source of RNAi toxicity is off-targeting, when non-targeted transcripts 
are down-regulated as a consequence of sequence complimentarily to the shRNA 
or miRNA sequence. In our previous study we have shown that shApoB and miApoB 
are differentially processed in vivo and that a pool of different guide and passenger 
strands was generated. To investigate possible off-target effects, the Smith-Waterman 
algorithm was used to predict the most abundant guide and passenger strand variants 
(Table 2). A total of 19 genes were predicted as off-targets in the liver for the guide 
and passenger strand of shApoB and 25 for miApoB. To investigate if any of the 
predicted interactions correlates with our experimental data, in vivo NGS data was 
manually screened for the predicted off-target gene expression and evaluation of the 
changes was performed (Table 2 and Fig. 6). From the 19 predicted off-target genes, 
11 were expressed in AAV-shApoB animals and 10 in AAV-miApoB-injected animals. 
Surprisingly, the expression of none of the predicted off-targets for both shApoB and 
miApoB was significantly changed in vivo (Table 2 and Fig 6). 
Discussion
The major challenge for the RNAi-based therapies is the delivery of siRNAs to the 
target tissue or organ for stable and long-term inhibition of a disease-related gene. 
Recent reports on the RNAi toxicity have initiated a discussion about the safety of 
such an approach. Although in the last few years much progress has been made 
in understanding the causes of toxicity and approaches to preclude adverse effects 
have been suggested, detailed studies on the differences between shRNA- or artificial 
miRNA-encoding constructs and the consequences for in vivo applications have not 
been reported. By using AAV delivery, we have compared the safety profiles of identical 
predicted siApoB sequences expressed as shApoB and miApoB in long-term in vivo 
studies. Detailed histological analyses, as well as comparison of endogenous miRNA 
and transcriptome expression revealed major differences between AAV-shApoB- and 
AAV-miApoB-injected animals, indicating that careful monitoring is necessary prior to 
proceeding clinical trials.
In vivo toxicity of shRNA was often linked to upregulation of liver enzymes ALT 
and AST in mice [8,10] and in non-human primates [35]. In our experiment, transient 
activation of liver transaminases was observed in AAV-miScr and AAV-miApoB animals 
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during the course of the experiment indicating mild dose-dependent toxicity. We have 
previously reported that such toxicity can be abolished by lowering the administered 
viral dose [24]. In contrast to our results, Ahn et al. described increased in ALT levels 
3 weeks p.i. after injection of adenovirus encoding shRNA against transcription factor 
Srebp1 and lipid transporter Fatbp5 [7]. Interestingly in their study, scrambled control 
hairpin did also cause increase in ALT levels, indicating that toxicity was associated 
with shRNA expression and was not due to adenoviral vector. This also suggests that 
shRNA liver toxicity is probably sequence-dependent. In another study, three-fourths 
of the tested shRNAs resulted in liver injury, while expression of others was well 
tolerated [10]. Although transient ALT and AST increase was detected in AAV-miScr- 
and AAV-miApoB-injected animals, no acute inflammation and no gross-changes of 
liver morphology in these groups were detected. 
Similar to previous studies, ApoB knockdown by AAV-shApoB and AAV-miApoB 
resulted in hepatic fat accumulation [36,37]. Surprisingly steatosis was not observed 
in murine studies with an ApoB antisense oligonucleotide [38]. By contrast, clinical 
trials with the human ApoB antisense oligonucleotide did reveal a trend toward an 
Figure 6. Changes in predicted shApoB and miApoB off-target gene expression. Smith-
Waterman algorithm was used to predict shApoB and miApoB off-target genes for the most abundant 
expressed variants of passenger and guide strands in mouse reference genome (15 May 2012 NCBI 
build 38.1). Predicted targets were manually screened for genes expressed in the liver that were 
detected in NGS transcriptome analysis. Grey and black bars represent fold change in AAV-shApoB 
and AAV-miApoB relative to AAV-shScr or AAV-miScr controls respectively. Kal’s test (Z-test) with 
Bonferroni correction was used to compare the RPKM value in the shApoB versus shScr or miApoB 
versus miScr. **p < 0.01 
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increase in intrahepatic triglyceride content [39]. Steatosis may be associated with 
inflammation and may progress to cirrhosis, therefore careful consideration and 
investigation of this consequence of lowering ApoB is necessary. Tep at al. reported 
that simultaneous silencing of Mtp and Dgat2 rescues siRNA-induced hepatic 
steatosis [48]. However Dgat2 silencing resulted in a significant increase of plasma 
ketones making this approach not attractive for clinical applications as elevated serum 
ketones can cause medical emergency. By contrast, double knockdown of ApoB and 
Dgat2 or Fabp5 did not result in reduction of lipid accumulation.
We observed that injections of AAV-shApoB, but not AAV-miApoB, caused 
increased hepatocyte proliferation. The reason for the observed proliferation would be 
hepatocyte damage due to RNAi-induced toxicity. Increased apoptotic and proliferative 
activity has been observed in murine liver expressing AAV-delivered shRNA targeting 
human alpha-1-antitripsin [10] and adenoviral-expressed targeting Srebp1 and Fabp5 
[7]. In our experiments we observed increased proliferation that was not associated 
with apoptosis, implying that apoptosis may have occurred earlier than 8 wk p.i. with 
AAV-shApoB. Another reason for the increased proliferation could be the hepatic 
steatosis. Indeed, It has been reported that increase in liver triglycerides may lead to 
increased oxidative stress in the hepatocytes and lipid-activated apoptosis [40]. The 
fact that miApoB does not affect liver proliferation excludes this possibility. Based on 
our data and previous reports, we can only conclude that increased liver proliferation 
due to shApoB expression is hairpin structure- and concentration-specific. It should 
be noted that AAV-miApoB- and AAV-miScr-injected animals did not reveal signs of 
increased liver proliferation, which could have important consequences for long-term 
correction, since AAV DNA forms episomal nuclear concatamers in the host cell 
nucleus, which are lost following cell division [41]. Those results also explain our 
previous observations where the silencing effect in AAV-shApoB-injected animals was 
less sustained than in AAV-miApoB-injected animals [24]. 
Saturation of the RNAi pathway and global de-regulation of endogenous miRNA 
processing as a consequence of overexpression of hairpin structures play an important 
role in RNAi-induced toxicity [8,10]. Castanotto et al. showed that both siRNAs and 
shRNAs against the HIV regulator gene Rev competed with the endogenous mir-21 
expression in vitro in HEK293T cells [42]. However the siRNA sequences used in that 
setting did not show competition with endogenous miRNA when expressed as artificial 
miRNA. In another study mir-21 was shown to be affected by expression of artificial 
miRNA against the hepatitis virus B (HBV) genome in Huh7 cells [43]. The competition 
with endogenous miRNA was dose-dependent as potent silencing was also achieved 
with lower doses where RNAi saturation was not observed. It has also been reported 
that shRNA-induced toxicity resulted in inhibition of mir-122 and let-7a in vitro and 
in vivo [8,10]. Our NGS analysis of small RNA profiles showed significant divergence 
between shApoB- and miApoB-transfected cells. In vivo of 7 tested miRNAs only 
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mir-133a was differentially expressed in the AAV-miApoB-injected group compared to 
AAV-shApoB-injected group. However we cannot exclude that complete NGS profiling 
of miRNA expression in vivo would allow identification of other differentially expressed 
endogenous miRNAs. Importantly in both in vitro and in vivo experiments, we did 
not observe global downregulation of endogenous miRNA expression indicating that 
therapeutic delivery of AAV-shApoB and AAV-miApoB did not induce toxic effects.
The NGS analysis of liver transcriptome revealed differential gene expression in 
AAV-shApoB- and AAV-miApoB-injected animals. As anticipated, lipid metabolism and 
transport genes were affected for both molecules. Interestingly, Bgn, a proteoglycan 
which can bind ApoB-containing lipoproteins and is involved in atherosclerosis 
[44], and Lpl is one of the key enzymes for lipoprotein catabolism which hydrolyzes 
triglycerides and VLDL-C [45], were upregulated for both AAV-shApoB and AAV-
miApoB. In addition to lipolysis, Lpl mediates the uptake and degradation of 
lipoproteins by cells. Our hypothesis is that the upregulation of these two genes 
might be a compensatory reaction to the strong ApoB decrease in murine liver but 
the biological significance of those changes needs to be determined. Apobec2, which 
is an ApoB mRNA editing enzyme, was downregulated in both treatment groups 
probably as a result of the low concentrations of ApoB in the liver of shApoB and 
miApoB animals. Although Abobec2 functions in liver are not fully investigated, 
its upregulation has been associated with tumorogenesis and development of 
hepatocellular carcinoma through hepatic inflammation [46]. By contrast Apobec2 
deficient mice did not reveal any abnormalities on health and survival [47]. 
Surprisingly, the majority of the lipid metabolism genes were differentially 
affected in AAV-shApoB and AAV-shApoB animals despite the same phenotypic 
effect. Recently, significant changes in many lipid metabolism genes following ApoB 
silencing with siRNA have been reported using TaqMan analysis [48]. Out of 96 genes 
which were investigated, 53 were downregulated more than 1,5 fold while only 7 
were upregulated. However when compared to our NGS data, only a few genes had 
a similar change in expression profile (Table S5). This may suggest that siRNA, shRNA 
and miRNA induce different gene expression profile despite the same phenotypic 
effect. However, it has to be noted that the siApoB used had a different sequence 
and the experiment was performed in LDL-R/CETP+/- hemizygous mice, which exhibit 
different lipid profile. Additionally the analysis was performed 2 wk p.i. with siApoB 
and at this time point gene expression changes may have been more pronounced. To 
our knowledge comparison of liver gene expression analysis after siRNA, shRNA and 
miRNA administration has not been performed. 
Besides lipid metabolism and transport other functions were also altered in murine 
liver by expression of AAV-shApoB or AAV-miApoB. Response to stimuli and drug 
metabolism were found to be affected in both shApoB and miApoB groups, but the 
genes involved showed minimal overlap. shApoB was found to affect genes involved 
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in cell growth and death, inflammation and MAPK pathway, which correlated with our 
findings on increased liver proliferation. miApoB affected genes involved in ion binding, 
nucleobase biosynthetic process and oxidative activity and processes. Previously, Ahn 
et al. described significant transcriptomic changes in mice after adenoviral deliver 
of shRNA [7], where a total number of 181 genes, were found to be upregulated 
while only 32 genes were found to be downregulated as a consequence of shRNA 
expression. Data generated from their study suggested that shRNA expression also 
upregulated genes involved in the RNAi pathway and proliferation. In contrast, we did 
not see significant upregulation of those genes, which might be due to the fact that 
we performed our analysis 8 weeks p.i. and because we used AAV as a delivery vector. 
Importantly we detected upregulation of inflammatory related genes exclusively in the 
AAV-shApoB group although no signs of inflammation in the liver could be found and 
in our previous experiments we did not measure IFN response activation [49]. Immune 
activation might indeed have caused hepatocytes’ damage in the AAV-shApoB sample 
resulting in increased proliferation and eventually loss of the knockdown effect. The 
consequences of the activation of genes involved in immune response solely by AAV-
shApoB needs to be further investigated by careful monitoring their expression over 
time and when different shRNAs and AAV doses are used. 
Another important observation was that none of the changes in gene expression in 
AAV-miApoB and AAV-shApoB resulted from aspecific down-regulation of off-target 
transcripts. Although we could not explain the changes in gene expression by off-
target prediction using the Smith-Waterman algorithm, we cannot exclude that some 
of the interaction may have been missed and other prediction methods like screening 
3’ UTRs of genes for perfect complementarity to siRNA seed region may be more 
accurate. miRNAs may regulate their targets by translational repression, therefore we 
might speculate that the off-target effects may be stronger at protein level.
In summary, our findings demonstrate that the incorporation of identical siRNA 
sequences in shRNA or artificial miRNA scaffolds induces differential effects on 
liver morphology, transcriptome and cellular miRNA expression. Despite effective 
silencing, same phenotypic effect and no signs of severe toxicity, multiple genes 
and functions were de-regulated by AAV-shApoB or AAV-miApoB. Mir-133a was 
upregulated in AAV-miApoB animals and might be one of the mediators responsible 
for the observed differences between shApoB and miApoB. Furthermore only 
expression of shApoB resulted in increased hepatocyte proliferation indicating the 
miApoB is a better candidate for future development of RNAi therapeutics of familial 
hypercholesterolemia. Finally, miApoB expression was limited to the liver due to the 
use of a tissue-specific promoter, while the presence of shApoB-derived siApoB was 
detected in spleen, heart, lung, kidney, and ileum. All those features of AAV-miApoB 
makes us consider the use of tissue-specific expression of therapeutic siRNA from 
miRNA scaffolds a safer option than shRNA. 
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Materials and methods
DNA constructs AAV production and purification
The design and cloning of the shApoB, shScr, miScr, miApoB and GFP expression vectors, 
scAAV8 vector production and purification has been described previously [24,49]. 
In vivo experiments
All animal experiments were conducted according to the guidelines of the local animal 
welfare committee. Six-to-eight-week-old male C57BL/6 mice received an intravenous 
AAV injection of 1×1011 gc per animal (~4×1012 gc/kg) via the tail vein. Treatment groups 
were n=5, mice were housed 6 per cage and feeding was performed ad libitum with 
regular chow. Heparinized blood samples were taken every two weeks p.i. from fasted 
mice. Mice were sacrificed at 8 weeks p.i. and liver and plasma were collected for analysis. 
Plasma levels of ALT, AST, and total cholesterol were analyzed on the automated clinical 
chemistry analyzer Modular Analytics P800 (Roche Diagnostics, Basel, Switzerland) at the 
Academic Medical Center (Amsterdam, the Netherlands). Statistical analysis was performed 
by ANOVA testing with Bonferroni post test and p<0.05 was considered significant.
GFP expression was analyzed in snap-frozen liver sections. Livers were cryosectioned 
at 5 μm and eGFP signal was visualized using standard fluorescence microscopy on 
a Leica fluorescent microscope (Leica Microsystems GmbH, Wetzlar, Germany). For 
analysis of liver fat accumulation, snap-frozen liver sections were cryosectioned at 
5 μm, fixed in 10% formalin and stained for 25 min in filtered 0.3 % Oil red O 
(Sigma, St. Louis, MO) solution in 60% isopropanol. Nuclei were counterstained for 
5 min in hematoxylin solution (Sigma, St. Louis, MO). Liver histology was assessed by 
hematoxylin-eosin (H&E) staining of frozen liver sections. 
Immunohistochemistry
Mouse liver samples were fixed with buffered 4% formalin (NBF) for 48 h and then 
routinely processed to paraffin blocks. Five-micrometer sections were cut, mounted 
on coated slides and dried overnight at 37°C. Slides were dewaxed in xylene and 
hydrated with the use of graded alcohols to tap water. Endogenous preoxidases were 
blocked by incubation in methanol supplemented with 0,3% peroxide. Heat induced 
endogenous antigen retrieval (HIER) was performed in the PreTreatment Module 
(PTModule; Thermo Fisher Scientific/Labvision, Fremont, CA) for 20 min at 98°C and a 
cool-down to 75°C in Tris-HCI + EDTA pH 9.0. After washing sections with running tap 
water, Ultra V Block (Thermo Fisher Scientific/Labvision, Fremont, CA) for 10 minutes 
at room temperature (RT). A sequential triple staining procedure [50] started with 
CD31 (LifeSpan Biosciences Inc., Seattle, WA) visualized by horseradish peroxidase 
(HRP) conjugated anti-rabbit IgG polymer and BrightDAB (both Immunologic, Duiven, 
The Netherlands). The DAB reaction product effectively shelters the first set of 
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antibodies and thus prohibits unwanted cross-reactions with later incubation steps. 
Staining was continued with anti-Ki67, clone SP6 (Thermo Fisher Scientific/Labvision, 
Fremont, CA) visualized by BrightVision alkaline phosphatase (AP) conjugated anti-
rabbit IgG polymer (Immunologic, Duiven, Then Netherlands) and Vector Blue (Vector 
Laboratories, Burlingame, CA, USA). Next, a second HIER step (10 min, 98C) using 
citrate buffer pH6. 0 was applied to remove all antibodies used but leaving the 
chromogens unchanged. Finally, CK18 (Abcam, Cambridge, UK) was visualized by 
BrightVision AP conjugated anti-mouse IgG polymer (Immunologic) and Vector Red 
(Vector Labs). Slides were weakly counterstained with hematoxylin diluted 1:5 in 
distilled water for 3 min, washed with tap water, completely dried at a hot plate and 
non-aqueous coverslipped with VectaMount (Vector Labs). Primary and secondary 
antibodies used in this study are listed in Table 1. Antibodies and conjugates were 
diluted in antibody dilutent (Immunologic) and Tris-buffered saline (TBS) was used 
as washing buffer for all further steps (three changes, 3 min each). HRP activity in 
brown was developed with Bright DAB (Immunologic) according to manufacturer’s 
instructions. Alkaline phosphatase (AP) activity in blue and in red was developed with 
the Vector Blue and Vector Red kits (Vector Laboratories, Burlingame, CA) with the 
use of a Tris-HCI buffer (100 mM, pH 8.2) according to manufacturer instructions. 
Spectral Imaging and proliferation quantification
Specimens were observed with a Leica BM5000 microscope equipped with plan 
apochromatic objectives (Leica Microsystems, Wetzlar, Germany). From all IHC triple 
stained slides, multispectral data sets of five random fields with Ki67 positive nuclei at 
200x were acquired using a Nuance imaging system (PerkinElmer/Caliper Life Science, 
Hopkinton, MA). Spectral libraries were created acquiring spectra from 420-720 nm at 
20 nm intervals from single-staining with DAB, Vector Blue, Vector Red and Hematoxylin. 
Spectral data sets from triple staining and control slides were acquired at the same 
wavelengths. To analyze the frequency of proliferating hepatocytes, MSI data sets were 
analyzed with InForm 1.4 image analysis software (PerkinElmer/Caliper Life Science) as 
earlier described for proliferating hepatocytes in rabbit liver by Van der Loos et al. [50]. 
The learn-by-example interface from the software segments hepatocytic and sinusoidal 
tissue compartments. Next, the number of proliferating hepatocytes by analyzing the 
number of cells in the hepatocytic tissue compartment with co-expression for cytoplasmic 
CK18 (Vector Red) and nuclear Ki67 (Vector Blue) was calculated. For comparison and 
validation of the automated procedure, two observers independently manually counted 
all Ki67-positive hepatocytes in the images which were used to create the algorithm.
Western blot analysis for detection of ApoB100 protein 
Murine plasma proteins from 8 wk p.i. (0.1 µl) were separated by electrophoresis 
on a 3–8% Tris-Actetate gel (Invitrogen) and blotted onto a 0.45-µm nitrocellulose 
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membrane (Invitrogen). The blot was incubated with a 1:2,000 dilution of a rabbit 
polyclonal anti-ApoB antibody (ab31992; Abcam, Cambridge, UK), followed 
by incubation with a 1:2,000 dilution of goat anti-rabbit antibody conjugated to 
horseradish peroxidase (P0448; Dako, Glostrup, Denmark). Antibody binding was 
detected by the Lumi-LightPLUS chemiluminescent detection kit (Roche Diagnostics, 
Basel, Switzerland). Equal loading of protein samples was confirmed by Ponceau S 
staining (Sigma, St Louis, MO).
Cell culture and transfections
The human embryonic kidney 293T (HEK293T) cell line was maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) containing 10% fetal calf 
serum, 100 U/ml penicillin and 100 U/ml streptomycin, at 37°C and 5% CO2. For small 
RNA next generation sequencing (NGS) cells were seeded in 6-well plates at a density 
of 4.5×105 cells per well in DMEM one day prior transfection. Transfections were 
performed with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions. RT reactions for siApoB expression in vivo and let-7a, 
let-7e, mir-26a, mir122, mir-133a, mir-199a and mir-221 expressions in vitro were 
performed with the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA) using 10 ng RNA and 3 µl custom-made specific RT-stem-loop primer 
(Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. 
Amplification of the beta actin gene was used as a RNA quality and loading control. 
siApoB copy number per cell was calculated based on the amplification plot of 
a dilution series of synthetic siApoB RNA standard (IDT, Coralville, IA). The trend 
line value of the standard line was used to calculate the siApoB copy number cell, 
assuming 15 pg RNA per cell [51]. Let-7a, let-7e, mir-26a, mir122, mir-133a, mir-199a 
and mir-221 levels were normalized to β-actin and the relative gene expression 2−ΔΔCt 
method of Livak and Schmittgen was used for analysis of PCR data [52].
RNA isolation, quantitative real-time RT-PCR (qRT-PCR), siRNA and miRNA 
Taqman assay
To determine ApoB mRNA knockdown and siApoB expression in vivo , total RNA was 
isolated from frozen liver sections at 8 weeks p.i. using Trizol (Invitrogen, Carlsbad, CA). 
Genomic DNA (gDNA) was removed by DNase treatment using TURBO DNase (Ambion, 
Austin, TX). First strand cDNA was reverse transcribed using random hexamer primers with 
the Dynamo kit (Finnzymes, Espoo, Finland). Real time PCR amplification was performed 
with ApoB- and beta actin-specific primers. PCR reaction conditions were: 95°C for 10 min, 
followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. The assays were performed 
on ABI 7000 or ABI 7500 (Applied Biosystems, Foster City, CA). ApoB expression levels 
were normalized to beta actin as an internal control, and the relative gene expression 2-ΔΔCt 
method of Livak and Schmittgen was used for analysis of PCR data [52].
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Next Generation Sequencing (NGS) of small RNA and liver transcriptome
For NGS analysis of small RNA, HEK293T cells were transfected with 4 µg shApoB- 
or miApoB-expression plasmids using Lipofectamine 2000 reagent and total RNA 
was isolated from cells 48 hr post-transfection using Trizol (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s protocol. Small RNA sequencing libraries were 
generated using high-quality total RNA as input and the NEXTflex Small RNA Sequencing 
kit (Bioo Scientific, USA). Briefly, the small RNA species were subjected to ligation 
with 3’ and 5’ RNA adapters, first strand reverse transcription, and PCR amplification. 
Sample-specific barcodes were introduced in the PCR step. The PCR products were 
separated on TBE-PAGE electrophoresis and the expected band around 140-160bp 
was recovered for each sample. The resulting sequencing libraries were quantified on 
a BioAnalyzer (Agilent). The libraries were multiplexed, clustered, and sequenced on 
an Illumina HiSeq 2000 (TruSeq v3 chemistry) with a single-read 36 cycles sequencing 
protocol and indexing. The sequencing run was analyzed with the Illumina CASAVA 
pipeline (v1.8.0), with demultiplexing based on sample-specific barcodes. The raw 
sequencing data produced was processed removing the sequence reads which were 
of too low quality (only “passing filter” reads were selected), and discarding reads 
that aligned against the PhiX control. In total, we generated 16016701 reads for 
sample miApoB, and 15843150 reads for sample shApoB. The NGS small RNA raw 
data set was analyzed using the CLC_bio genomic workbench (CLC Bio, Aarhus, 
Denmark). The obtained reads were adaptor-trimmed, which decreased the average 
read size from ~36bp to ~25bp. The custom adapter sequenced used for trimming 
all the bases extending 5’ was: GTGACTGGAGTTCCTTGGCACCCGAGAATTCCA. All 
reads containing ambiguity N symbols, reads shorter than 15 nt, longer than 55 
nt in length and reads represented less than 10 times were discarded. To relatively 
represent the expression counts for the small RNAs obtained in the experiment, reads 
per million (rpm) or percentage of reads based on the total number of reads matching 
the reference shApoB or miApoB sequence were calculated Finally, to identify the 
differences in cellular miRNA reads between the miApoB and shApoB samples the 
small RNA data sets were annotated to miRBase, Release 18 and grouped based on 
the mature miRNA sequences, the rpm were calculated and the fold change between 
miApoB and shApoB samples was calculated.
To analyze liver transcriptome, total RNA was isolated from frozen liver sections 
of representative animals at 8 weeks p.i. with AAV-shApoB, AAV-miApoB, AAV-shScr, 
AAV-miScr or PBS using Trizol (Invitrogen, Carlsbad, CA). RNA sequencing libraries 
for the Illumina sequencing platform were generated using high-quality RNA as input 
and the Illumina TrueSeq RNA v2 Sample preparation kit. Briefly, poly-A containing 
mRNA molecules were purified using poly-T oligo-attached magnetic beads. Following 
purification, the mRNA was fragmented via incubation for 5 min at 94°C with the 
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Illumina-supplied fragmentation buffer. The first strand of cDNA was next synthesized 
by reverse transcription using random oligo primers. Second-strand synthesis 
was conducted by incubation with RNase H and DNA polymerase I. The resulting 
double-stranded DNA fragments were subsequently endrepaired, and A-nucleotide 
overhangs were added by incubation with Taq Klenow lacking exonuclease activity. 
After the attachment of adaptor sequences, fragments were PCR-amplified using 
Illumina-supplied primers. The resulting sequencing libraries were quantified on a 
BioAnalyzer (Agilent). The libraries were multiplexed, clustered, and sequenced on 
an Illumina HiSeq 2000 (TruSeq v3 chemistry) with a single-read 36 cycles sequencing 
protocol and indexing. The sequencing run was analyzed with the Illumina CASAVA 
pipeline (v1.8.0), with demultiplexing based on sample-specific barcodes. The raw 
sequencing data produced was processed removing the sequence reads which were 
of too low quality (only “passing filter” reads were selected), and discarding reads that 
aligned against the PhiX control. Each read file (sample), in the FASTQ format, was 
individually aligned against the Mouse reference genome (15 May 2012 NCBI build 
38.1) using CLC Bio- Genomic Workbench. The expression abundance for all genes 
was quantified using the reads per kilobase of exon model per million mapped reads 
(RPKM) measure [53]. Expression data was compared using Kal’s Z-test with Bonferroni 
correction. Smith-Waterman algorithm was used to predict off-target genes in Mouse 
reference genome (15 May 2012 NCBI build 38.1) for the most abundant expressed 
variants of both passenger and guide strands of shApoB and miApoB. Small RNA and 
transcriptome NGS was carried out by Macrogen Inc. (Seoul, Korea).
The NGS data discussed in this publication have been deposited in NCBI’s Gene 
Expression Omnibus [54] and are accessible through GEO Series accession number 
GSE39187 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39187).
Functional analysis
For the ApoB functional interactions, online database resource search tool for the 
retrieval of interacting genes (STRING) was used, which allowed annotation of 
functional interactions of ApoB protein in cell (http://string-db.org/) [55]. For the 
genes that were identified RPKM gene expression values were compared to PBS or 
shScr and miScrand and fold change between sample and control was calculated. 
Upregulation of genes (fold change > 1,5) was marked in green and downregulations 
(fold change < -1,5) were marked in red.
For the transcriptome analysis, RPKM gene expression values were compared 
to PBS using Kal’s test (Z-test) with Bonferroni correction. All genes that changed 
significantly (p<0,05) and were expressed higher than 0,1 (RPKM>0,1) were included 
in the further analysis. Functional analysis of the significantly changing genes was done 
with the functional annotation tool DAVID (Database for Annotation, Visualization 
and Integrated Discovery v6.7; National Institute of Allergy and Infectious Diseases, 
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NIH) that allows finding combination of genes under study with respect to a reference 
list [56,57]. The annotations were done simultaneously with the reference to Gene 
Ontology databases (GOTERM_BP_FAT and GOTERM_MF_FAT, www.geneontology.
org) and to KEGG pathway database (KEGG_PATHWAY; www.genome.ad.jp/
kegg/pathway.html). The redundancy in the gene list was manually analyzed and 
significant annotations were grouped in 8 categories and the percentage of genes 
in each category was calculated with reference to all genes that were annotated in 
DAVID analysis. 
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Table S2. Changes in miRNA expression in shApoB versus miApoB samples. Cellular small RNA data 
sets were annotated to miRBase (release 18, November 2011) and grouped based on the mature 
miRNA sequences and reads per million (rpm) were calculated. For each miRNA, proportion of the 
reads and the fold change between shApoB and miApoB (rpm) samples were calculated. If the 
proportion of the given miRNA from the shApoB sample was lower than proportion of the same 
miRNA in the miApoB (rpm) sample then this was represented by the negative value. Kal’s test 
(Z-test) with Bonferroni correction was used to compare the proportions of miRNAs in the miApoB 
(rpm) versus shApoB sample. **p < 0.01
Name miApoB (rpm) shApoB (rpm) Fold change p value
mir-4521 2829 15 -188,60 0
mir-378c 5146 51 -100,90 <0,01**
mir-4326 462 13 -35,54 0
mir-720 688 52 -13,23 0
mir-3182 171 13 -13,15 0
mir-4454 68347 5281 -12,94 0
mir-4791 116 12 -9,67 0
mir-877 910 106 -8,58 <0,01**
mir-483 91 11 -8,27 0
mir-1280 2104 264 -7,97 0
mir-4286 15254 2127 -7,17 0
mir-4484 691 106 -6,52 <0,01**
mir-1260a 15492 2454 -6,31 0
mir-1260b 2977 494 -6,03 0
mir-4455 592 100 -5,92 <0,01**
mir-452 176 31 -5,68 <0,01**
mir-3127 51 10 -5,10 <0,01**
mir-1250 203 40 -5,08 0
mir-1299 176 35 -5,03 0
mir-4713 208 42 -4,95 0
mir-585 54 11 -4,91 <0,01**
mir-193a 302 63 -4,79 <0,01**
mir-551b 67 14 -4,79 <0,01**
mir-365a 83 18 -4,61 <0,01**
mir-1246 1872 406 -4,61 <0,01**
mir-2110 470 105 -4,48 <0,01**
mir-1268a 110 25 -4,40 0
mir-1247 78 18 -4,33 <0,01**
mir-3176 121 28 -4,32 0
mir-4473 82 19 -4,32 <0,01**
mir-1268b 116 27 -4,30 0
mir-4485 216 51 -4,24 0
mir-760 201 50 -4,02 <0,01**
mir-1227 44 11 -4,00 <0,01**
mir-210 11150 2794 -3,99 <0,01**
mir-1262 95 24 -3,96 <0,01**
mir-627 87 22 -3,95 <0,01**
mir-4470 135 36 -3,75 0
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mir-1261 52 14 -3,71 <0,01**
mir-3074 104 30 -3,47 <0,01**
mir-378i 1134 329 -3,45 <0,01**
mir-29c 339 100 -3,39 0
mir-504 81 24 -3,38 <0,01**
mir-3615 300 89 -3,37 0
mir-4746 168 50 -3,36 <0,01**
mir-491 341 103 -3,31 0
mir-505 33 10 -3,30 <0,01**
mir-193b 125 38 -3,29 <0,01**
mir-1290 178 56 -3,18 <0,01**
mir-1269b 1747 566 -3,09 <0,01**
mir-320c-1/2 188 61 -3,08 <0,01**
mir-1914 52 17 -3,06 <0,01**
mir-151b 326 108 -3,02 <0,01**
mir-146a 655 222 -2,95 <0,01**
mir-326 863 293 -2,95 <0,01**
mir-320a 58157 19821 -2,93 0
mir-4687 92 32 -2,88 <0,01**
mir-1249 180 63 -2,86 <0,01**
mir-573 37 13 -2,85 <0,01**
mir-3928 60 22 -2,73 <0,01**
mir-940 245 91 -2,69 <0,01**
mir-671 6969 2624 -2,66 0
mir-92b 69 26 -2,65 <0,01**
mir-3620 559 213 -2,62 <0,01**
mir-211 26 10 -2,60 <0,01**
mir-375 1962 762 -2,57 <0,01**
mir-328 783 311 -2,52 <0,01**
mir-1343 170 68 -2,50 <0,01**
mir-1180 4978 1995 -2,50 0
mir-4423 52 21 -2,48 <0,01**
mir-3136 95 39 -2,44 <0,01**
mir-148a 2964 1231 -2,41 <0,01**
mir-1269a 12 5 -2,40 <0,01**
mir-378d-1/2 1454 611 -2,38 <0,01**
mir-24-2 45 19 -2,37 <0,01**
mir-423 11893 5028 -2,37 0
mir-1255a 90 39 -2,31 <0,01**
mir-642b 46 20 -2,30 <0,01**
mir-501 376 164 -2,29 <0,01**
mir-2277 187 82 -2,28 <0,01**
Table S2. continued
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mir-942 410 182 -2,25 0
mir-133a-1/2 90 40 -2,25 <0,01**
mir-22 78 35 -2,23 <0,01**
mir-9-1/2/3 18571 8401 -2,21 <0,01**
mir-145 42 19 -2,21 <0,01**
mir-3943 24 11 -2,18 <0,01**
mir-574 392 180 -2,18 <0,01**
mir-1468 26 12 -2,17 <0,01**
mir-320d-1/2 93 43 -2,16 <0,01**
mir-339 18019 8358 -2,16 <0,01**
mir-3173 47 22 -2,14 <0,01**
mir-185 19368 9097 -2,13 <0,01**
let-7b 516 243 -2,12 <0,01**
mir-330 328 157 -2,09 <0,01**
let-7d 243 117 -2,08 <0,01**
mir-27a 165 80 -2,06 <0,01**
mir-28 1355 657 -2,06 <0,01**
mir-422a 101 49 -2,06 <0,01**
mir-296 358 175 -2,05 <0,01**
mir-744 3109 1523 -2,04 <0,01**
mir-1306 128 63 -2,03 <0,01**
mir-138-1/2 731 360 -2,03 <0,01**
mir-589 1938 974 -1,99 0
mir-378a 2067 1040 -1,99 <0,01**
mir-425 17334 8748 -1,98 0
mir-378f 537 275 -1,95 0
mir-151a 18918 9890 -1,91 0
mir-106b 18130 9486 -1,91 0
mir-542 107 56 -1,91 <0,01**
let-7c 3092 1628 -1,90 <0,01**
mir-629 5082 2682 -1,89 0
mir-708 3957 2093 -1,89 0
mir-320b-1/2 706 374 -1,89 0
mir-769 17874 9484 -1,88 0
mir-551a 139 74 -1,88 <0,01**
mir-345 7651 4077 -1,88 0
mir-29b-2 75 40 -1,88 <0,01**
mir-3944 298 160 -1,86 0
mir-1303 24 13 -1,85 <0,01**
mir-590 230 126 -1,83 <0,01**
mir-25 1151 635 -1,81 0
mir-5008 79 44 -1,80 <0,01**
Table S2. continued
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let-7i 2615 1458 -1,79 0
mir-152 4037 2334 -1,73 0
mir-1266 38 22 -1,73 <0,01**
mir-98 797 462 -1,73 0
mir-129-1/2 1111 649 -1,71 0
mir-27b 195 114 -1,71 <0,01**
mir-34a 16816 9849 -1,71 0
mir-628 46 27 -1,70 <0,01**
mir-548ab 100 59 -1,69 <0,01**
mir-1910 44 26 -1,69 <0,01**
mir-103a-2 1171 694 -1,69 0
mir-146b 11389 6806 -1,67 0
mir-4421 35 21 -1,67 <0,01**
mir-497 633 380 -1,67 0
mir-324 1118 682 -1,64 0
mir-194-1/2 7139 4362 -1,64 0
mir-139 36 22 -1,64 <0,01**
let-7g 19609 12000 -1,63 0
mir-7-1/2/3 123822 76717 -1,61 0
mir-1285-2 534 331 -1,61 <0,01**
mir-31 4700 2916 -1,61 <0,01**
mir-1307 1418 880 -1,61 0
mir-616 32 20 -1,60 <0,01**
mir-486 28634 17950 -1,60 0
mir-132 408 258 -1,58 0
mir-1286 17 11 -1,55 0,11
mir-93 49978 32504 -1,54 0
mir-101-2 53740 34952 -1,54 0
mir-217 39 26 -1,50 <0,01**
mir-3065 240 161 -1,49 <0,01**
mir-346 392 263 -1,49 <0,01**
mir-605 59 40 -1,48 <0,01**
mir-502 63 43 -1,47 <0,01**
mir-550a-1/2 328 225 -1,46 <0,01**
mir-103a-1 53323 37037 -1,44 0
mir-181c 1037 721 -1,44 <0,01**
mir-874 6180 4320 -1,43 <0,01**
mir-484 22583 15790 -1,43 0
mir-503 2035 1445 -1,41 0
mir-128-1/2 5142 3663 -1,40 0
mir-4677 53 38 -1,39 <0,01**
mir-188 236 170 -1,39 <0,01**
Table S2. continued
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mir-5585 54 39 -1,38 <0,01**
mir-548j 22 16 -1,38 0,13
mir-3130-1/2 59 43 -1,37 <0,01**
mir-17 208165 151899 -1,37 0
mir-204 177 130 -1,36 <0,01**
mir-218-1/2 32185 23741 -1,36 0
mir-186 79819 58927 -1,35 0
mir-548an 125 93 -1,34 <0,01**
mir-548aa-1/2 165 124 -1,33 <0,01**
mir-149 7087 5329 -1,33 0
mir-30b 15097 11479 -1,32 <0,01**
mir-1252 13 10 -1,30 0,29
mir-500a 822 638 -1,29 <0,01**
mir-181b-1/2 4027 3128 -1,29 <0,01**
mir-182 53787 42345 -1,27 0
mir-191 156325 123307 -1,27 0
mir-92a-1 694 548 -1,27 <0,01**
mir-1305 29 23 -1,26 0,14
let-7a-1/2/3 17874 14242 -1,26 0,00
mir-3909 257 205 -1,25 <0,01**
mir-576 259 207 -1,25 <0,01**
mir-1915 15 12 -1,25 0,30
mir-3662 30 24 -1,25 0,14
mir-4467 15 12 -1,25 0,30
mir-935 572 459 -1,25 <0,01**
mir-192 24042 19301 -1,25 0
mir-3140 66 53 -1,25 <0,01**
mir-548f-1/2/3/4 353 286 -1,23 <0,01**
mir-196a-1/2 16566 13441 -1,23 0
mir-130b 3712 3073 -1,21 0
mir-5699 65 54 -1,20 <0,01**
mir-3157 49 41 -1,20 0,09
mir-625 247 208 -1,19 <0,01**
mir-3611 38 32 -1,19 0,14
mir-891a 13 11 -1,18 0,40
mir-125b-1/2 12077 10462 -1,15 <0,01**
mir-598 637 557 -1,14 <0,01**
mir-618 714 629 -1,14 <0,01**
let-7e 2670 2361 -1,13 <0,01**
mir-362 13573 12026 -1,13 <0,01**
mir-1292 89 79 -1,13 0,05
mir-556 45 40 -1,13 0,17
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mir-219-1 292 263 -1,11 <0,01**
mir-18a 20829 18939 -1,10 <0,01**
mir-26b 6658 6060 -1,10 0
mir-1257 213 195 -1,09 <0,01**
mir-30a 54010 49483 -1,09 0
mir-489 13 12 -1,08 0,52
mir-580 65 60 -1,08 0,15
mir-652 169 157 -1,08 <0,01**
mir-651 136 127 -1,07 <0,01**
mir-33a 153 143 -1,07 <0,01**
mir-4792 291 273 -1,07 <0,01**
mir-499a 37 35 -1,06 0,32
mir-1301 1479 1409 -1,05 <0,01**
mir-19b-1 581 555 -1,05 <0,01**
mir-190b 24 23 -1,04 0,45
mir-34c 2365 2286 -1,03 <0,01**
mir-532 4923 4763 -1,03 <0,01**
mir-195 957 930 -1,03 <0,01**
mir-16-1/2 30082 29378 -1,02 0
mir-181d 1926 1883 -1,02 <0,01**
mir-2355 359 352 -1,02 <0,01**
mir-20b 52 51 -1,02 0,31
mir-1287 64 63 -1,02 0,27
mir-449a 70 69 -1,01 0,25
mir-99b 726091 721490 -1,01 0
mir-30d 57480 57397 -1,00 <0,01**
let-7f-1/2 11474 11467 -1,00 0
mir-23b 10 10 1,00 0,69
mir-133b 4 4 1,00 0,80
mir-3150a 18 18 1,00 0,59
mir-3174 12 12 1,00 0,66
mir-222 171 173 1,01 0,12
mir-190a 160 162 1,01 0,13
mir-1296 1177 1197 1,02 <0,01**
mir-641 434 444 1,02 <0,01**
mir-455 629 647 1,03 <0,01**
mir-338 148 153 1,03 0,20
mir-4786 29 30 1,03 0,58
mir-181a-1/2 11483 11939 1,04 <0,01**
mir-30e 128424 133609 1,04 0
mir-424 6753 7108 1,05 <0,01**
mir-140 1893 2035 1,08 <0,01**
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mir-454 128 138 1,08 0,40
mir-215 681 738 1,08 0,06
mir-1298 10 11 1,10 0,85
mir-26a-1/2 41047 46025 1,12 0
mir-21 101618 116255 1,14 0
mir-15a 4445 5096 1,15 <0,01**
mir-199a-1/2 13 15 1,15 0,92
mir-1278 13 15 1,15 0,92
mir-3613 3708 4324 1,17 0,25
mir-107 1545 1833 1,19 0,81
mir-15b 3097 3679 1,19 0,77
mir-196b 15868 18894 1,19 0,65
mir-5094 189 226 1,20 1,00
mir-3938 128 154 1,20 0,96
mir-450a-1/2 3134 3804 1,21 0,55
mir-125a 30443 36957 1,21 0,06
mir-548l 22 27 1,23 0,93
mir-548ag-1/2 79 97 1,23 0,86
mir-10b 1644920 2065460 1,26 0
mir-1-1/2 205 261 1,27 0,51
mir-4517 54 70 1,30 0,66
mir-548k 995 1293 1,30 0,05
mir-548t 13 17 1,31 0,81
mir-106a 1183 1572 1,33 <0,01**
mir-660 926 1236 1,33 <0,01**
mir-30c-1/2 24713 33382 1,35 0
mir-561 225 304 1,35 0,17
mir-421 1791 2438 1,36 <0,01**
mir-548e 566 787 1,39 <0,01**
mir-10a 3814906 5321388 1,39 0
mir-4652 15 21 1,40 0,64
mir-548h-1/2/3/4/5 144 204 1,42 0,12
mir-221 8370 12046 1,44 0
mir-212 358 526 1,47 <0,01**
mir-148b 146 215 1,47 0,05
mir-548n 61 90 1,48 0,21
mir-183 62636 92828 1,48 0
mir-2964a 16 24 1,50 0,48
mir-340 6854 10352 1,51 0
mir-548d-1/2 488 744 1,52 <0,01**
mir-331 118 182 1,54 <0,01**
mir-99a 155658 241891 1,55 0
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mir-1276 25 39 1,56 0,30
mir-450b 1194 1865 1,56 <0,01**
mir-2467 116 182 1,57 <0,01**
mir-548z 15 24 1,60 0,38
mir-100 471 764 1,62 <0,01**
mir-5683 35 57 1,63 0,15
mir-301a 149 249 1,67 <0,01**
mir-548w 100 173 1,73 <0,01**
mir-548o 76 133 1,75 <0,01**
mir-101-1 13 23 1,77 0,26
mir-582 495 885 1,79 <0,01**
mir-548aq 20 36 1,80 0,14
mir-941-1/2/3/4 3125 5688 1,82 <0,01**
mir-378g 221 416 1,88 <0,01**
mir-24-1 14 28 2,00 0,11
mir-199b 183 376 2,05 <0,01**
mir-548y 957 2069 2,16 0
mir-20a 62666 139055 2,22 <0,01**
mir-95 219 500 2,28 <0,01**
mir-548b 151 365 2,42 <0,01**
mir-1271 5483 13299 2,43 0
mir-579 22 54 2,45 0,00
mir-301b 271 703 2,59 <0,01**
mir-361 2307 5985 2,59 <0,01**
mir-1284 15 42 2,80 0,00
mir-96 27894 91513 3,28 <0,01**
mir-374b 448 1537 3,43 0,00
mir-126 115 399 3,47 <0,01**
mir-577 1403 5197 3,70 0
mir-624 59 234 3,97 0
mir-374a 486 1934 3,98 <0,01**
mir-548c/2/am 61 243 3,98 0
mir-32 139 626 4,50 0
mir-549 11 76 6,91 <0,01**
mir-548i-1/2/3/4 65 542 8,34 <0,01**
mir-18b 40 0 NA <0,01**
mir-29a 39 0 NA <0,01**
mir-124-1/2/3 53 0 NA <0,01**
mir-135b 0 10 NA <0,01**
mir-147b 11 0 NA <0,01**
mir-153-1/2 0 16 NA <0,01**
mir-184 12 0 NA <0,01**
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mir-203 13 0 NA <0,01**
mir-216a 0 11 NA <0,01**
mir-216b 10 0 NA <0,01**
mir-342 51 0 NA <0,01**
mir-378b 43 0 NA <0,01**
mir-449b 0 6 NA <0,01**
mir-500b 55 0 NA <0,01**
mir-548a-1/2 0 16 NA <0,01**
mir-548a-3 10 0 NA <0,01**
mir-548ad 0 5 NA <0,01**
mir-548al 0 6 NA <0,01**
mir-548au 0 16 NA <0,01**
mir-548g/x/2 10 0 NA <0,01**
mir-548u 0 10 NA <0,01**
mir-550a-3 12 0 NA <0,01**
mir-592 27 0 NA <0,01**
mir-597 17 0 NA <0,01**
mir-615 10 0 NA <0,01**
mir-643 10 0 NA <0,01**
mir-653 83 0 NA <0,01**
mir-664 48 0 NA <0,01**
mir-766 0 11 NA <0,01**
mir-887 15 0 NA <0,01**
mir-888 0 11 NA <0,01**
mir-934 13 0 NA <0,01**
mir-937 17 0 NA <0,01**
mir-1255b-1/2 16 0 NA <0,01**
mir-1272 10 0 NA <0,01**
mir-1273c 38 0 NA <0,01**
mir-1273d 10 0 NA <0,01**
mir-1275 128 0 NA 0
mir-1285-1 12 0 NA <0,01**
mir-1288 35 0 NA <0,01**
mir-1294 0 12 NA <0,01**
mir-1295a 34 0 NA <0,01**
mir-1304 194 0 NA 0
mir-3131 20 0 NA <0,01**
mir-3158-1/2 14 0 NA <0,01**
mir-3178 88 0 NA 0
mir-3184 12 0 NA <0,01**
mir-3196 16 0 NA <0,01**
mir-3200 13 0 NA <0,01**
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mir-3605 0 10 NA <0,01**
mir-3661 14 0 NA <0,01**
mir-3676 32 0 NA <0,01**
mir-3691 11 0 NA <0,01**
mir-3912 0 13 NA <0,01**
mir-4461 39 0 NA <0,01**
mir-4497 36 0 NA <0,01**
mir-4523 25 0 NA <0,01**
mir-4645 12 0 NA <0,01**
mir-4664 13 0 NA <0,01**
mir-4665 11 0 NA <0,01**
mir-4742 11 0 NA <0,01**
mir-4804 11 0 NA <0,01**
mir-5100 88 0 NA 0
mir-5187 10 0 NA <0,01**
mir-5579 0 22 NA <0,01**
mir-5698 11 0 NA <0,01**
mir-5701-1/2 61 0 NA <0,01**
Table S2. continued
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Table S5. Comparison of lipid-related gene expression profiles in AAV-shApoB, AAV-miApoB and 
siApoB injected animals based on our NGS data and siApoB Taqman data from Tep et al. (48). For 
each entry the fold change between sample and respective negative control were calculated. If 
expression of a given gene in the sample was lower than expression in the negative control the fold 
change had a negative value.
Gene AAV-shApoB AAV-miApoB siApoB
Aacs -1,11 -1,29 -2,60
Acaca -2,50 -1,55 -2,08
Acacb -2,51 1,07 -4,81
Acat2 1,04 1,49 -2,14
Acly -2,34 1,06 -1,75
Acsf2 -1,40 1,13 2,00
Acsl1 -1,62 -1,29 -1,26
Acsl3 -1,25 1,35 -1,85
Acsl4 -2,63 1,96 -2,02
Acsl5 -1,64 -1,13 -2,24
Acss2 -1,49 -1,18 -3,49
ActB 1,49 1,69 1,00
Adi1 1,24 1,20 -1,78
Agpat1 1,52 1,20 -1,27
Agpat2 -1,12 1,11 -1,67
Agpat3 -1,36 1,30 -1,67
Agpat4 1,04 1,26 10,00
Agpat5 2,12 1,63 -1,05
Agpat6 1,42 1,17 -1,25
Agpat9 1,90 1,67 -1,11
Angptl4 1,94 -1,22 -4,76
ApoA1 1,16 -1,13 -1,93
ApoB -11,83 -3,12 -8,27
ApoC3 1,26 -1,63 -1,00
ApoE 1,50 -1,23 -1,08
Baat -1,21 1,30 -1,39
Cds1 -1,93 1,08 -1,86
Chpt1 1,18 -1,13 -1,45
Cyb5r3 1,31 -1,49 -1,91
Cyp27a1 -1,54 -1,06 -1,77
Cyp39a1 -1,79 1,79 -3,00
Cyp46a1 1,46 -1,17 -1,27
Cyp7a1 1,27 1,76 1,19
Cyp7b1 -2,20 1,17 -2,47
Cyp8b1 1,06 -1,36 -1,57
Dgat1 1,34 1,17 -5,55
Dgat2 -1,12 1,07 -1,90
Dhcr24 -1,34 1,29 -1,80
Dhcr7 -1,39 1,46 -1,25
Elovl1 1,74 -1,06 -3,55
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Elovl2 1,14 1,77 -3,80
Elovl3 -2,03 1,51 1,79
Elovl4 -1,79 1,14 -5,22
Elovl5 -1,52 1,24 -3,19
Elovl6 -1,42 1,31 -3,49
Fads1 -1,83 1,12 -3,72
Fads2 -2,08 2,07 -2,00
Fads3 1,09 1,32 -2,45
Fasn -2,63 1,32 -1,62
Fdft1 1,21 1,20 -2,87
Fdps 1,54 1,08 -1,09
Gpat 1,88 1,24 -1,92
Gpr65 1,01 3,02 -1,11
Haao 1,07 -1,41 -1,47
Hmgcr -1,28 1,82 -2,06
Hmgcs1 -1,44 1,59 -9,09
Hsd17b6 -5,37 -1,30 -1,96
Hsd3b7 -1,38 1,14 -2,52
Idi1 -1,56 1,19 -1,19
Ldlr -1,75 1,23 -1,42
Lpcat4 (Agpat7) 1,38 1,44 -4,54
Lrp8 ND ND 4,17
Lycat (Agpat8) ND ND -1,72
Mogat1 ND ND 1,96
Mogat2 ND ND 1,19
Mtp -1,85 1,21 -1,59
Mvd 1,20 1,66 -1,81
Mvk -1,59 1,09 1,96
Pcsk9 -2,69 1,02 -1,59
Pcyt2 1,10 -1,30 -1,63
Pmvk 1,13 1,34 -3,21
Ppap2a -1,47 1,31 -50,53
Ppap2b -1,03 1,38 -1,07
Ppap2c -1,49 1,03 -1,13
Ppara -1,32 1,06 -1,37
Ppard -1,58 2,19 -2,16
Pparg 2,16 1,47 -2,00
Ppia 1,01 -1,21 -1,09
Scap -1,01 -1,04 -1,04
Scarb1 -1,79 1,42 -1,14
Scd1 -3,14 -1,63 -4,92
Scd2 -1,25 2,24 2,08
Table S5. continued
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Sgpl1 -1,99 1,10 -1,09
Sgpp1 1,09 1,46 -1,02
Slc27a5 1,03 1,20 -1,75
Soat1 1,49 3,80 -1,96
Soat2 -1,47 -1,46 -1,81
Splc1 ND ND -1,35
Srebf2 -1,59 1,35 -1,41
Stard3 1,39 1,19 -1,20
Tm7sf2 1,62 -1,04 -2,55
Vldlr ND ND -1,04
Xpnep3 -2,19 1,83 1,35
Table S6. Antibodies used in the study
Antibody Host Code Dilution Incubation time/temp
CK-181 Rabbit 1924-1 1:200 60 min, RT
Ki67 (Clone SP6)2 Rabbit RM-9106-S0 1:2000 60 min, RT
CD313 Rabbit LS-B4737-250 1:50 Overnight, 4ºC
Cleaved Caspase-34 Rabbit 9661L 1:200 60 min, RT
AP Polymer anti-Rabbit5 - MON-APP201 undiluted 30 min, RT
HRP Plymer anti-Rabbit5 - MON-APP202 undiluted 30 min ,RT
RT- room temperature
1 Epitomics,Inc, Burlingame, CA 
2 Thermo Fisher Scientific/Labvision, Fremont, CA
3 LifeSpan Biosciences Inc., Seattle, WA
4 Cell Signaling Technology Inc., Danvers, MA
5 MONOSAN, Uden, The Netherlands
Supplementary Table 5. continued
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Abstract
RNA interference (RNAi) emerges as a potent approach for inhibition of disease-
related genes. However overexpression of RNAi inducers may cause cytotoxicity 
because of saturation of the endogenous microRNA (miRNA) processing pathway. 
Expression of short hairpin RNA (shRNA) or artificial miRNA from constitutive or tissue 
specific polymerase II (pol II) promoters has been shown to reduce RNAi toxicity in vivo 
and in vitro and controlling and limiting expression by using inducible pol II promoters 
would allow time- and dose-dependent expression of therapeutic shRNA or miRNA 
when the inducer is administered. In this study we evaluated the GeneSwitch (GS) 
system for inducible expression of artificial miRNA targeting Apolipoprotein B100 
(miApoB). Highly effective luciferase reporter inhibition by GS-miApoB was observed 
after induction with mifiprestone (MFP) and the effect was dependent on the amount 
of the GeneSwitch transactivator (TA). Deletion analysis of the core elements of the 
GS pol II promoter, the TATA box (TATA) and initiator sequence (INR) revealed that 
both are important for the functioning of the promoter in response to the inducer 
and any deletions result in loss of function. When TA and GS-miApoB encoding 
cassettes were placed in 4 different orientations in a single backbone, variant #3, 
where the transcription occurs in the opposite directions, showed the best luciferase 
reporter knockdown when MFP induced and least basal activity when non-induced. 
Quantification of small interfering RNA (siRNA) processed from the different GS 
variants revealed that the variant #3 expressed the highest amount of molecules. 
Finally, we showed that 4 miRNAs targeting the Huntingtin gene (Htt) cloned into 
the GS variant #3 demonstrated increased GFP and siRNA expression when induced 
with MFP. Our results demonstrate that the GeneSwitch system is capable of driving 
expression of artificial miRNA in a controlled manner in vitro when placed on a single 
backbone without compromising its properties. Controlled expression of therapeutic 
miRNA with the GeneSwitch system may constitute additional safety measure to limit 
toxicity of RNAi based gene therapy.
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Introduction
One of the goals of the RNAi gene therapy is the delivery of inhibitory molecules to 
the targeted tissue to achieve stable and therapeutic inhibition of disease related genes. 
However the ability to express high levels of shRNA/miRNA for extended periods of time 
creates the need for drug-regulated gene expression systems. shRNA have been shown 
to induce acute toxicity when over-expressed in vivo, which leads to fatality in mice [1,2], 
particularly when potent polymerase III (pol III) promoters are used to drive expression 
of shRNA, resulting in saturation of the endogenous RNAi machinery leading to the 
global deregulation of gene expression. The toxicity may be circumvented by expressing 
shRNA from the weaker pol II promoters which can be tissue specific or inducible [3-7], 
but the exact rules for successful expression of shRNA from pol II promoters are far 
from understood. As an alternative to shRNA, artificial miRNA scaffolds can be used as 
miRNA are naturally expressed from pol II promoters [8]. Inducible expression of artificial 
miRNA can provide an additional safety level where expression can be quantitatively and 
temporally controlled. 
Several inducible gene expression systems have been developed including 
tetracycline, rapamycine, IPTG, ecdysone, and MFP dependent technologies. [9-12]. 
Generally they consist of two elements: the first is a chimeric protein capable of 
modulating gene expression in a drug-dependent manner and the second is an 
inducible promoter which is often a minimal pol II promoter linked to sequences 
recognized by the chimeric protein. Additionally, two mechanisms of gene regulation 
can be distinguished, called On- and Off-switch. In the first mechanism, the chimeric 
transactivator protein binds specifically to its DNA recognition sequence within 
the inducible promoter in the presence of the inducer, which in consequence 
activates gene expression. In the second mechanism the chimeric protein-repressor 
is constantly bound to its recognition sequences and upon induction dissociates 
allowing transcription. Any inducible gene expression system should fulfill several 
requirements for safe and long term gene therapy application including a low basal 
expression in the absence of inducer and a high induction ratio. Another important 
safety requirement is that the chimeric proteins used in inducible systems, in active or 
inactive form, do not interfere with endogenous gene expression, because chimeric 
proteins are formed from potent transcription factors that can lead to unspecific 
activation of endogenous promoters and thus interfere with cellular processes [13]. 
The safety aspects should also be determined for all inducible system components 
within the context of immune system activation. 
The GeneSwitch regulated expression is one of the best characterized systems 
for inducible gene expression [11,12,14-16]. It exploits a hybrid transactivator 
(TA) containing a DNA binding domain from the yeast Gal4 protein (Gal4 BD), a 
truncated ligand binding domain from human progesterone receptor (PR) and a 
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p65 transcriptional activation domain of the human NF-kappa B transcription factor 
(hp65). The second component is the GeneSwitch inducible promoter, which consists 
of minimal pol II promoter with upstream activation sequences (Gal4) that can be 
recognized by Gal4 BD domains of the TA protein. The system is induced by MFP, 
which is an anti progestin that binds to the PR domain of the TA protein. Upon 
induction the TA changes its confirmation and as a dimer specifically binds to the Gal4 
sites to activate gene transcription. The major advantage of the system is that it lacks 
virally- or bacterially-derived components thus limiting a potential immune reaction 
to TA expression. Another advantage of the system is its inducer, which is a marketed 
drug with well characterized pharmacokinetics whereas the induction occurs at sub-
therapeutic concentrations [17]. On the other hand, MFP has been shown to interfere 
with biological pathways which increase toxicity risk for applications where prolonged 
exposure to the inducer may be necessary [18]. Additionally some of the interactions 
of TA domains have been already described. Expression of TA for one month resulted 
in transcriptional changes in the liver [13]. However they were not associated with 
any biochemical or morphological changes, this aspect needs more attention. 
Unlike the doxycycline and tetracycline (Tet) inducible systems, GeneSwitch has 
not been validated for RNAi induction. [19-24]. The former systems are derived 
from the bacterial tetracycline inducible system where tetracycline repressor protein 
(TetR) controls expression of the TetA protein that pumps tetracycline antibiotic out 
of the cell by binding to tetracycline responsive elements (TRE) upstream of the 
TetA promoter. Addition of tetracycline (or doxycyline) leads to a change in the TetR 
confirmation which dissociates from the promoter region and allows expression of 
TetA. Tetracycline-inducible systems such as TetOn, TetOff or Trex have been shown 
to be able to control shRNA or artificial miRNA expression in vitro and in vivo [19-24]. 
Regulated TetOff expression of shRNA targeting Polo-kinase 1 (Plk1) resulted in 
97% mRNA knockdown in vitro [22]. Subsequently the Plk1 protein was inhibited 
up to 86% which correlated with a significant inhibition of tumor cell growth [22]. 
Additionally, a conditionally replicating Human immunodeficiency virus (HIV)-based 
vector that stably expresses an inducible antiviral shRNA against HIV-1 was proposed 
as vaccine for HIV infections [23]. Upon doxycyline induction, virus was shown to 
spread efficiently to all HIV-susceptible cells. Subsequent doxycycline withdrawal the 
constitutive shRNA expression cassette was active resulting in viral inhibition [23]. 
Proof-of-concept has also been established in transgenic mice enabling inducible and 
reversible expression of shRNA against Replication protein A, subunit 3 (Rpa3) which 
resulted in a block of cell proliferation and rapid atrophy of the intestinal epithelium 
which led to weight loss and lethality within 8–11 day after shRNA induction [24]. 
However, the use of TetOn and TetOff systems in preclinical and clinical studies is 
limited because they are dependent on bacterially derived –potentially immunogenic 
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proteins [25-27]. Other systems validated for shRNA or artificial miRNA expressions are 
the IPTG and ecdysone inducible systems [28,29]. The first one was shown to tightly 
regulate and induce shRNA targeting luciferase and tumor suppressor protein p53 in 
both transiently transfected cells and established stable clones [29]. Knockdown of 
the p53 protein in vitro was also demonstrated with the ecdysone-inducible system 
[30], where dose- and time-dependent inhibition of p53 was associated with changes 
in cell morphology and concomitant reduction of p21, downstream target of p53. 
Withdrawal of the inducer completely reversed the phenotype.
In the current study we evaluated the GeneSwitch system for inducible expression 
of an artificial miRNA that efficiently targets ApoB. In order to facilitate usage 
of the GeneSwitch system in vivo, its structural elements were incorporated in a 
single backbone in 4 different variants, which were later evaluated for knockdown 
efficiency, basal expression and inducibility. Variant #3, where the two elements are 
transcribed in an antisense orientation, was identified as the best configuration as it 
demonstrated lowest basal expression when non-induced and highest activation rate 
in the induced state. Finally to check the system robustness, inducible expression of 
four additional miRNAs targeting the Htt gene was shown for variant #3. Our data 
demonstrate the feasibility of the GeneSwitch inducible miRNA expression system 
that should be considered for future therapeutic RNAi applications.
Results
Knockdown efficacy of GS-miApoB depends on TA concentration  
and duration of the induction
We have previously identified and tested in vivo a highly active artificial miRNA 
targeting Apolipoprotein B100 (miApoB) [31]. However, the knockdown effect 
decreased over time and some signs of mild toxicity have been observed. Therefore, 
as a next step we developed a regulated miApoB expression based on the MFP-
inducible GeneSwitch system. The two components of the GeneSwitch system were 
a chimeric TA that activates transcription exclusively in presence of MFP and the 
miApoB expressed from the GeneSwitch promoter (GS-miApoB) in response to TA 
binding (Fig. 1a). As a negative control, a scrambled miRNA not targeting any gene in 
the mammalian genome was placed under the control of the GeneSwitch (GS-miScr) 
or CMV promoters (CMV-miScr). Constitutive expressed miApoB (CMV-miApoB) 
was used as positive control. All constructs expressed green fluorescent protein 
version emerald (EmGFP), which allowed monitoring of the transfection efficacy 
and MFP induction (Fig. 1a). The inhibitory effect of GS-miApoB was evaluated 
by co-transfecting human embryonic kidney 293T (HEK293T) cells with a reporter 
expressing renilla luciferase that contained the ApoB target sequence in its 3’UTR 
(Luc-ApoB) and increasing amounts of the TA-encoding plasmid (Fig. 1b). By adding 
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10 nM MFP 24 h post transfection, transcription from GS-miApoB was induced and 
luciferase luminescence was measured 48 h later. As a negative control CMV-miScr 
or GS-miScr were used where the renilla/firefly luciferase ratio was set at 100% and 
the relative inhibition of the Luc-ApoB reporter was calculated. 
In the absence of TA, basal expression resulted in ~60% knockdown of Luc-ApoB 
both in MFP induced and non-induced state (Fig 1b). When increasing amounts of 
the TA plasmid were added, relative luciferase inhibition in non-induced cells was 
between 60% and 85% and upon MFP induction even stronger knockdown was 
measured (Fig. 1b). Addition of 10 ng TA to GS-miApoB resulted in lowest basal 
expression and highest induction rate therefore it was chosen for other experiments.
Because GeneSwitch inducible expression peaks between 24 and 72 h after MFP 
induction, the maximal inhibitory effect was determined over time. HEK293T cells 
were co-transfected with 50 ng GS-miApoB, 10 ng Luc-ApoB and 10 ng TA plasmids 
(Fig. 1c). Twenty four hours after transfection cells were induced with MFP and after 
another 24, 48, and 72 h samples were harvested and luciferase inhibition was 
measured. Maximal Luc-ApoB knockdown was observed 48 h after MFP induction 
and it was ~80% in induced cell compared to ~50% in non-induced cells. After 72 h 
the Luc-ApoB knockdown was weaker and was 51% and 22% in MFP induced and 
non-induced cells, respectively (Fig. 1c).
GeneSwitch promoter analysis reveals that TATA box and INR are essential 
components and play important role in MFP induction
Initially we confirmed that the GeneSwitch system is capable of driving miApoB 
expression and established the optimal TA concentration and MFP induction time. Next, 
the inducible promoter was optimized to reduce the miApoB basal expression levels since 
without MFP induction, a ~50% knockdown of Luc-ApoB was already observed. Based 
on manual sequence identification, two core components of the GeneSwitch promoter, 
a TATA box and an initiator element (INR) were identified. In order to evaluate their 
function for basal expression and/or maximal induction of GS-miApoB, mutants lacking 
TATA (ΔTATA-miApoB), INR (ΔINR-miApoB) or both TATA and INR (ΔTATAΔINR-miApoB) 
were designed (Fig. 2a). HEK293T cells were co-transfected with 50 ng GS-miApoB, 
ΔTATA-miApoB, ΔINR-miApoB or ΔTATAΔINR-miApoB together with 10 ng of Luc-ApoB 
reporter and 10 ng TA plasmid. By adding 10 nM MFP transcription of miApoB was 
induced and Luc-ApoB knockdown was measured 48 h post induction with reference to 
CMV-miScr and GS-miScr controls. Upon induction luciferase knockdown by GS-miApoB 
was 64% while it was 31%, 34% and 36% for ΔTATA-miApoB, ΔINR-miApoB and 
ΔTATAΔINR-miApoB mutants (Fig. 2b). Moreover, none of the deletion constructs was 
MFP induced above basal levels indicating that the TATA and INR elements are essential 
for transcriptional activity of the GeneSwitch promoter. Additionally no GFP expression 
from the deletion mutants was observed (data not shown). 
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Incorporation of GS-miApoB and TA elements in a single backbone results in 
high MFP inducibility and high basal expression levels 
Inducible systems where all components can be integrated in a single backbone are 
desirable for therapeutic RNAi applications. Therefore the TA and GS-miApoB elements 
were placed adjacent to each other in a single vector backbone (Fig. 3a). The TA 
expression cassette was cloned upstream to GS-miApoB resulting in sense orientation 
of the two elements (Fig. 3a). HEK293T cells were co-transfected with 50 ng of the 
GS-miApoB single backbone variant with 10 ng of Luc-ApoB. Twenty four hours post 
transfection cells were induced and after another 48 h GFP induction was monitored. 
High GFP expression was observed for both GS-miScr and GS-miApoB only upon MFP 
Figure 1. Structure and knockdown efficacy of miRNA targeting ApoB (miApoB) expressed 
from the GeneSwitch system. (a) Schematic representation of the GeneSwitch system for inducible 
expression of artificial miRNA. The system consists of two structural components: the transactivator 
protein (TA) expressed from the CMV promoter and miRNA expressing construct (GS-miApoB). Gal4 
BD - Yeast Gal4 DNA binding domain, hPR-LBD - Human progesterone receptor ligand binding 
domain, p65 - Human NF-kB activation domain subunit, Gal4- Gal4 BD binding site, TATA- TATA 
box, INR- initiator sequence, EmGFP- Emerald Green Fluorescent Protein (b) Knockdown of Luc-ApoB 
reporter by GS-miApoB. Cells were transfected with 10 ng Luc-ApoB reporter, 50 ng GS-miApoB 
expressing plasmid and 10, 50, 100 or 250 ng of GeneSwitch TA expressing plasmid. Twenty four 
hours after transfection medium was changed and samples were induced with 10 nM MFP (+MFP) 
or were not induced (-MFP). Renilla and firefly luciferase were measured 48 h post-MFP induction. 
Renilla luciferase expression was normalized to firefly luciferase expression. CMV-miApoB was used 
as a positive control, CMV-miScr and GS-miScr served as negative controls and were set at 100%. 
Data are represented as mean values ±SD from a representative experiment from three independent 
experiments. (c) Knockdown of the Luc-ApoB reporter, by GS-miApoB at 24, 48 and 72 h post-MFP 
induction. Cells were transfected with 10 ng Luc-ApoB reporter, 50 ng GS-miApoB expressing plasmid 








Figure 2. Structure and knockdown efficacy of miApoB expressed from a single backbone 
GS-miApoB. (a) Schematic representation of GS-miApoB for inducible expression of artificial miApoB, 
where all structural components were placed in a single backbone. The names of the structural 
components are indicted in Fig. 1. Arrows represent the direction of transcription (b) Representative 
image of GFP fluorescence 48 h without (-MFP) or after induction with 10 nM MFP (+MFP). Cells were 
transfected with 10 ng Luc-ApoB reporter and 50 ng GS-miApoB expressing plasmid. Pictures were 
taken using the same exposure and magnification settings. (c) Changes in the number of GFP positive 
cells after MFP induction. Experimental setup was as described in (b) 1000 events were counted with 
flow cytometry and fold change of GFP expression was calculated for each construct by dividing the 
amount of cells GFP positive after MFP induction by the number of GFP positive cells without MFP 
induction. (d) Knockdown of Luc-ApoB reporter, by the single backbone GS-miApoB system. Cells 
were transfected with 10 ng Luc-ApoB reporter and 50 ng GS-miApoB expressing plasmid. Twenty 
four hours after transfection medium was changed and samples were either induced with 10 nM 
MFP (+MFP) or were not induced (-MFP). Renilla and firefly luciferase were measured 48 h post-
induction. Renilla luciferase expression was normalized to firefly luciferase expression. CMV-miApoB 
was used as a positive control, CMV-miScr and GS-miScr served as negative controls and were set at 
100%. Bars with stripes represent negative controls. Data are represented as mean values ±SD from a 
representative experiment from three independent experiments.
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a
Figure 3. Structure and knockdown efficacy of GS-miApoB expressed from the GeneSwitch 
system with consecutive deletions in the inducible promoter. (a) Schematic representation of 
GS-miApoB for inducible expression of artificial miRNA, where several structural parts were deleted. 
Three different GeneSwitch deletion variants were designed where the TATA box (ΔTATA-miApoB), 
the INR sequence (ΔINR-miApoB) or both components were deleted (ΔTATAΔINR –miApoB) (b) 
Knockdown of Luc-ApoB reporter, by GS-miApoB after induction with the different GeneSwitch 
deletion variants: ΔTATA-miApoB, ΔINR-miApoB or ΔTATAΔINR–miApoB. Cells were transfected 
with 10 ng Luc-ApoB reporter, 50 ng GS-miApoB, ΔTATA-miApoB, ΔINR-miApoB or ΔTATAΔINR–
miApoB and 10 ng of the TA plasmid. Reaction conditions were as described in Fig. 1b. Bars with 
stripes represent negative controls. Data are represented as mean values ±SD from a representative 
experiment from three independent experiments.
induction (Fig. 3b). Quantification of GFP positive cells with flow cytometry revealed 
that there were ~4 fold more GFP positive cells for GS-miScr and GS-miApoB when 
induced with MFP compared to non-induced cells (Fig. 3c). To determine whether the 
induction observed on GFP correlates with Luc-ApoB knockdown by the GS-miApoB 
single backbone variant, luciferase assay was performed. Surprisingly for the single 
backbone GS-miApoB variant MFP induction did not further decrease Luc-ApoB 
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up to 80% indicating that the basal expression with the single backbone GS-miApoB 
was greater than with the two plasmids system. Reduction of the GS-miApoB and 
MFP concentrations did not show an improvement in basal expression which still 
resulted in ~80% Luc-ApoB knockdown (data no shown).
Inducibility and basal expression depends on the positioning and orientation 
of GS-miApoB and TA elements within a single backbone
It has been shown that the expression and activity of the inducible systems depends on 
the orientation of expression cassettes in a single backbone [32-34]. To achieve optimal 
induction and minimal basal expression, the TA and GS-miApoB elements were cloned 
in different orientations resulting in 4 distinct variants (Fig. 4a). In all variants GS-miApoB 
was cloned upstream of TA expression cassette. In variant #1 both cassettes were in sense 
orientation. In variant #2 GS-miApoB and TA cassettes were in a head-to-head orientation. 
In variant #3 and #4 GS-miApoB and TA cassettes were opposite and antisense to each 
other, respectively (Fig. 4a). HEK293T cells were co-transfected with 50 ng of variants 
#1-#4, induced with MFP 24h later and 48 h post induction, Luc-ApoB knockdown was 
measured (Fig. 4b). As anticipated, the different orientations varied in terms of basal 
expression and induction. Variants #1 and #2 exhibited mild induction and low basal 
activity. For variant #1 the Luc-ApoB knockdown was 32% and 38% for non-induced and 
MFP induced cells, respectively. For variant #2 knockdown was 28% for non-induced and 
42% for MFP induced cells respectively. Variants #3 and #4 exhibited lowest basal activity 
and highest induction rate. For variant #3 basal expression resulted in 25% knockdown 
of Luc-ApoB, which was stronger upon induction and reached 59%. Similarly variant #4 
resulted in 22% and 51% knockdown when non-induced and MFP induced, respectively.
Next, the correlation was determined between the inhibitory effect, induction rate, 
and the number of processed siApoB molecules from the GS-miApoB variants #1-#4 
Figure 4. Structure and knockdown efficacy of GS-miApoB expressed from a single 
backbone with four different orientations of the GeneSwitch and TA elements. (a) Schematic 
representation of variants #1 - #4 of the single backbone GS-miApoB, with different orientations of 
the GeneSwitch and TA elements In variant #1 both cassettes were in sense orientation. In variant 
#2 GS-miApoB and TA cassettes were in head-to-head orientations. In variant #3 and #4 GS-miApoB 
and TA cassettes were opposite and antisense to each other, respectively. The names of the structural 
components are indicted in Fig. 1a. Arrows represent direction of transcription. (b) Knockdown of 
the Luc-ApoB reporter, by the single backbone GS-miApoB system variants #1 to #4. Cells were 
transfected with 10 ng Luc-ApoB reporter and 50 ng GS-miApoB variants #1-#4. Reaction conditions 
are as described in Fig. 1b. Bars with stripes represent negative controls. Data are represented as 
mean values ±SD from three experiments analyzed with the factor correction method. (c) siApoB 
expression in HEK293T cells from the single backbone GS-miApoB variants #1-#4. RNA was isolated 
48 hours post-MFP induction and siApoB-specific small RNA TaqMan was performed. siRNA copy 
number per cell was calculated based on the amplification plot of a dilution series of synthetic siApoB 
RNA standard (IDT, Coralville, IA). The trend line value of the standard line was used to calculate the 
siApoB copy number cell, assuming 15 pg RNA per cell [39]. 
▶
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(Fig. 4c). Small RNA specific Taqman assay was designed for detecting the guide strand 
of miApoB and the amount of molecules per cell was calculated based on synthetic 
standard line. All variants showed a clear increase of the amount of siApoB molecules 
per cell after MFP induction. Variant #1 expressed the highest amount of siApoB 
molecules compared to other variants. Variants #3 and #4 exhibited lowest basal 
expression and highest induction rate which is in line with Luc-ApoB knockdown data.
Variant #3 where the GS-miApoB and TA elements were positioned opposite to each 
other showed the best configuration for inducible expression of artificial miRNA targeting 
ApoB. To check if this is a general rule, we tested the inducibility of four additional 
efficient miRNAs targeting the Htt gene cloned in GS variant #3. miH10, miH12, miS7 
and miS15 are targeting different regions of Htt and have been already validated as 
potent huntingtin inhibitors (data not shown). HEK293T cells were co-transfected with 
50 ng of GS-miH10, GS-mH12, GS-miS7 or GS-miS15 variants #3 and 48 h post MFP 
induction total RNA was isolated (Fig. 4b). The induction was measured by quantifying 
the siRNA molecules expressed with and without MFP induction using specific small RNA 
Taqman assay. The results show between 4 and 7 times siRNA induction proving the 
robustness of GS variant #3 for inducible miRNA expression (Fig. 5a). 
Discussion
Recent developments towards clinical applications of RNAi made it apparent that 
regulable and temporal expression may be necessary to circumvent toxicity resulting 
from aspecific off-targeting effects or oversaturation of the endogenous miRNA 
pathway. Inducible systems have been widely used for control of gene expression. 
These systems are composed of a chimeric transcription factor, inducer and a 
promoter that reacts upon transcription factor binding. The GeneSwitch inducible 
system is one of the promising candidates for RNAi gene therapy since it lacks 
bacterially derived components and the MFP inducer is an already approved drug 
with known pharmacokinetics. Although the GeneSwitch system can effectively 
regulate gene expression in vivo and in vitro using plasmid or viral delivery, to date 
there are no reports of its application for RNAi induction. We addressed this question 
by optimizing miApoB expression from the GeneSwitch system initially using a two-
plasmid system and later by combining the GeneSwitch elements in four different 
orientations in a single backbone. 
The transactivator and promoter elements are essential parts of each inducible 
system that characterize its parameters: basal expression, fold induction, and 
maximum expression levels. Therefore, we investigated the optimal conditions for 
minimal basal activity without induction with MFP and the maximal inducibility after 
addition of inducer. By increasing the amount of TA plasmid the basal expression of 
the inducible promoter also increased suggesting that even in non-active state TA is 
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of 4 different artificial miRNAs targeting Htt 
from GeneSwitch expression system, variant 
#3. (a) Representative image of GFP fluorescence 
48 h without (-MFP) or after induction with 10 nM 
MFP (+MFP). Cells were transfected with variant #3 
of GS-miH10, GS-miH12, GS-miS7 or GS-miS15 
expressing plasmid. As a control CMV-miScr 
was used. Pictures were taken using the same 
exposure and magnification settings. (b) siH10, 
siH12, siS7, siS15 expression in HEK293T cells 
from the GeneSwitch variant #3. Experimental 
setup was as described in (a). RNA was isolated 
48 h post-MFP induction and siRNA-specific small 
RNA Taqman was performed. siRNA expression 
levels were normalized to beta-actin as an internal control, and the relative gene expression 2-ΔΔCt method 
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capable of binding to Gal4 elements in the GeneSwitch promoter. Another important 
aspect of the inducible systems is their temporal control of gene expression. The 
effect of the induction is dose dependent and increases until it reaches maximal 
expression. Generally after 24 h the expression using GeneSwitch system reaches 
maximum level in vitro [11,35], however in our case 24 hours time was not sufficient 
to observe increase in luciferase inhibition. The maximal knockdown of luciferase was 
observed after 48 hours and after 72 hours the inhibition of luciferase was weaker. 
In this study, we also carried out deletion analysis of the GeneSwitch promoter 
to identify regions that control the responsiveness and the spatiotemporal gene 
expression. Manual analysis of the GeneSwitch promoter identified common elements 
of pol II promoters: a TATA box and an INR sequence [36,37]. Deletion analysis showed 
that both TATA box and INR are essential components of the GeneSwitch promoter and 
any perturbations resulted in a functional loss probably due to inefficient transcription. 
An interesting alternative to the promoter modification is to incorporate more Gal4 
sequences upstream to the promoter, which can improve promoter inducibility. This 
was already shown for mIFNb expression with the GeneSwitch inducible system [14]. 
Although we did not optimize the TA expression cassette itself an interesting option 
is to use tissue specific promoters for expression of the TA protein. This would lower 
the extent of unregulated expression associated with the constitutive TA expression 
from the CMV promoter. Alternatively TA can be expressed from the promoter that, 
like the transgene, is responsive to MFP. In this auto-inducible system, the TA can 
induce both the transgene and its own expression.
A vector based regulated expression for GeneSwitch system has already been 
validated in vitro and in vivo using mouse interferon beta (mIFNb) [14]. Similarly to our 
studies four variants of a single backbone expression system with different orientations 
were tested and all 4 variants resulted in mIFNb in vitro induction raging from 
360 – 1480 fold. In two variants (pGT23 and pGT24) the mIFNb cassette was cloned 
upstream of TA expression cassette in sense and opposite orientations respectively. 
In two other (pGT25 and pGT25) the TA expression cassette was upstream of mIFNb 
and was cloned in sense and head-to-head orientations respectively. This means that 
pGT23 is equivalent to our variant #1, pGT24 is variant #3 and pGT25 is GS-miApoB. 
pGT26 does not have equivalent in our study. The variant which exhibited the greatest 
induction was pGT23 followed by pGT26, pGT24 and pGT25. Interestingly, all single 
backbone variants outperformed the two-plasmid system in the inducible rate and 
the level of mIFNb expression but all construct, when induced, expressed less mIFNb 
than the constitutive CMV promoter. Surprisingly, in vivo measurement of IP-10, 
which is a validated biomarker for mIFNb showed a different trend and the variant 
that resulted in the best IP-10 induction was pGT26 followed by variants pGT25, 
pGT24 and pGT23. In vivo all variants were as active as the two-plasmid system in 
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IP-10 induction and they were also outperforming CMV expressed mIFNb. Despite 
the similar approach to optimize the GeneSwitch system, a direct comparison to our 
results is not feasible because the luciferase knockdown is caused by an increase of 
the siRNA amount which in consequence inhibits the protein expression. Additionally 
the exact mechanism of the GeneSwitch system induction has not been investigated 
thus a high protein expression may be a combination of an increased transcription 
and increased translation or both. By contrast to reported induction of mIFNb, our 
results show much lower induction of expressed siRNA: 4-6 fold increase in MFP 
induced cells compared to the non-induced cells. 
Inducible expression is an interesting approach to avoid potential problems that 
can be associated with therapeutic RNAi applications. It has been reported that shRNA 
can lead to severe toxicity when high doses are used [1,2] and that by lowering siRNA 
expression -either using pol II promoters or by incorporation of a siRNA sequence in 
an artificial miRNA scaffold [9]- toxic side effects can be abolished. In our previous 
study, we have demonstrated a more sustained ApoB target knockdown by miApoB 
over the shApoB in long-term in vivo experiments [31]. Nonetheless, the inhibitory 
effect of miApoB expressed with a liver-specific promoter and shApoB was lost after 
27 weeks. Additionally it has been shown that processing of shRNA and miRNA may 
lead to unanticipated silencing of other genes (off-targeting) which also can cause 
toxicity. Because of the complexity of RNAi processing in vivo, these interactions 
are difficult to predict and evaluate. Still RNAi toxicity has been shown to be dose 
dependent therefore limiting the expression of siRNA molecules with inducible 
systems may reduce potential risk. Although the present study provides a proof of 
concept for controlling siRNA expression in vitro, the reduction of the toxicity of 
GeneSwitch expressed miRNA in vitro and in vivo needs to be further investigated.
An important aspect is the robustness of the GeneSwitch system, which should be 
capable of expressing any miRNA. We have shown that variant #3 was also capable 
of driving expression of 4 miRNAs targeting Htt. Unequivocal induction of both GFP 
and miRNA expression was observed. Additionally gene knockdown in vivo, using 
the GeneSwitch system, needs to be investigated. The plasmids described in this 
study could be used in the context of viral vectors such as AAV for a long-term 
expression in vivo. Beside Htt knockdown for Huntington disease and ApoB for FH, 
other potential applications that can be treated with GeneSwitch inducible RNAi 
include cancer and viral infections (HIV, Hepatitis B virus and Hepatitis C virus).
In conclusion, we have tested the GeneSwitch system and constructed a single 
backbone to express the artificial miRNA targeting ApoB and Htt. This vector enabled 
regulation of the miRNA expression and proved efficient in Luc-ApoB knockdown 
in vitro. Combination of the AAV delivery and the inducible expression of an artificial 
miRNA would allow a long-term therapeutics effect simultaneously limiting possible 
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side effects. This will provide an additional safety level for future clinical applications 
compared to the ubiquitously expressed shRNA/miRNA.
Materials and methods
DNA constructs
GeneSwtich miApoB (GS-miApoB) construct was made by amplification of a 1384 bp 
fragment of pCDNA6.2 construct containing EmGFP and miApoB using pr967 and 
pr968 primers and ligating into the NcoI and KpnI sites of the pIF1683 (Inovio, San 
Diego, CA). The pIF1683 contains minimal pol II promoter with 4 upstream activation 
elements (Gal4). The construction of pCDNA6.2 containing miRNA targeting ApoB 
has been described previously [36]. Similarly negative scrambled control miRNA 
(GS-miScr) was made by PCR amplification o pcDNA6.2-GW/EmGFP-miR-neg 
(Invitrogen, Carlsbad, CA) using the same primer set. The GeneSwitch TA plasmid 
was constructed by amplification of 2200 bp fragment of pGS1984 (Inovio, San 
Diego, CA) using primers pr965 and pr966 and ligating into the XbaI and RsrII sites of 
the pTRCGW vector (Inovio, San Diego, CA). pGS1984 contains TA under the control 
of the beta-actin promoter. The end construct expressed TA protein form constitutive 
CMV promoter. All miRNA and primer sequences are listed in Table S1.
The GeneSwitch inducible promoter mutation variants variant were designed 
as followed. Promoter fragments of 200 bp with desired mutation (ΔTATA, ΔINR, 
ΔTATAΔINR) were synthesized and cloned into pIDTsmart vector resulting in 
pIDTsmartΔTATA, pIDTsmartΔINR, pIDTsmartΔTATAΔINR vectors (IDT, Coralville, IA). 
Then pIDTsmartΔTATA smart was digested with EcoRI and XhoI ligated into pIF1683 
plasmid digested with the same restriction sites resulting in ΔTATA-miApoB construct. 
ΔTATAΔINR-miApoB was constructed analogously to ΔTATA-miApoB construct. ΔINR-
miApoB was made by with EcoRI and BglI digestion of pIDTsmartΔINR and ligation 
into the same restriction sites of pIF1683.
The GeneSwitch single backbone variant was designed as followed. The GS fragment 
(1223 bp) was cut from pIF1683 plasmid by SbfI and Acc65I digestion and ligated into 
the PstI and Acc65I digested pKS+ (Stratagene, La Jolla, CA) resulting in pKS-GS plasmid. 
Next the TA expressing plasmid was digested with SspI and FspI and blunt ligated into 
BamHI sites of pKS-GS resulting in pKS-GS-TA plasmid. To replace beta-actin for CMV 
promoter in the TA expression cassette, the GS-TA fragment (2539 bp) was obtained 
by NheI digestion of pKS-GS-TA and ligated into SpeI digested pTRCGW. The construct 
was named as pTRC-GS-TA. Finally, the 1384 bp fragment of pCDNA6.2 construct 
containing EmGFP and miApoB was PCR amplified using primers miRfw and miRrv and 
ligated into the SacII and NotI sites of the pTRC-GS-TA resulting in a single backbone 
GS-miApoB construct. GeneSwitch orientations #1-#4 were designed as followed. The 
TA expression cassette was digested with KpnI and ligated into GS-miApoB construct, 
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which was digested with the same enzyme. The insert was ligated in sense or antisense 
orientations resulting in variant #1 and variant #3. To create variants #2 and #4 the 
GS-miApoB expression cassette in variants #1 and #3 was inverted by SbfI digestion 
and relegation. The presence of miApoB was verified by sequencing.
To create vectors expressing miRNA targeting Htt, 278 bp fragments of pCDNA6.2 
constructs containing miH10, miH12, miS7 and S15 were PCR amplified with primers 
prGS3fw and prGS3rv and the inserts were blunt ligated into DraV and EcorV digested 
variant #3 construct. Construction of the Luc-ApoB reporter vector has been described 
before [38] Generation of this reporter vector has been described previously. All the 
sequences of the oligonucleotides used in this study are listed in Table S1.
Cell culture and transfections
The human embryonic kidney (HEK293T) cell line were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Life Technologies, Grand Island, NY) containing 
10% fetal calf serum, 100 U/ml penicillin and 100 U/ml streptomycin, at 37°C and 
5% CO2. For luciferase assay or siRNA expression analysis, cells were seeded in 96- 
or 24-well plates at a density of 3×104 or 1.2×105 cells per well, respectively, in 
DMEM one day prior transfection. Transfections were performed with Lipofectamine 
2000 reagent (Life Technologies, Grand Island, NY) according to the manufacturer’s 
instructions. Cells were induced with 10 nM mifiprestone (Sigma) which was prepared 
the day of the induction from the 1mM stock. 
Luciferase assay
HEK293T cells were transfected with 10 ng Luc-ApoB reporter, 50 ng GS-miApoB 
expressing plasmid and 10, 50, 100 or 250 ng of TA expressing plasmid or with 10 ng 
Luc-ApoB reporter or 50 ng of GeneSwitch variants #1- #4. Twenty four hours after 
transfection medium was changed and samples were induced with 10 nM Mifiprestone 
(+MFP) or were not induced (-MFP). Renilla and firefly luciferase were measured at 
indicated time points post-MFP induction. Renilla luciferase expression was normalized 
to firefly luciferase expression. CMV-miApoB was used as a positive control, CMV-miScr 
and GS-miScr served as negative controls and were set at 100%. Transfected cells were 
assayed at 48 h post-transfection in 20 µl 1x passive lysis buffer (Promega, Madison, 
WI) using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). 
Flow cytometry
Cells were transfected with 10 ng Luc-ApoB reporter and 50 ng of GS-miApoB 
single backbone variant. Twenty four hours after transfection medium was changed 
and samples were induced with 10 nM Mifiprestone (+MFP) or were not induced 
(-MFP). Cells were fixed and analyzed on FACSCalibur flow cytometer instrument 
(BD Biosciences, San Jose, CA). 1000 events were counted and fold change of GFP 
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expression was calculated for each construct by dividing the amount of cells GFP 
positive after MFP induction by the number of GFP positive cells without MFP induction.
siRNA and miRNA detection by small RNA Taqman assay
RT reactions for siApoB, siH10, siH12, siS7 and siS15 expression were performed 
with the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA) using 10 ng RNA and 3 µl custom-made specific RT-stem-loop primers (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instructions. The TaqMan 
assay was done in 20 µl using 1,33 µl cDNA, 1 µl custom-made siRNA-specific primer 
with FAM-labeled fluorogenic probe (Applied Biosystems) and 10 µl TaqMan 2× 
Universal PCR Master Mix (Applied Biosystems). Amplification of the beta actin gene 
was used as a RNA quality and loading control. For siApoB copy number per cell 
was calculated based on the amplification plot of a dilution series of synthetic siRNA 
standards (IDT, Coralville, IA). Tenfold dilutions (100 pg – 1 fg) of the guide strand of 
the synthetic siRNA oligo were used to create a standard line. The copy number of 
each dilution was calculated according to the formula 1 mol = 6.02 × 1023 molecules. 
The trend line value of the standard line was used to calculate the siRNA copy number 
per cell, assuming 15 pg RNA per cell. siH10, siH12, siS7 and siS15 expression levels 
were normalized to beta actin as an internal control, and the relative expression 2-ΔΔCt 
method of Livak and Schmittgen was used for analysis of the induction [40].
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Many diseases, including hereditary diseases, viral infections, hepatitis, cirrhosis, 
fatty liver disease, and cancer can affect the liver. Most of these are characterized 
by altered expression of disease-related genes and in some cases progression of the 
disease may be stopped or even reversed when the disease-related gene is inhibited. 
Therefore, when inhibition of a “faulty gene” expression is therapeutically beneficial, 
RNAi is a suitable approach for treatment of liver diseases. The research presented 
in this thesis covered the design, optimization and comparison of RNAi inducers for 
treatment of FH by targeting ApoB. However, the results presented in this thesis can 
be applied for developing RNAi-based therapeutics for other diseases as well.
Development of RNAi-based gene therapy of FH  
by targeting ApoB
The ApoB protein constitutes a structural part of VLDL-C and LDL-C two classes of 
lipoproteins that are considered atherogenic. Increased circulating levels of LDL-C and 
VLDL-C are often associated with development of cardiovascular diseases [1]. In this 
thesis we focused on ApoB knockdown for treatment of FH using shRNA (shApoB) 
and artificial miRNA (miApoB). This approach, in combination with an effective AAV 
delivery method, can provide potent long-term inhibition of ApoB and in consequence 
lowering of plasma cholesterol. In chapter 2, we reported that shApoB specifically 
reduce LDL-C in diet-induced dyslipidemic mice, whereas HDL-C remained unaffected 
[2]. We also reported increased lipid accumulation, which is now recognized to be 
a commonly observed side effect of ApoB inhibition. In chapter 3, the knockdown 
efficacy of pol II-expressed shRNA and artificial miRNA was compared. Our results 
demonstrated that pol II-expressed artificial miRNA have a superior efficacy profile 
when compared to shRNA. Therefore, in chapter 4 we compared the long-term efficacy 
of shApoB and miApoB in vivo. Although miApoB performed significantly better in 
silencing ApoB than shApoB, the inhibitory effect mediated by both molecules was 
lost over the 27 week experiment. We also discovered that shApoB and miApoB are 
differentially processed in vitro. In chapter 5, we further investigated the consequences 
of these differences by analyzing the effects of shApoB and miApoB expression on 
liver morphology, transcriptome and endogenous miRNA profile. Finally, in chapter 6 
we developed the GeneSwitch regulated expression system for miApoB allowing gene 
expression to be turned “on and off”. 
FH is a recessive genetic disorder characterized by very high levels of LDL-C and 
early cardiovascular disease which are often caused by mutations in Ldl-r or ApoB 
[3,4]. There are two types of FH: the heterozygous form in which the patient has one 
normal allele and one mutated, and the homozygous form in which the patient has 
two mutated alleles. To date there is no cure for this disease and the primary goal 




and/or symptomatic drug treatment in order to decrease the risk of atherosclerosis [5]. 
Currently inhibitors of HMG-CoA (statins) are the most effective and best tolerated 
lipid-lowering agents. However these drugs are not always effective in all patients 
[4] and the response may depends on the mutation underlying the disease. Statins 
also have rare but serious adverse effects, including muscle damage, which may 
lead to acute kidney failure. Additionally high dose of statins may cause liver toxicity 
and as a consequence statins are not an appropriate treatment for patients with 
active liver diseases. For patients who do not respond to the maximal dose or have 
contraindications, other cholesterol inhibiting drugs including bile acid resin, niacin, 
fibrate or cholesterol absorption inhibitors may be used as a alternative treatment 
or combined with lower dose of statins. However even combined treatment for 
some patients especially with homozygous form of FH does not lead to a satisfactory 
reduction of LDL-C. For the most severe cases orthotropic liver transplantation maybe 
considered, but clearly this is not an option for the majority of FH patients. 
Because some patients cannot be effectively treated with conventional lipid 
lowering therapies, several novel approaches have been developed either as alternative 
therapy or to be used combined with standard therapies. These approaches target 
genes or miRNA involved in lipid metabolism, in order to lower LDL-C levels. Examples 
include antisense oligonucleotides to Pcsk9, ApoB, mir-122, inhibitors of Mtp and 
siRNA against Pcsk9, Mtp or ApoB [6-12]. With the exception of the Mtp inhibitor, 
which is a small molecule, these new drugs are oligonucleotides inducing mRNA 
cleavage, translational repression or inhibiting miRNA functions.
The antisense oligonucleotide to ApoB (mipomersen, commercial name Kynamro) 
developed by ISIS Pharmaceuticals is the most extensively studied as an alternative 
FH therapy. An antisense oligonucleotide is a nucleic acid that binds to the target 
RNA sequence and in consequence inactivates the gene of interest by triggering 
RNAse H-dependent or independent cleavage mechanisms [13,14]. In phase 3 clinical 
studies on patients with homozygous and heterozygous FH, Kynamro showed an 
average 36% LDL-C reduction. The most notable side effect was liver fat accumulation 
accompanied by increase in liver enzymes suggesting liver toxicity, and potentially 
limiting its clinical applicability. Recently Kynamro also revealed its efficacy in a small 
phase 2 study in patients with the heterozygous form of FH, that were intolerant 
to statins. The average reduction of ApoB was 46% which subsequently resulted 
in 47% reduction of LDL-C [15]. One of the disadvantages of this approach is the 
fact that the drug has to be delivered weekly via subcutaneous injections for stable 
therapeutic effect. By contrast, our results showed that AAV delivered shApoB can 
provide a long-term phenotypic correction with a single intravenous administration. 
It is argued that the therapeutic goal in FH should be a reduction of cholesterol of 
at least 30%.  Indeed, our data showed that a 32% can be achieved with as low 




and the highest dose 1012 gc/animal resulted in 95% reduction of ApoB mRNA and 
undetectable level of ApoB protein in plasma.
Lomitapide, a small molecule inhibiting Mtp may provide a clinical benefit that 
is comparable to Kynamro [16]. The Mtp protein is responsible for binding and 
shuttling individual lipid molecules between membranes and a normal function of 
Mtp is necessary for synthesis of the ApoB containing lipoproteins VLDL-C and LDL-C. 
Lomitapide has been evaluated in more than 900 FH patients in clinical trials, and an 
average LDL-C decrease of 40% was measured [17]. Since Mtp works at a level of 
lipoprotein synthesis that is comparable to ApoB, its inhibition was also associated 
with increased fat accumulation in the liver and increase in liver enzymes. Other side 
reported effects were gastrointestinal problems associated with an increase in dosage. 
In contrast to the above mentioned drugs, miravirsen- a LNA oligonucleotide 
inhibiting mir-122 was not developed specifically for FH but for treatment of HCV 
viral infections [18]. LNA is chemical modification of oligonucleotides, which improve 
its affinity to RNA target concominant with higher specificity and stability compared 
to non-modified oligonucleotides. Mir-122 constitutes about 70% of all liver 
miRNAs, and it has been shown to play an important role in HCV viral replication 
[19]. Clinical trials using Miravirsen showed more than 100-fold reduction of viral 
plasma RNA levels compared to baseline. Interestingly, a reduction of the cholesterol 
levels in all patients was also reported indicating that targeting mir-122 can also 
potentially be used in treatment of FH. On the safety aspects, elevated ALP levels 
were measured, which is considered as a marker of liver injury equivalent to ALT and 
AST. Similarly to siRNA and antisense drugs, LNA therapeutics for FH would require 
re-administration for stable correction of cholesterol. One of the larger disadvantages 
of mir-122 inhibition is that this is not a direct approach targeting proteins involved in 
lipid metabolism. In fact, inhibition of endogenous miRNA may result in deregulation 
of multiple liver functions. For example, mir-122 knockout mice displayed hepatic 
inflammation, fibrosis, and a high incidence of hepatocellular carcinoma, suggesting 
that mir-122 has a tumor suppressor role in hepatocytes [20].
Another alternative strategy to treat FH is to induce RNA interference by delivering 
siRNA targeting ApoB or Pcsk9. siRNA administration has been reported to decrease 
ApoB levels and plasma cholesterol in mice and recently also in non-human primates 
[11,21]. Tekmira has reported a roughly 20% inhibition of ApoB and LDL-C following 
siRNA administration in a phase I clinical trial [22]. However the initial efficacy trial 
has been terminated as one of the patients treated at the highest dose experienced 
an adverse event comprised of flu-like symptoms, cytokine release and transient 
hypotension consistent with stimulation of the immune system. This confirms 
the notion that siRNA can be potent activators of immune response in humans, 
corroborating previous studies in rodents. In all studies discussed thus far increased 




of ApoB. Another approach is to use siRNA targeting Pcsk9 which plays important 
role in Ldl-r turnover and degradation. The efficacy of siRNA targeting Pcsk9 has 
already been shown in vivo in mice and primates [12]. In NHP, a single dose of siRNA 
targeting Pcsk9 resulted in a rapid, durable, and reversible lowering of plasma Pcsk9 
which resulted in ~70% inhibition of ApoB and ~60% reduction of LDL-C [12]. 
No increase in liver enzymes has been reported. Unfortunately, the authors did not 
include evaluations of lipid accumulation in liver. siRNAs targeting ApoB or Pcsk9 
suffer a similar limitation to antisense oligonucleotides, being the that regular siRNA 
injections would be required for a long-term phenotypic effect.
In contrast to the previously described studies, our data show the feasibility of 
long-term correction of LDL-C in plasma after a single intravenous injection of AAV 
encoding shRNA targeting ApoB (chapter 2). AAV have unique properties such as 
low immunogenicity, the lack of integration into the host genome and the natural 
occurrence of different serotypes with unique transductional proprieties. In our studies 
serotype 8 was used which has been shown to efficiently transduce liver in mice and in 
NHP [23,24]. The AAV delivered DNA was engineered into a self-complementary form 
that has been shown to provide more rapid and potent transduction compared to 
single stranded AAV. However our approach was found to have some disadvantages. 
First, we observed a dose-dependent increase in liver lipid accumulation. As discussed 
previously, this seems to be a common side effect of all ApoB targeting therapies. It 
remains to be seen whether this will preclude further development of ApoB targeting 
therapies, and in the Kynamro clinical trials it was reported that liver fat may stabilize 
or decline in patients who continue treatment beyond a year [25]. Steatosis may 
be associated with inflammation and may progress to cirrhosis, thus liver lipid 
accumulation side effect should be minimized for safe and long term therapy. An 
attractive approach would be to block the accumulation of hepatic triglycerides by 
the simultaneous inhibition of another target involved in lipid metabolism. Indeed 
Merck has recently reported that simultaneous inhibition of Mtp and Dgat2 genes 
with siRNA resulted in decrease in plasma cholesterol and attenuation of hepatic fat 
accumulation induced by Mtp silencing [26]. Surprisingly double knockdown of ApoB 
and Dgat2 or ApoB and Fatbp5 did not result in reduction of lipid accumulation [10].
A significant problem in evaluating treatment efficacy for FH is the species-specific 
difference in plasma lipid profile in model animals. Wild-type mice have very high 
levels of anti-atherogenic HDL-C and low pro-atherogenic LDL-C levels. Hence, high fat 
diets or genetic manipulations are necessary in order to generate models for familiar 
hypercholesterolemia and coronary atherosclerosis [2,11,27]. Nonetheless, mice with 
a human-like lipid profile are now available and can be used in preclinical studies [11]. 
NHPs demonstrate the closest overall match to dyslipidemic humans are sometimes 
considered the optimal animal model for target validation and drug discovery. However 




observed [28]. For future development of RNAi gene therapy of FH a careful selection 
of the animal model needs to be done to estimate properly all possible side effects.
The long-term expression provided by AAV vectors can also be seen as a major 
disadvantage, especially when side effects are being observed during the treatment as it 
would be impossible to discontinue the therapy. Therefore, in subsequent chapters 3-6 we 
focused on minimizing possible side effect resulting from AAV-RNAi gene therapy for FH.
Expression of shRNA with different promoters
In our initial experiment (chapter 2), we did observe a loss of the ApoB inhibition over 
time which was associated with strong shRNA expression. Therefore, in chapter 3 
pol II promoters were used as these provide moderate levels of expression. It has been 
reported that pol II promoters, like the CMV promoter and the liver-specific hAAT 
promoter, are capable of driving shRNA expression in vitro and in vivo, which resulted 
in lower shRNA toxicity [29,30]. An alternative strategy to direct expression of shRNA 
is to embed the siRNA sequence in artificial miRNA. Artificial miRNAs are sometimes 
called 2nd generation RNAi, but this phrase is misleading because miRNA and shRNA 
may behave very differently [31-33]. When driven by pol II promoters, both miRNA 
and shRNA are less toxic compared to pol III [31,32]. Therefore to optimize pol II 
shRNA expression,  we designed a number of constructs targeting luciferase with 
different termination signals hairpin stem lengths expressed from the CMV promoter 
[34]. Surprisingly none of the shRNA configurations tested resulted in strong luciferase 
knockdown. We believe that this was due to inefficient processing of shRNA by RNAi 
machinery as pol II transcription start and termination can be shifted on both 5’ and 3’ 
ends of the hairpin. In contrast,  2 out of 3 designed CMV expressed miRNAs resulted 
in 80% inhibition of their targets which was similar to pol III-expressed shRNA [34].  
To date only a few examples of direct expression of shRNA from pol II promoters 
have been reported [29,35,36]. Son et al. showed successful silencing of JNK with 
shRNA expressed with prostate specific antigen promoter in androgen-responsive 
prostate cancer cells [36]. Giering et al. reported successful long-term inhibition of 
the envelope surface antigen of HBV in vivo with shRNA expressed from a liver-
specific promoter [29]. They also reported that CMV promoter expressing 25 bp length 
hairpin with pA resulted in ~40% inhibition of luciferase, but in our experiments this 
approach resulted in only ~20% inhibition of luciferase. This discrepancy may be 
explained by different sequences of the hairpin used in both studies. Yuan et al. 
reported effective inhibition of Lamin B2 by shRNA fused to GFP gene and followed 
by standard polyadenylation signal [37]. This finding is in contrast to previous reports 
where 5’ and 3’ overhangs of shRNA were shown to inhibit Dicer processing [38]. We 
hypothesize that these GFP-fused shRNA resemble artificial miRNA rather than shRNA 




confirm the feasibility of shRNA expression from pol II promoters, we demonstrated 
that using artificial miRNA is less laborious and provides more efficient gene silencing. 
A number of tissue specific and inducible promoters has been described [39,40], 
allowing restriction of the expression of therapeutic siRNA to the target tissue or 
enabling the expression to be turned “on” and “off”.
Long-term efficacy and processing of shRNA  
and miRNA targeting ApoB in vivo
In a subsequent work (chapter 4), we focused on the efficacy of shRNA and miRNA 
targeting ApoB in vitro and in vivo. To minimize possible side effects we used the 
liver specific LP1 promoter to express miRNA targeting ApoB. The efficacy of such 
an approach may be questioned because a tissue specific promoter was anticipated 
not to provide sufficient expression levels to induce phenotypic effect [41]. Since 
the dose which we used was comparable to the one used in the Grimm et al. study 
(2x1011 gc/mice) we anticipated that the shRNA would cause toxicity and therefore 
the silencing effect can be lost over the time and the miRNA would provide stable 
ApoB inhibition. Surprisingly the inhibitory effect diminished for both molecules 
over the 27 weeks experiment despite that miApoB expressed less molecules and 
expression was limited to the liver. Artificial miRNAs have been shown to be non 
toxic in brain while expression of shRNA resulted in cellular damage [31,33]. Hence, 
one of the reasons of the discrepancies might be the targeted organ. The central 
nervous system (CNS) is considered immune privileged due to its isolation behind the 
blood-brain barrier and lack of conventional lymphatic drainage [42,43]. Although it 
is possible that immune response against shRNA and miRNA play important role in 
RNAi toxicity, in our studies no liver inflammation was observed in any experimental 
group. Additionally our own results did not show interferon response in AAV-shApoB-
injected animals [2]. Rather, the loss of efficacy was associated with viral DNA loss 
over time of the experiment which suggested liver toxicity. However at week 27, 
no obvious signs of hepatocellular toxicity in AAV-shApoB and AAV-miApoB groups 
were detected, suggesting that adverse effects may have taken place earlier in time. 
There are several reports on long-term RNAi efficacy in mice, rats and NHP. Most 
commonly siRNAs were used which required repeated administration for a stable effect. 
Only a limited number of reports on long term efficacy of AAV-shRNA or AAV-miRNA 
in vivo have been pulished; Chen et al. reported significant inhibition of HBV for 
120 days after single injection of 1x1012 gc AAV-shRNA [44]. Similarly to our results 
AAV-shRNA reached peak in inhibition around 23 wk p.i. and then the inhibition effect 
gradually decreased with time. It should be noted that in their experiment the AAV 
vectors were infused through intrasplenic injection, which is not a commonly used (or 




expression targeting sAg was detected for more than one year in murine liver [29]. 
However the doses used in their studies were 3x1011 and 1x1012 gc/mice which are 3 
fold and 10 fold higher than we used (chapter 4). The authors showed sAg inhibition 
data for 100 days; however they mention that shRNA expression could be detected for 
more than one year. Interestingly while the effect of the higher dose was stable, the 
inhibition provided by the lower dose became weaker over the time.
Initially, we assumed that shApoB and miApoB processing would result in 
identical siApoB targeting sequences that would mediate the phenotypic effect 
of LDL-C lowering. To our surprise, and despite the predictions, NGS sequencing 
revealed that embedding identical siRNA sequences into shRNA or miRNA scaffolds 
results in processing of a diverse pool of siApoB sequences with different 5’ and 3’ 
ends. The length of the processed products varied with shApoB products between 
19 and 23 nt long, 21 being the most abundant, and miApoB products between 23 
and 25 nt and 24 being the most abundant. miRNAs are endogenously processed 
by Drosha which cleaves off flanking sequences and subsequently Dicer cleaves the 
loop and mature miRNA duplex is formed [45]. shRNAs are generally processed by 
Dicer which cleaves off the loop, however hairpins with a stem shorter than 19 bp 
may be processed independently from Dicer [46]. Recently, it has been reported that 
such non-canonical processing uses Ago2 cleavage and yield only a single ~33 nt 
strand that can effectively induce RNAi (Y.P.Liu, personal communication, 2012). 
In our experiments, an important observation was that shRNA processing resulted 
in a wider range of siRNA variants than miRNA processing. Small number of NGS 
reads represented shRNA that was cut once as the passenger or guide strand and 
were still linked to the loop. Small number of reads representing the loop of shApoB 
and miApoB were also detected. The relevance of these findings still needs to be 
investigated but these cleavage products may result in non specific interactions as 
single stranded siRNA (ss-siRNA) were shown to enter the RISC complex, activate 
RNAi and effectively inhibit gene expression [47,48]. Because ss-siRNA are less stable 
than dsRNA and are rapidly degraded by nucleases, their application in RNAi so far 
was limited. However recent reports show that chemical modification can stabilize 
ss-siRNA and provide potent inhibition of gene expression via RNAi [47,48].
 Another important observation was that the abundance of guide and passenger 
strands varied between shApoB and miApoB. The siApoB passenger strand was 
detected in a very high percentage of the reads from miApoB. Similarly to our results, 
Gu et al. recently reported that mainly the guide siRNA strand of a shRNA was pulled 
down with Ago2 while both guide and passenger strands were detected from a 
miRNA scaffold associated with Ago1/2/3/4 [49]. Additionally, the passenger strand 
from the miRNA was not cleaved and eliminated as efficiently as from the shRNA. 




into non-activated Ago complexes rendering those sequences ineffective at inducing 
knockdown. Our findings indicate that differential processing and Ago loading of 
siRNAs originating from different scaffolds may have important consequences as 
all siRNA variants can be loaded into RISC and this will increase the occurrence of 
possible aspecific interactions. These distinct differences in processing and loading 
have critical implications for future design of RNAi-based therapeutics. 
RNAi toxicity due to oversaturation of the cellular 
miRNA processing
RNAi toxicity due to oversaturation of the cellular miRNA processing seems to be 
one of the major obstacles for therapeutic RNAi applications. It has been shown 
that pol II-expressed shRNA and artificial miRNA reduce the risk of endogenous RNAi 
pathway saturation. Our results confirmed the feasibility of tissue specific expression 
of artificial miRNA which resulted in phenotypic changes in vivo. Nonetheless, the 
knockdown induced by both shApoB and miApoB diminished over time in a dose-
dependent manner. Loss of the effect was previously attributed to saturation of 
endogenous RNAi pathway, in particular Exportin 5 which leads to global deregulation 
of miRNA expression and has been associated with induced liver toxicity [50]. 
However in chapter 4 and 5 we did not observe saturation of the endogenous miRNA 
pathway but rather, the loss of the effect was associated with loss of virally delivered 
DNA [2] . By lowering the dose stable inhibition of ApoB was achieved indicating the 
critical role of dose in relation to RNAi toxicity. McBride and Grimm have reported 
similar results indicating that RNAi associated toxicity is dose dependent and that by 
lowering the dose the toxicity can be abolished [31,50]. It is possible that competition 
with endogenous RNAi pathway occurs at multiple levels and saturation of Exportin 
5 and deregulation of endogenous miRNA levels may not be the only cause for RNAi 
toxicity. In fact, it has been recently reported that overexpression of shRNA in vivo not 
only saturates Exportin 5, but also all 4 human Ago proteins [51]. Because artificial 
miRNA enter the RNAi pathway “earlier” than shRNA, it was speculated that this may 
slow their loading onto RISC and thereby reduce their competition with other small 
RNAs or RNAi factors. This, together with the differential loading onto Ago proteins 
support the fact that miRNA has better intrinsic properties for therapeutic RNAi. 
Nonetheless, the efficacy of AAV delivered shRNA targeting HCV virus in non-human 
primates has been demonstrated [24]. The authors reported that high-expression 
levels of shRNA from pol III promoter resulted in dose dependent hepatocellular 
toxicity, but this problem was overcome by promoter modification which resulted 
in lower siRNA expression. These results suggest that RNAi toxicity may well be 
conserved in humans and further optimization of RNAi mediators as well as delivery 





Perhaps the biggest challenge of RNAi therapy is to eliminate unintended inhibition 
of transcripts, known as “off-targeting”. The side-effect is reminiscent of transcript 
regulation by endogenous miRNAs, where the seed region plays a key role in target 
recognition. Because seed-target interactions are often difficult to predict in the 
design stage RNAi therapeutics can potentially affect a large number of genes. Snøve 
et al. reported that roughly 75% out of 359 siRNA sequences that were previously 
published had a risk of elucidating non specific effects although their sequences were 
believed to be highly specific to the target gene [52]. Despite the complexity of the 
prediction, the authors argue that many target-specific siRNA can be designed by 
using more stringent prediction methods. In chapter 5 we showed that expression 
of shRNA and miRNA exerted distinct changes on liver gene and miRNA expression, 
which resulted in distinct phenotypic changes. Based on the shApoB/miApoB 
processing data we performed detailed off-target prediction analysis using the 
Smith-Waterman algorithm and these results were verified with NGS transcriptome 
analysis in vivo. Notably, none of the genes predicted in the analysis were found to 
be significantly affected for both miRNA and shRNA, but expression levels of several 
non-predicted genes were affected. Although our off-target prediction covered only 
the most abundant variants of siApoB guide and passengers strands and some off-
targets may have been missed this was still surprising. An important observation is 
that the majority of these genes were upregulated in shApoB and in miApoB, whereas 
in case of off-targeting gene downregulation is expected. This may suggest that the 
observed changes may be a result of various different mechanisms. Of these, AAV 
infection, RNAi expression and ApoB knockdown may be among the most relevant. 
Additionally miRNAs may regulate their targets by translational repression; therefore 
we might speculate that the off-target effects may be stronger at protein level. 
Recently Ahn et al. reported global changes in gene expression in the liver after 
delivering adenoviral vector expressing shRNA [53]. We have shown that expression of 
identical siRNA sequences from shRNA or miRNA expression in liver results in differential 
gene expression in liver, and multiple genes and functions were found to be affected. 
Interestingly Biglycan (Bgn) and Lipoprotein lipase (Lpl) were upregulated for both AAV-
shApoB and AAV-miApoB. Additionally apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 2 (Apobec2) was downregulated in both groups. These common 
changes may be specific results of the strong ApoB knockdown in the liver.  Despite the 
same phenotypic effect (i.e. lowering of circulating cholesterol concentrations), genes 
involved in lipid metabolism were differentially affected in AAV-shApoB compared to 
AAV-miApoB animals. In AAV-shApoB injected mice, NGS analysis revealed upregulation 
of genes involved in MAPK pathway, which confirmed liver histology data. Surprisingly 




of inflammatory genes but we did not observe hepatic inflammation histologically. A 
possible explanation would be that the AAV-shApoB induced inflammation at earlier 
time points and the increased proliferation is consequence of liver injury. However we 
did not observe an increase in liver transaminases enzymes in AAV-shApoB-injected 
animals. Both AAV-miScr (control) and AAV-miApoB-injected animals did exhibit mild 
upregulation of ALT and AST around 4 and 6 wk p.i. but no increase of hepatocyte 
proliferation was detected. Our results are similar to those of Ahn et al. who reported 
increased liver and apoptosis proliferation in liver as a consequence of shRNA expression 
without signs of inflammation [53]. In fact it is known that even low shRNA doses may 
induce mild hepatic damage, followed by compensatory hepatocyte proliferation in 
mice, without a clinical phenotype [54]. Moreover, mild hepatic injury with active Myc 
oncogene can accelerate tumorogenesis and cause mortality. This suggests caution 
regarding potential induction of cancerogenesis by stable shRNA expression in liver. Still 
similar studies on miRNA expression and cancerogenesis have to be initiated. 
Some endogenous miRNA were found to be affected by expression of both 
shApoB and miApoB and surprisingly a large number of miRNAs were upregulated. It 
is still unclear whether the observed transcriptome and cellular miRNA changes were 
a specific effect of shApoB/miApoB expression or ApoB inhibition or a combination 
of both. In recent years, it has become apparent that beside miRNA also other non-
coding RNAs tRNAs, rRNAs, snRNA and snoRNAs are implicated in development and 
progression of many diseases [55,56]. In our NGS analysis we focused exclusively at 
the expression of endogenous miRNA and we believe that an analysis of the complete 
small RNA transcriptome needs to be included in future studies.
Regulated RNAi expression
The RNAi field is a newcomer in the therapeutic armamentarium and one of the big 
challenges is to improve its safety. Our data indicate that constitutive expression of 
shRNA and miRNA does have a significant impact on cellular small RNA and gene 
expression in vivo. This finding led us to develop inducible expression of artificial miRNAs, 
as described in chapter 6. Previous efforts to develop regulable RNAi have resulted in 
the identification of a number of inducible systems (Table 1). These systems typically 
utilize a small molecule to activate a chimeric transcription factor, which by binding 
to its recognition sequences which allow spatio-temporal and quantitive control of 
shRNA or miRNA expression. This minimizes risk of toxicity resulting from uncontrolled 
and sustained siRNA or gene overexpression. However, chimeric transcription factors 
may introduce another source of toxicity as they may be immunogenic or modulate 
expression of endogenous genes. With some of the systems high basal expression in 
the absence of the inducer may be a problem. Several groups have reported successful 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































in vitro and in vivo [57-65]. However the effectiveness and safety of any of those 
inducible systems has not been investigated in humans.
The tetracycline inducible system (Tet On) is one of the best characterized. It has been 
shown to express artificial miRNA targeting luciferase which upon induction resulted 
in specific inhibition in luciferase expressing transgenic mice [62]. This suppression was 
reversible and 12 days after doxycyline removal luciferase activity returned to basal levels. 
Moreover, expression of the artificial miRNA resulted in few or no changes in the expression 
of endogenous miRNAs in induced state compared to non-induced showing that reversible 
silencing of gene expression does not disrupt endogenous miRNA processing. On the 
other hand, because components of the Tet On system are derived from bacterial proteins, 
the system is highly immunogenic. Additionally the tetracycline-inducible system has a 
relatively high background of expression in the un-induced state [63]. A main drawback 
is that doxycycline is commonly used as an antibiotic in agriculture thus it can be found in 
meat and other food sources, which can result in unintended induction.
The Ecdysone inducible system is more tightly regulated and the components of the 
system do not affect mammalian physiology due to short half life [57,64]. The system 
has been shown to regulate expression of shRNA against the tumor suppressor p53 
gene, which resulted in phenotypic changes in vitro. Remarkably, withdrawal of the 
inducer resulted in complete reversal of the cellular phenotype. The ecdysone inducible 
system has been shown to drive expression endogenous mir-122 in vitro [64] and 
embedding of siRNA in the mir-122 scaffold resulted in a potent inhibition of luciferase. 
The main disadvantage of the system is the inducer, which is a steroid hormone derived 
from D.melanogaster, which can possibly interfere gene expression in animals. 
Another system which has been shown to express shRNA is the rapamycine 
regulated system [65]. It employs a different mechanism of transactivator activation. In 
contrast to doxycycline and ecdysone, it does induce transactivator dimerization rather 
than allosteric changes. The system is composed entirely from human derived proteins 
thus the risk for immunogenicity is minimized. This system exhibits superior inducibility 
in several cell lines compared to other inducible systems [66]. The main drawback in 
its application is the fact that rapamycine is immunosuppressive drug which limits its 
clinical application. Yet, a rapamycine analog, which is biologically non active, has 
been shown to efficiently act as inducer without compromising system properties [65].
The GeneSwitch system is composed of two components: the first one is the 
GeneSwitch regulatory protein, which upon induction dimerizes and binds to the 
regulatory sequence of the second component- the inducible promoter. Although it is 
not known to drive expression of shRNA or miRNA, it has some potential advantages 
over the other inducible system. Most importantly the transactivator protein lacks 
bacterial derived sequences which minimize the risk of immune reaction. Additionally 
the mifiprestone is a registered drug with extensively characterized activity and 




for expression of artificial miRNA targeting ApoB. Our results indicated that system is 
able to express miApoB in regulated and dose-dependent manner in vitro. Moreover, 
we have shown that the system is versatile and potentially expresses miRNA targeting 
Htt. We have cloned the two core components: the GeneSwitch transactivator and 
the inducible promoter driven miRNA in a single expression cassette, which facilitates 
production of rAAV. Combination of AAV delivery with inducible expression of miRNA 
targeting disease-related genes holds a great promise to induce specific gene knockdown 
concurrent with lack of toxic side effects. However validation of the efficacy, inducibility 
and safety of the GeneSwitch system in vivo still needs to be performed.
Concurrent with the ongoing efforts to employ inducible systems to inhibit disease 
related genes, a novel method to regulate gene expression by endogenous RNAi has 
been developed [69,70]. Many miRNAs are expressed in a tissue specific manner and 
have an important role in maintaining tissue specific functions and differentiation. For 
example mir-142-3p is specifically expressed in a hematopoietic cell lineage and it is 
able to regulate target transcripts by binding to specific target sequences. Fusion of 
mir-142-3p sequence to foreign transgene has been shown to inhibit gene expression 
in hematopoietic lineage cells, including APCs in both in vitro and in vivo setup which in 
consequence leads to attenuation of the immune response against foreign transgenes 
[71-73]. This approach can be applied for treatment of homozygous diseases where 
patients often do not express certain proteins and protein substitution therapy often 
fails due to immune response. Our initial concept studies have confirmed this finding 
as ovalbumin (OVA) expression was maintained in murine muscle when mir-142-3p 
binding site were placed in 3’UTR. By contrast expression of OVA lacking mir-142-3p 
binding sites was lost over the time, which was associated with appearance of anti-OVA 
specific antibodies. The safety aspects of such an approach need to be investigated. For 
example, the levels of endogenous miRNA expression including mir-142-3p need to be 
determined because a highly expressed transgene containing miRNA binding sites may 
lead to depletion of mir-142-3p or other miRNAs and result in global deregulation of 
gene expression in hematopoietic cells. 
Altered miRNA expression is likely to contribute to many human diseases including 
cancer where it is implicated in regulating the malignant progression of cancer. This 
could be employed for the development of disease therapeutics based on cellular 
miRNA expression or inhibition. For example mir-9 has been found to be important 
in breast cancer as it overexpression is associated in increased cell motility and 
invasiveness [74]. Inhibiting mir-9 by using a ‘miRNA sponge’ in highly malignant cells 
inhibits metastasis formation. ‘miRNA sponge’ contains multiple (6-8) bulged tandem 
binding sites for a miRNA linked to a transgene of interest but it contains more 
binding sites (6-8), which often are not perfectly complementary. Additionally many 
miRNAs are downregulated in disease states. In breast cancer- expression of mir-31 in 




metastasis is to restore endogenous levels by delivering vectors expressing mir-31 in 
tissue-specific or cancer-specific manner. It has been shown that expression of ABC 
transporter genes in HCC can be mediated by cellular miRNA [75]. A total number of 79 
miRNAs were found to be downregulated and 12 ABC transporters were upregulated 
in HCC patients [77]. In vitro verification revealed that mir-101 and mir-135 regulate 
the expression level of cholesterol transporter ABCA1 and mir-199a/b and mir-296 of 
multidrug resistance transported ABCC1. These findings may lead to novel treatment 
strategies, where endogenous levels of downregulated miRNAs may be artificially 
increased. By contrast, ‘miRNA sponges’ can be used to inhibit expression levels of 
endogenous miRNA to achieve therapeutic effect. For example, this approach have 
been used to decrease endogenous mir-122 levels, which in consequence resulted 
in 30% reduction of plasma cholesterol in mice [78]. Both approaches, inhibition of 
endogenous miRNA and restoration of physiological expression are attractive targets 
for future therapeutics. Therefore concomitant with screening for novel miRNA 
targets, attention should be directed to the safety of such approaches.
Challenges and future perspectives of RNAi
Despite the initial hope and excitement about RNAi, along with new developments 
several issues are being discovered. One of the major challenges is to achieve long term 
efficacy of RNAi therapeutics without side effects. So far, there are no sufficient data 
on long-term RNAi treatment and its side-effects. Additionally, the number of safety 
studies in NHP is very limited. Several RNAi clinical trials have been initiated during past 
few years but only synthetic siRNA, LNA and antisense oligonucleotides have been used. 
AAV-delivered RNAi therapeutics have not been brought to clinical trials due to intrinsic 
limitations of the approach. A major advantage would be the single dosage that should 
be sufficient to result in a long-lasting therapeutic effect. For the future gene therapy 
applications, it is desirable to employ inducible expression of shRNA or miRNA that would 
allow expression of the molecules within a therapeutic window and avoid toxicity. 
A comprehensive analysis of side effects is necessary to improve the safety profile 
of RNAi. Simply employing a more rational design of shRNA targeting Htt resulted in 
lowering off-target effects. Promising approaches to improve the properties of miRNA 
are optimization the flanking sequences and the use of different miRNA scaffolds. This 
may lead to better processing and improved strand selection for RISC incorporation.
A second important challenge is the efficient delivery of RNAi to the target 
organ. AAV-delivered shRNA or miRNA is a powerful approach for long-term RNAi 
therapeutics in the liver. By using different AAV serotypes with specific cellular 
tropism, narrowed targeting can be achieved. Additionally, new serotypes may exhibit 
better transduction efficacy, which in consequence would result in lowering the dose 
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Summary in English 
The liver plays a major role in the metabolism and has a number of functions in the 
body, including glycogen storage, decomposition of red blood cells, plasma protein 
synthesis, hormone production, and detoxification. Familial hypercholesterolemia 
(FH) is a genetic disorder characterized by high levels of low density lipoprotein 
cholesterol (LDL-C) and increasing the risk of cardio vascular diseases. FH and many 
other liver diseases can possibly be treated with RNA interference (RNAi). RNAi is a 
natural process of regulation of gene expression by binding of small RNA molecules 
to complementary sequences in the mRNA of a gene and hence inducing its 
degradation or translational repression. In this thesis, we aimed at developing a safe 
and robust RNAi-based therapy for FH by inhibiting Apolipoprotein B100 (ApoB). 
ApoB is a primary component of the  low density lipoprotein (LDL), a lipoprotein that 
transports “bad” cholesterol LDL-C. 
In chapter 2 we tested the inhibitory potential of adeno-associated virus (AAV) 
delivered shRNA targeting ApoB (shApoB). AAV-shApoB induced a strong knockdown 
of ApoB mRNA and protein levels which correlated with a reduction in total cholesterol 
levels and elevated lipid accumulation in the liver. In this study, shApoB was transcribed 
by the polymerase III (pol III) promoter, which provides high expression levels. This 
probably resulted in (mild) hepatotoxity, when high doses of AAV-shRNA were used.
Therefore, in chapter 3, we explored the possibility of using the weaker pol II 
promoters to express shRNA. Pol II promoters can also be tissue specific or regulated, 
which would provide additional safety level for gene therapy applications. However 
pol II expression of shRNA was not optimal, therefore we developed artificial miRNA as 
an alternative to shRNA expression. Artificial miRNA demonstrated target knockdown 
efficiency similar to that of shRNA, while expressing less siRNA molecules. 
In chapter 4, the long-term efficacy of AAV delivered shRNA and artificial miRNA 
targeting ApoB (shApoB and miApoB, respectively) in vivo was investigated. As 
additional safety measure miApoB was expressed from the liver specific LP1 promoter. 
AAV-shApoB and AAV-miApoB provided potent gene knockdown, which resulted 
in a clear phenotypic effect of cholesterol reduction. Interestingly, the strong ApoB 
knockdown effect was quickly lost over the time for AAV-shApoB while AAV-miApoB 
had a more sustained effect. Analysis of shApoB and miApoB revealed differential 
processing that may have implications for their off-targeting and toxic effects in vivo.
The consequences of the differential functioning and processing of shApoB 
and miApoB were further investigated in chapter 5 by histological, transcriptome 
and pathway prediction analysis. Interestingly, AAV-shApoB but not AAV-miApoB 
increased hepatocytes proliferation and affected genes involved in cell proliferation 
and death as well as immune response. Additionally, endogenous miRNA profile was 




RNAi has been designed and tested as a further step towards safer and robust RNAi 
gene therapy. The mifepristone-inducible GeneSwitch system was used to express 
several artificial miRNAs. We optimized the system components in order to minimize 
basal expression and maximize gene induction rate. In vitro, GeneSwitch expressed 
miRNA demonstrated sequence specific and dose dependent target knockdown 
indicating that the system can be applied in the future for regulated RNAi expression.
In conclusion, we have shown that RNAi therapy using AAV-delivered artificial 
miRNA is a promising approach for treatment of FH and possibly other liver diseases. 
Our mechanistic studies revealed differences in shRNA and miRNA processing and 
functioning in vivo. Finally, our findings have significant impact on understanding and 
overcoming toxicity and off-targeting related problems of RNAi based gene therapy 





De lever heeft een aantal belangrijke metabolisme functies in het lichaam, waaronder 
glycogeen opslag, afbraak van rode bloedcellen, plasma-eiwit synthese, hormoon 
productie en ontgifting. Familiaire hypercholesterolemie (FH) is een genetische 
ziekte gekenmerkt door hoge plasma concentraties van low density lipoproteïne 
cholesterol (LDL-C)  die het risico van hart en vaatziekten verhogen. FH en vele andere 
leverziekten kunnen mogelijkerwijs worden behandeld met RNA interferentie (RNAi). 
RNAi is een natuurlijk proces waarbij  genexpressie gereguleerd wordt doordat  kleine 
RNA moleculen zich binden aan complementaire sequenties van het messenger RNA 
(mRNA) van een gen. Hierdoor wordt het mRNA afgebroken  waardoor de translatie 
naar eiwit niet kan plaatsvinden, zogenaamde translationele repressie. 
In dit proefschrift hebben we ons gericht op het ontwikkelen van een veilige 
en robuuste op RNAi-gebaseerde therapie voor FH door het remmen van het 
afschrijven van mRNA dat codeert voor het eiwit Apolipoprotein B100 (ApoB). ApoB 
is een hoofdcomponent van low density lipoprotein (LDL), een lipoproteine dat het 
“slechte” cholesterol LDL-C vervoert. In hoofdstuk 2 hebben we de remming van 
ApoB getest door met behulp van adeno-associated virus (AAV) shRNA (shApoB) 
in de levercellen te introduceren. Inderdaad veroorzaakte AAV-shApoB een sterke 
vermindering van ApoB mRNA en eiwit. Dit correleerde met een verlaging van totaal 
cholesterol in het bloedplasma en een opstapeling van vet in de lever. In dit onderzoek 
werd shApoB afgeschreven door de polymerase III (pol III) promoter, hetgeen leidt tot 
hoge expressieniveaus.  Bijwerkingen, zoals (milde) toxiciteit in de lever,  ontstonden 
waarschijnlijk door de hoge doseringen van AAV-shRNA.
In hoofdstuk 3, hebben we daarom de mogelijkheid van het gebruik van de zwakkere 
pol II promoters onderzocht om shRNA tot expressie te brengen. Pol II promoters kunnen 
bovendien ook weefselspecifiek of gereguleerd zijn, hetgeen een extra niveau van 
veiligheid voor gentherapie toepassingen mogelijk maakt. Omdat de pol II expressie van 
shRNA niet optimaal was, hebben we artificieel miRNA ontwikkeld als alternatief voor 
shRNA expressie. Artificiële miRNA hebben aangetoond efficiënt knockdown te geven 
van het target gen, vergelijkbaar met die van shRNA, terwijl ook bekend is dat miRNA 
minder siRNA moleculen genereren. In hoofdstuk 4 is de langdurige werking van ApoB 
knockdown door shRNA of artificiële miRNA (respectievelijk shApoB en miApoB) in vivo 
geïntroduceerd door AAV vergeleken. Als veiligheidsmaatregel is miApoB expressie 
gestuurd door de lever-specifieke LP1-promoter. AAV-shApoB en AAV-miApoB gaven 
sterke knockdown, die resulteerde in een duidelijk fenotypisch effect van cholesterol 
verlaging. Een belangrijke bevinding was dat het sterke knockdown-effect van AAV-
shApoB snel was verdwenen, terwijl het AAV-miApoB effect aanhield. Analyse van 
shApoB en miApoB liet zien dat het verschil in de manier van verwerking gevolgen heeft 




Het verschil in functioneren en de manier van verwerken van shApoB en miApoB 
zijn verder onderzocht in hoofdstuk 5 met behulp van histologie en transcriptome en 
pathway voorspelling analyse. AAV-shApoB maar niet AAV-miApoB zorgde voor een 
versnelde hepatocyte proliferatie door een effect op genen die betrokken zijn bij de 
celproliferatie en celdood. Ook genen die betrokken zijn bij de immuunreactie waren 
aangedaan. Daarnaast was het miRNA profiel zowel in vitro als in vivo verschillend 
aangedaan door beide moleculen. 
Hoofdstuk 6 beschrijft het ontwerp en het onderzoek dat gedaan is met een 
induceerbaar RNAi voor een veiliger en robuuste manier van RNAi gentherapie. 
Hiervoor is het Mifepristone-induceerbaar GeneSwitch systeem gebruikt om 
verschillende artificiële miRNAs te expresseren. We hebben de componenten van 
het systeem geoptimaliseerd op de basale expressie te minimaliseren en de gen 
introductiegraad te verhogen. GeneSwitch geëxpresseerde miRNA lieten in vitro een 
sequentie-specifieke en dosis-afhankelijke knockdown zien, wat een toekomst biedt 
voor dit systeem in de gereguleerde RNAi expressie.
Samenvattend hebben we aangetoond dat door AAV afgeleverde artificiële 
miRNAs de deur openen voor veelbelovende nieuwe therapieën van FH en 
mogelijkerwijs andere leverziekten. Deze basale studies naar de werking hebben 
uitgewezen dat shRNA en miRNA in vivo verschillen in de manier van verwerken en 
functioneren. Ten slotte hebben onze bevindingen een belangrijke invloed op het 
inzicht in het tegengaan van toxiciteit en specificiteits problemen bij gentherapie in 





Wątroba odgrywa bardzo wa 
.
zną rolę w metabolizmie oraz pełni wiele istotnych 
dla organizmu funkcji włą czają c magazynowanie glikogenu, rozkład czerwonych 
krwinek, syntezę białek osocza. produkcję hormonów oraz detoksykację. Rodzinna 
hipercholesterolemia (FH) jest chorobą genetyczną, którą charakteryzuje wysoki 
poziom LDL (lipoprotein o niskiej gę sto ’sci) cholesterolu zwię kszających ryzyko chorób 
układu krą  
.
zenia. FH, a tak 
.
ze wiele innych chorób wątroby mo
.
ze by ’c potencjalnie 
leczone przy pomocy mechanizmu interferencji RNA (RNAi). RNAi jest naturalnym 
procesem regulacji ekspresji genów w którym małe czą steczki RNA wią  
.
zą c się do 
sekwencji w mRNA genu, wywołują zjawisko wyciszania lub wyłą czania danego genu. 
Celem tej pracy było opracowanie skutecznej, a przede wszystkim bezpiecznej terapii 
FH w oparciu o mechanizm interferencji RNA i wyciszanie genu Apolipoproteiny B100 
(ApoB). Białko ApoB jest jednym z głównych składników lipoprotein o niskiej gę sto ’sci 
(LDL), które odpowiedzialne są za transport "złego" cholesterolu LDL-C..
W rozdziale 2 testowali ’smy shRNA przeciwko ApoB (shApoB), który był 
dostarczany za pomocą wirusa zale 
.
znego od adenowirusów (AAV). AAV-shApoB 
spowodował silne wyciszenie genu oraz białka ApoB, co w konsekwencji spowodowało 
spadek poziomu cholesterolu we krwi i jednoczesne zwię kszenie zawarto’sci lipidów w 
wą trobie. W tym badaniu shRNA było produkowane przez promotor polimerazy RNA 
klasy III, który wykazuje wysoki poziom ekspresji. Prawdopodobnie dlatego wysokie 
dawki AAV-shRNA spowodowały (łagodne) uszkodzenie wą troby.
Dlatego te 
.
z, w rozdziale 3, zbadali ’smy mo 
.
zliwo ’s ’c zastosowania słabszych 
promotorów polimerazy RNA II do ekspresji shRNA. Promotory polimerazy RNA II 
mogą zwię kszy ’c bezpiecze ’nstwo terapii genowej poniewa 
.
z, w przeciwie  ’nstwie do 
promotorów pol III, mogą one by ’c regulowane, a tak 
.
ze tkankowo-specyficzne- czyli 
aktywne tylko w danym typie tkanki. Poniewa 
.
z uzyskana prez nas ekspresja shRNA 
przy wykorzystaniu promotorów pol II nie była optymalna, jako alternatywę u 
.
zyli ’smy 
sztuczne czą steczki mikro RNA (miRNA), które wykazały skuteczno’ s ’c porównywalną 
do shRNA produkowane przez pol III.
W rozdziale 4, zbadali ’smy długoterminową skuteczno ’s ’c shRNA oraz sztucznego 
miRNA przeciwko genowi ApoB (odpowiednio shApoB i miApoB) w warunkach in vivo. 
Jako dodatkowy zabezpieczenie miApoB było produkowane przez promotor polimerazy 
RNA klasy II, specyficzny dla komórek wą troby (LP1 promotor). Zarówno AAV-shApoB 
oraz AAV-miApoB spowodowały silne wyciszenie genu ApoB, co zaowocowało 
wyra ’znym fenotypem w postaci obni 
.
zonego poziomu cholesterolu we krwi. Co 
ciekawe, silny efekt wyciszenia genu ApoB przez AAV-shApoB szybko ustał, podczas 
gdy efekt wywołany przez AAV-miApoB był bardziej długotrwały. Analiza shApoB i 
miApoB ujawniła, 
.
ze obydwie czą steczki ulegają ró 
.
znej obróbce w komórkach, co mo 
.
ze 






znicowej obróbki oraz działania shApoB oraz miApoB były kolejno 
badane przez nas w rozdziale 5 poprzez analizę histologiczną , transkryptomu (profilu 
ekspresji genów) oraz komórkowych szlaków metabolicznych. Co ciekawe, wyłą cznie 
AAV-shApoB spowodował wzrost ilo ’sci dzielą cych się komórek wą troby (hepatocytów) 
oraz wzrost ekspresji genów biorą cych udział w procesach rozmna 
.
zania i ’smierci 
komórek oraz odpowiedzi immunologicznej. Ponadto, wpływ shApoB oraz miApoB 





W rozdziale 6, w celu dalszego zwię kszenia bezpiecze ’nstwa i skuteczno’ sci terapii 
genowej, zaprojektowali ’smy i przetestowali ’smy system do regulowanej ekspresji 
sztucznych czą steczek miRNA. W tym celu u 
.
zyli ’smy system GeneSwitch który mo 
.
ze by ’c 
regulowany zwią zkiem chemicznym- Mifepristonem. W celach ulepszenia wła ’sciwo ’sci 
systemu tzn. zmniejszenia podstawowej ekspresji oraz zwię kszenia maksymalnej aktywacji 
systemu, poszczególne komponenty systemu zostały szczegółowo zbadane. W badaniach 
in vitro wykazali ’smy, 
.
ze system GeneSwitch umo 
.
zliwia specyficzne oraz regulowane, w 
zale 
.





ze by ’c stosowany w przyszło ’sci w celach terapii genowej opartej na RNAi.
Podsumowują c, wykazali ’smy, 
.
ze terapia genowa za pomocą wirusów AAV oraz 
sztucznych czą steczek miRNA jest obiecują cą metodą leczenia FH oraz innych chorób 
wą troby. Badania mechanistyczne wykazały ró
.
 znice w obróbce i funkcjonowaniu 
shRNA i miRNA w warunkach in vivo. Nasze wyniki mają istotny wpływ na zrozumienie 
oraz rozwią zanie problemów zwią zanych z bezpiecze ’nstwem i skutkami ubocznymi 
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rodzicom.  Mamo i Tato - dzię kuję Wam za wszystko, za Wasze wychowanie i za 
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